HBV Pre-C/C Variation: Geographical and Functional Aspects by Boner, Winifred
HBV pre-C/C variation; geographical and functional aspects
by
Winifred Boner
A thesis presented for the degree 
of Doctor of Philosophy
in
The Faculty of Science 
at the 
University of Glasgow
Institute of Virology 
Church Street 
Glasgow 
G11 5JR March 1997
ProQuest Number: 11007686
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 11007686
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
!0 <$0? 
Cpil
GLASGOW
UNIYEESm
LIBRARY
David and Michael
Contents
Page
Title
List of Tables 
List of Figures 
Acknowledgements 
Summary 
Abbreviations
Chapter 1 Introduction
1. Epidemiology and geographic distribution of
hepatitis B viruses 1
2. Outcome of infection 2
2.1 Clinical features and course of infection 2
2.2 Clinical features and course of infection of anti-HBe-positive 
Mediterranean and Chinese cases 3
2.3 Hepatocellular carcinoma (HCC) 4
Taxonomy and classification of HBV 5
3.1 Subtypes 5
Structure and molecular biology of HBV life cycle 6
4.1 Structure 6
4.2 Genomic organisation 7
4.3 Genes and their protein products 8
4.3.1 Surface gene 8
4.3.2 Core gene 9
4.3.3 X gene 13
4.3.4 Polymerase gene 17
4.4 Attachment and entry 17
4.5 Uncoating and transport of DNA to nucleus 19
4.6 Transcription and regulatory elements 19
4.7 Translation
4.8 Encapsidation and replication
4.9 Assembly and release
5. Immune response to HBV, focusing on HBcAg
5.1 Humoral immune responses
5.2 T-cell responses
5.2.1 Cytotoxic T lymphocytes (CTL)
5.2.2 Thelper lymphocytes
5.3 Interferon
5.4 Tolerance
6. Genetic variability
6.1 Pre-C
6.2 Core
6.3 X  gene and c/'s-acting regions
6.3.1 X g en e
6.3.2 Core promoter and enhancers
6.4 The role of CTL in genetic variability
6.5 Interferon therapy and pre-C/C variability
7. Aims of thesis
Chapter 2 Materials
2.1 Bacterial strains
2.2 Bacterial growth medium
2.3 Chemicals
2.4 Radiochemicals
2.5 Enzymes
2.6 Human sera
2.7 Buffers
2.8 Kits
2.9 Plasmids
2.10 Miscellaneous
22
22
25
27
28
30
30
32
34
34
37
37
40
46
46
47
50
55
56
57
57
57
60
61
61
61
63
64
64
Chapter 3 Methods
3.1 DNA extraction from serum
3.1.1 Proteinase K method 66
3.1.2 N a O H  m e t h o d  6 6
3.2 Removal and purification of oligonucleotides from column 66
3.3 Polymerase chain reaction
3.3.1 First round PCR 67
3.3.2 Second round PCR 68
3.3.3 PCR mutagenesis 69
3.3.4 Screening for inserts using the PCR 69
3.4 Purification of PCR products and DNA
3.4.1 Geneclean method 69
3.4.2 Using the Geneclean kit 70
3.4.3 QIAquick gel extraction kit 70
3.5 Mini-gel submarine agarose electrophoresis 70
3.6 DNA sequencing
3.6.1 Using the Sequenase™ version 2.0 DNA sequencing kit 71
3.6.2 Biotinylated sequencing 71
3.6.3 Running the sequencing reactions 72
3.7 Restriction enzyme digestion of DNA 73
3.8 Ligation 73
3.9 Preparation of competent cells 74
3.10 Transformation of E.coli 74
3.11 DNA purification from plasmid 74
3.12 Peptide synthesis 75
3.12.1 Synthesis of tetrameric peptides 75
3.12.2 Synthesis of monomeric peptides 75
3.13 Cleavage and deprotection of peptides 76
3.14 Analysis of peptides
3.14.1 Mass spectrometry 77
3.14.2 Amino acid analysis 77
3.15 Reverse phase high pressure liquid chromatography (HPLC) 77
3.16 Purification of peptides 77
3.17 Storage of peptides 78
3.18 Dissolution of peptides 78
3.19 Enzyme linked immunosorbant assay (ELISA) 78
3.20 Separation of peripheral blood mononuclear cells from
whole blood 79
3.21 Lymphoproliferation assay
3.21.1 Using whole blood 80
3.21.2 Using separated peripheral blood mononuclear cells 81
3.22 Cloning of Uiase in vaccinia virus 81
3.23 Sera and antibodies used in vaccinia analysis 82
3.24 Immunoprecipitation and Western blotting of vaccinia
generated proteins 82
Chapter 4 Results: Section 1
4.1 Reconstruction experiments: Testing sensitivity of detection of
mixed populations by sequencing 84
4.1.1 Methods 85
4.1.2 Results 85
4.2 Extraction of DNA from serum 85
4.2.1 Methods 86
4.2.2 Result 86
4.3 Conclusions 86
Chapter 5 Results: Section 2, Chinese Study
5.1 Background 88
5.2 Aims 89
5.3 Patients 90
5.4 Methods 90
5.5 Results
5.5.1 Sequencing 92
5.5.2 Serinel 5 prevalence 93
5.5.3 Functional studies on HBeAg 93
5.5.4 Phylogenetic analysis 94
5.6 Discussion 94
5.7 Further plan of investigation
5.7.1 Mutating the encapsidation signal 97
5.7.2 Variability in other HBV proteins 97
5.7.3 Mutations in the core promoter 98
Chapter 6 Results: Section 3, Mediterranean Study
6.1 Aims 99
6.2 Selection of patients 99
6.3 Methods 101
6.4 Statistical analysis 101
6.5 Results
6.5.1 Relationship between pre-C and core mutations 102
6.5.2 Clinical correlates and distribution of mutations in
HBe to anti-HBe seroconverters 103
6.5.3 Timing and distribution of mutations in continuously
anti-HBe positive patients 103
6.6 Discussion 104
6.7 Implications 106
Chapter 7 Results: Section 4, Overlapping peptide series
7.1 Aims 108
7.2 Preliminary study
7.2.1 Background 108
7.2.2 Oligopeptides 109
7.2.3 Methods 110
7.2.4 Results 110
7.2.5 Conclusions of the preliminary study 111
7.3 Overlapping peptide series: Synthesis
7.3.1 Peptide synthesis 111
7.3.2 Dissolution of branched peptides 112
7.3.3 Monomeric synthesis 113
7.3.4 Dissolution of monomeric peptides 113
7.3.5 Purification of peptides 113
7.3.6 Amino acid analysis of peptides 113
7.4 Functional analysis of HBcAg peptides 113
7.4.1 Lymphoproliferation studies: results 114
7.4.2 B-cell studies: results 116
7.4.3 Conclusions and discussion 118
7.5 Future work 121
Chapter 8 Results: Section 5, Expression of HBcAg
8.1 Aim 122
8.2 Selection of HBcAg sequences to be cloned and expressed 123
8.3 Strategies employed in the cloning of HBcAg: methods
and results 123
8.5 Conclusions 127
Chapter 9 General discussion and future work 128
Appendix 1 Primer sequences
Appendix 2 One and three letter abbreviations for amino acids 
Appendix 3 List of publications arising from this thesis
Tables
4.1 The relative mixtures of plasmids A and C.
5.1 Patient characteristics.
6.1 Statistical analysis of amino acid substitutions in 
patients who seroconverted from HBeAg to anti-HBe 
during the period of observation and went into clinical 
remission.
6.2 Statistical analysis of amino acid substitutions in 
patients who seroconverted from HBeAg to anti-HBe 
during the period of observation and sustained active 
disease.
6.3 HBcAg amino acid changes in sequential samples from 
continuously anti-HBe positive patients with active 
hepatitis.
6.4 Statistical analysis of amino acid substitutions in HBcAg 
in patients with active disease who remained anti-HBe 
positive throughout the period of observation.
7.1 Configuration, sequence and charge of peptides used in 
preliminary study.
7.2 Peptide name, sequence and charge from the initial 
overlapping peptide series.
7.3 Solubilities of peptides from the initial synthesis.
7.4 Solubility results for peptides on addition of three lysine 
or aspartic acid residues.
7.5 Peptide name, sequence and charge from the monomeric 
peptide synthesis.
7.6 Solubility results for the 30- and 20-mer monomeric 
synthesis.
Following
page
83
88
101
101
101
101
107
108 
109
109
110 
110
Following
page
7.7 Clinical details of patients tested in the 
lymphoproliferation assay.
7.8 Sequence of aa 1 -30 of HBcAg from patients analysed 
by lymphoproliferation assays.
7.9 Sequences of the variant peptides derived from the 
PBMC series of patients.
111
112
112
Figures
Chapter 1
1.1 Schematic cross-sectional representation of the 
structural organisation of the hepatitis B virion.
1.2 Genomic organisation of hepatitis B virus.
1.3 Schematic structure of the hepatitis B virus HBcAg.
1.4 Model of the hepatitis B virus core protein dimer.
1.5 Predicted secondary structure of the hepatitis B 
virus encapsidation signal.
1.6 Classical and revised models for initiation of reverse 
transcription in hepatitis B virus.
1.7 Dual role of P-s interaction in the hepatitis B virus 
replication cycle.
1.8 Schematic representation of the pre-C/C ORF.
1.9 Variability in HBcAg observed in individuals with 
chronic HBV infection.
1.10 Variability in HBcAg in patients with severe hepatitis.
1.11 Variability in HBxAg and related c/'s-acting elements.
Chapter 4
4.1 Autoradiograph of part of the pre-C region sequenced 
directly from BC1/C3 PCR products of plasmids A. 
and C, indicating the level of detection of A i896-
4.2 Eithidium bromide stained 1% (1xTBE) agarose gel 
showing the C1/C2 PCR products of DNA extracted 
by the NaOH method and the proteinase K method.
4.3 Eithidium bromide stained 1% (1xTBE) agarose gel 
showing the C3/C4 PCR products of DNA extracted 
by the NaOH method and the proteinase K method.
Following
page
6
7
12
12
22
23
24  
36
39
39
45
83
84
84
Following
page
Chapter 5.
5.1 Distribution of amino acid substitutions in HBcAg. 90
5.2 The pre-C region of 23 HBV sequences from Genbank
database. 91
5.3 Comparisons of molecular size and antigenicity of wild
type HBeAg and proline to serine mutant. 91
5.4 Unrooted maximum likelihood tree of 23 HBV sequences. 92
5.5 The predicted RNA structure of the encapsidation signal
of HBV. 93
Chapter 6
6.1 Clinical data, number and distribution of amino acid 
substitutions in patients who seroconverted to anti-HBe
during the period of observation. 98
6.2 Clinical data, number and distribution of amino acid
substitutions in continuously anti-HBe positive patients. 98
6.3 Serological profiles and HBc amino acid changes in
selected anti HBe positive patients with active hepatitis. 99
Chapter 7.
7.1 Reactivity of anti-HBe positive serum with varying amounts
of peptides (414-a, -b, -c and -d). Serum diluted 1:50. 107
7.2 Reactivity of anti-HBe positive serum with varying amounts
of peptides (414-a, -b, -c and -d). Serum diluted 1:200. 107
7.3 Hydrophobicity/philicity plot of HBcAg. 108
7.4 Whole blood assay responses to HBcAg peptides
(Thi, Th2 and ThPn) and HBcAg in five non-symptomatic 
chronic carriers and a control patient (anti-HBe negative). 111
7.5 Whole blood assay responses to PHA in five non-symptomatic
chronic carriers and a control patient. 111
7.6 PBMC response to peptides (Th1( Th2, ThPn and P22-16M)
Following
page
and HBcAg in a patient with acute self-limiting hepatitis. 111
7.7 Lymphoproliferative response of peripheral blood 
mononuclear cells to the overlapping peptide series in
patients with fulminant, acute or chronic hepatitis or HCC. 111
7.8 Reactivity of anti-HBe positive and negative serum
to the overlapping peptide series. 113
7.9 Monomeric and branched peptides (P22-4, -5 and -6) tested
against anti-HBe positive sera. 114
7.10 IgG ELISA results of patient PBMC13 tested against the
variant peptides S1 to S. 114
7.11 IgM ELISA results of patient PBMC13 tested against the
variant peptides S1 to S. 114
Chapter 8
8.1 Eithidium bromide stained 1% (1xTBE) agarose gel showing the
products of restriction enzyme digestion of pT7Blue inserts with 
Eco R1 and Hin dm. 121
8.2 A mapplot analysis of Gr49. 121
8.3 A mapplot analysis of Gr82. 122
8.4 Eithidium bromide stained 1% (1xTBE) agarose gel showing the
result of screening for inserts by PCR. 122
8.5 Eithidium bromide stained 1% (1xTBE) agarose gel showing the
products of restriction enzyme digestion of pKK223.3 inserts with 
Eco R1 and Hin dm. 122
Acknowledgements
Firstly, I would like to thank Professors J.H. Subak-Sharpe, B. 
Clements and D. McGeoch for giving me the opportunity to work in the 
Institute of Virology.
I am particularly grateful to my supervisor Dr Bill Carman for his 
(unbelievable at times) enthusiasm and help throughout the project 
and in the writing of this thesis. Whether I shall ever forgive him for 
introducing me to sequencing is another matter..!
I am indebted to the members of lab 109, both past and present, for 
their continual help and technical assistance throughout the project, 
and for making the lab such an enjoyable place to work. In particular, I 
wish to thank my good friend Dr. Lesley Wallace for always being 
around when I needed help and for her valuable comments on this 
thesis.
I would like to thank Dr. Howard Marsden and the members of his 
laboratory for making my ‘stay’ most enjoyable and, of course, for all 
their help and expertise with the synthesis of my peptides. In particular 
I would like to thank Gillian McVey for introducing me to the ‘tea break’!
I would also like to thank the staff of the washroom, media and store 
who are fundamental to the smooth running of the department.
I greatly appreciate the contribution of the following collaborators: Dr
H.J. Schlicht (University of Ulm, Germany) for undertaking the cloning, 
expression and analysis of U i856 in vaccinia virus (Chapter 5). Dr. E.C. 
Holmes (University of Oxford, U.K.) who carried out the phylogenetic 
analysis (Chapter 5). Dr. Mark Thursz (St Mary’s, Paddington, London) 
for carrying out part of the statistical analyses (Chapter 6). Professor 
Hadziyannis (Hippokration Hospital, Athens, Greece) for provision of
patient samples (Chapter 6) and analysis of the my peptides in T and B 
cell studies (Chapter 7) and for continuing with this work.
I would like to thank my mum and dad for their continual support - not 
just financially - throughout my time at University. I am extremely 
grateful both to them and David’s parents, Peter and Eileen Walsh, for 
their help with babysitting, without which I do not think I would ever 
have finished writing this thesis.
Finally, thanks to my husband, David, for his encouragement, endless 
help and for still being my friend despite having to read this thesis, not 
forgetting his financial support (are we quits now?) and to my son, 
Michael, who just makes life that extra bit special.
The author was the recipient of a Glaxo scholarship. All work 
presented, unless otherwise stated, is by the author,s own efforts.
Winifred Boner March 1997
Acknowledgement to Professor Hadziyannis
In Chapter 7, where Athens follows a study number, this indicates that the 
results presented in these studies were obtained from experiments carried 
out in Athens and these experiments were undertaken by Professor 
Hadziyannis’s laboratory.
Summary
Infection with hepatitis B virus (HBV) can lead to a spectrum of disease 
manifestations, from asymptomatic acute hepatitis to fulminant hepatitis. 
Why such a spectrum should occur is not clear but the immune response 
to HBV has often been implicated. Normally, after seroconversion to anti- 
HBe, HBV DNA levels fall and disease activity is minimal. However, a 
group of individuals from the Far East and the Mediterranean were 
identified as having continued exacerbations of disease activity even after 
seroconversion to anti-HBe.
This thesis examines variation in HBcAg from sequential serum samples 
of these individuals, and analyses the distribution of amino acid 
substitutions in relation to B- and Thelper cell epitopes.
In the first study, the distribution of HBcAg amino acid substitutions was 
compared in Chinese patients with different pre-core (pre-C) variants. One 
variant has a serine at amino acid (aa) 15 of pre-C, and the other is the 
common Aisae which introduces a stop codon at aa 28. The serinel 5 strain 
is shown here to produce antigenically normal amounts of HBeAg. Both 
variants have been shown to be mutually exclusive, probably due to 
sequence requirements for encapsidation, and are separate lineages. 
Sequential sequencing of HBcAg showed that in those individuals with 
Ai896 there are significantly more aa substitutions, and that these are 
associated with Th and B-cell epitopes.
In the second study, sequential samples were examined from individuals 
from the Mediterranean who either seroconverted to anti-HBe or who were 
continually anti-HBe, the results showed that selection of A i896 is 
temporally associated with aa substitutions in HBcAg. In seroconverters 
went into remission, aa substitutions occurred in the Th epitope from aa 
50 to 69 (p=0.00045), but in anti-HBe positive patients with ongoing
disease these occurred in B-cell epitopes (p=0.0007 for aa 74 to 83). 
Analysis of the timing of these substitutions showed that they are not 
associated with multiple flares of hepatic activity.
Comparison of the results of the two studies shows that the distribution of 
HBcAg substitutions differs in the Chinese and the Mediterranean groups.
An overlapping peptide series, covering the entire HBcAg, was 
constructed to test the hypothesis that the observed variants which arose 
during infection represented immune escape; either humoral, Thelper cell 
escape or both. Several patients failed to react to their homologous 
peptide in lymphoproliferation assays suggesting that the lack of response 
is not due to variation in Thelper cell epitopes. The results from the 
lymphoproliferation studies defined the Thelper epitope - previously 
described at aa 1 to 20 - as lying between aa 14 and 23. Antibody binding 
and T-cell studies indicated that branched chain peptides work in both 
systems, and that they are more reactive in ELISA when compared to 
monomeric peptides. Several of the patients studied in the B-cell assay 
reacted to peptides spanning aa 1 to 43, possibly indicating a putative B- 
cell epitope in this region.
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Chapter 1
Introduction
1. Epidemiology and geographic distribution of hepatitis B 
virus
Human hepatitis B virus (HBV) infection constitutes a major global health 
problem, with an estimated 300 million infective carriers world-wide 
(Takano et at, 1995). Geographic patterns of HBV prevalence are known 
to vary greatly world-wide with the incidence of HBV infection ranging 
from <10% in areas of low endemicity to 30-80%  in areas of intermediate 
and high endemicity; of the latter, prevalence is greatest in South East 
Asia and sub-Saharan Africa. Occurrence of chronic HBV carriers also 
follows this pattern with <1% and between 2-15%  of the adult population 
of these areas being chronically infected.
In the areas of low endemicity, infection occurs principally in adults and is 
transmitted predominantly via sexual contact and intravenous-drug abuse, 
whereas in areas of intermediate and high endemicity transmission occurs 
primarily via either the maternal-infant route or through close contact in 
early life. Host factors appear to play a role in the route of transmission. In 
sub-Saharan Africa, transmission is mostly in childhood (Skinhoj, 1979), 
whereas in South East Asia transmission is primarily from mother to baby 
(Stevens et al, 1979). This is probably related to the high rate of HBeAg 
positivity in chronic carriers in this latter group. It is unclear why this group 
fail to clear HBeAg. As HBeAg positivity correlates with infectivity, this 
predisposes these individuals to transmitting to their children. In contrast 
to an adult-acquired infection, where <5% will develop chronic hepatitis, if 
a child is infected perinatally then the risk of the infection leading to
1
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chronicity is 95%. This incongruity is probably partially due to induction of 
tolerance to HBeAg in utero (discussed in Chapter 1, section 6.4). 
Although chronicity is a minority outcome in the adult, persistent infection 
occupies a central role in the biology of HBV as most of the mortality is a 
consequence of this outcome.
It appears that the only source or reservoir of HBV for human infections is 
humanity itself. No animal reservoir is known. HBV has been 
experimentally transmitted to chimpanzees (Maynard et al, 1971) and with 
less effect to African green monkeys, gibbons and rhesus monkeys. 
However, there is no evidence that non-human primates are important 
sources of human infections.
2. Outcome of infection
2.1 Clinical features and course of infection
The incubation period of acute hepatitis can range from 4 to 28 weeks: in 
most cases the interval is between 8 to 16 weeks. Symptoms include: 
headache, malaise, anorexia, nausea, jaundice, and moderate fever 
(temperatures of 37.5-39°C) and usually last for 2-10 days. Increased 
levels of the liver enzymes, alanine aminotransferase (ALT) and aspartate 
aminotransfersae (AST), are good indicators of infection.
During acute infection, hepatitis B surface antigen (HBsAg) levels 
eventually fall and antibodies to HBsAg (anti-HBs) are produced. On 
complete recovery these antibodies maintain immunity in the individual to 
further infection by HBV. Acute HBV infection is normally self-limiting but 
in rare cases (-1 %  of the total number of cases), the disease can become 
aggressive causing severe damage to the liver; this is known as fulminant 
hepatitis and is often fatal. The mortality in such cases is very high, with 
one in two cases dying within 10 days of the onset of symptoms.
2
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If HBsAg is still detectable in the serum after 6 months, the patient is then 
classified as a chronic hepatitis B carrier. Most cases of chronic hepatitis 
B virus infection have a preceding history of symptomatic acute hepatitis 
B.
In HBV carriers a state of low-level viraemia usually develops after 
elimination of hepatitis B e antigen (HBeAg) from the blood, while HBsAg 
persists to circulate. This is thought of as the ‘healthy’ carrier state (or 
chronic persistent hepatitis). However, in some individuals symptoms 
persist - known as chronic active hepatitis.
Despite hepatitis B core antigen (HBcAg) being an internal component of 
HBV, antibodies to HBcAg (anti-HBc) are produced by virtually 100% of 
HBV infected patients very early in infection, and therefore their 
appearance is of no prognostic value.
In contrast, antibodies to HBeAg (anti-HBe) may not develop or appear at 
various times after anti-HBc and are frequently correlated with viral 
clearance. ALT levels are often raised at the time of seroconversion to 
anti-HBe, indicating liver cell damage with no apparent cell damage 
thereafter.
If an individual fails to seroconvert to anti-HBe, virus titres remain high 
and extensive liver damage usually results. Thus, seroconversion to anti- 
HBe is a crucial step in virus elimination.
2.2 Clinical features and course of infection of anti-HBe- 
positive Mediterranean and Chinese cases
An interesting group of patients with HBV DNA present in their serum, 
measurable by dot-blot hybridisation, yet who were anti-HBe positive, was 
discovered in southern Europe and in the Far East (Hadziyannis et al,
3
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1983; Chu et al, 1985). This group of patients were unusual in that 
disease progressed - sometimes rapidly - despite the presence of anti- 
HBe. Interest was then focused onto the pre-core (pre-C) gene, as this is 
the region involved in synthesis of HBeAg, leading to the discovery of a 
variant of HBV that was unable to produce HBeAg (Carman et al, 1989, 
Brunetto et al, 1989a) - the HBeAg-minus strain. Findings by Brunette et 
al (1991), suggested that the HBeAg producing strain of HBV caused a 
milder form of hepatitis than that seen in those with HBeAg-minus strain.
The major routes of transmission in Southern Europe and the Far East are 
different. Transmission in the Far East is primarily vertical (mother-to- 
baby, at or around the time of birth). This is due to the prolonged duration 
of HBeAg in these patients. Whereas HBV in Southern Europe is acquired 
via horizontal transmission early in childhood. Why females in the Far 
East remain HBeAg positive into their child-bearing years is not clear but 
this does account for the different transmission routes between these 
geographical areas.
2.3 Hepatocellular carcinoma (HCC)
HCC has a world-wide distribution and, numerically, is one of the major 
cancers in the world. The association between HCC and HBV infection is 
strong (Beasley, 1982). The percentage of chronic carriers is higher 
among patients with HCC than among the rest of the population 
(Szmuness, 1978). There is at least a 100-fold increased risk of 
developing HCC if you are a chronic carrier (Beasley et al, 1991).
The high incidence of HCC in woodchucks (Marmota monax) residing in 
the Philadelphia Zoo, led to the identification of the woodchuck hepatitis 
virus (W HV) (Summers et al, 1978). As HCC has yet to be described in 
the chimpanzee, the woodchuck is currently used to study the molecular 
mechanisms of HCC development. Animals chronically infected with
4
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hepadnaviruses, e.g. woodchucks, develop hepatomas (Chen et al, 1986). 
Integrated viral DNA has been found in tumours (Zhou et al, 1987) 
although the mechanism of hepatocarcinogenesis is far from clear.
3. Taxonomy and classification of HBV
A genetic classification of HBV strains was originally performed by 
Okamoto et al (1988) on 18 HBV whole genome clones. This identified 
four genotypes, designated A to D, based on nucleotide divergences of 
8% or more between the strains. Norder et al (1992) extended this study 
to 32 HBV strains, this time only examining the surface (S) gene 
sequence. The results obtained confirmed the original classification, 
showing that classifying HBV genomes on the basis of the S gene alone is 
feasible. Their results also showed a higher divergence between 
genotypes and serotypes than had been previously reported, resulting in 
the designation of two new genotypes E and F.
3.1 Subtypes
HBsAg variation leads to stable subtypes, defined by monospecific 
polyclonal antibodies. Antigen reactivities that are found on all recognised 
HBsAg isolates are known as determinant a. Le Bouvier et al (1972), and 
Bancroft et al (1972), described the mutually exclusive determinants d  or y  
and w or r respectively, enabling the distinction of four major HBsAg 
subtypes, adw, adr, ayw  and ayr. Determinant d  has a lysine at amino 
acid 122, y  an arginine (Peterson et al, 1984). Determinant w has a lysine 
at amino acid 160 and ra n  arginine (Okamoto eta l, 1988).
Additional serological specificities have allowed the identification of four 
serotypes of ayw and two of adw. Thus, there are eight defined subtypes, 
ayw l, ayw2, ayw3, aywA, ayr, adw2, adw4 and adr. The q determinant 
was originally found on all HBsAg subtypes except adw4. Subsequently,
5
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lack of q was also demonstrated in some adr subtypes, adr strains can 
therefore be defined as either adrq+ or adrq-. Strains specifying acfw are 
found in groups A, B, C and F, and those specifying ayw  in groups A, B, D 
and E (Norder et al, 1992). Strains specifying r  have so far only been 
found in group C.
The world-wide molecular epidemiology of HBV, based on S-gene 
sequences, has shown that E and F genotypes originated in aboriginal 
populations of W est Africa and the New World respectively. Genotype A 
is found in North-western Europe and sub Saharan Africa, genotypes B 
and C are confined to original populations of the Far East, while genotype 
D is widespread; however it is the predominant genotype found in the 
Mediterranean and the Near East (Magnius and Norder, 1995).
4. Structure and molecular biology of HBV life cycle
4.1 Structure
Electron microscopy of partially purified preparations of HBV from human 
serum revealed three types of particles:
1. 43nm double-shelled particles - termed 'Dane particles’ - are now 
known to be the intact virion.
2. 20nm spheres, usually present in 103-106 excess over virions
3. 20nm diameter filaments, varying in length. (Robinson and Lutwick, 
1976; Dane et al, 1970)
All three display HBsAg on their surface. Dane particles contain the L, M 
and S proteins in approximately equimolar amounts, whereas the 20nm 
particles are mainly composed of the S protein, a variable amount of M 
protein and, in limited quantity, host-derived lipids. In addition, the 
filaments also contain some L protein. The L and M protein are thought to 
mediate binding and entry of the virus into hepatocytes (discussed below
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in Chapter 1, section 4.4). Only Dane particles contain nucleic acid; 
therefore, only this type of particle is infectious. The filaments and 
spheres are produced in vast quantities during infection. The reason for 
this is still unclear: one possibility is that these ‘dummy’ particles serve to 
adsorb neutralising anti-HBs.
HBsAg surrounds the nucleocapsid, which consists of a 21 Kd 
phosphoprotein, HBcAg. Virion cores are known to contain the viral DNA 
polymerase, which is covalently bound to the HBV DNA, and a protein 
kinase. Figure 1.1 shows a schematic model of HBV.
4.2 Genomic organisation
HBV belongs to the Hepadnaviridae family. The genome was first isolated 
in 1974 (Robinson and Lutwick, 1976) and at 3.2 kilobases (Kb), it is the 
smallest DNA virus known to infect man .
The circular genome displays two remarkable asymmetries that sets it 
apart from all other viral genomes. The first is a length asymmetry in the 
two strands: one DNA strand is unit length, while its complement is 
variably less than this. The full length strand is complementary to the viral 
messenger RNAs (mRNAs) and is thus designated to be of minus polarity. 
Hence, the shorter complementary strand is termed the plus strand. The 
position of the 5’ end of the plus strand is fixed but the 3’ end is variable. 
The genome is therefore only partially double stranded (Delius et al, 
1983), possessing a single-stranded gap region from 20-80% of unit 
length. Circularity is maintained by a 5’ cohesive terminus of 224 base 
pairs (bp) (Sattler and Robinson, 1979).
The second asymmetry occurs at the 5 ’ termini: minus strand DNA 
contains protein in covalent linkage at this position (Gerlich and 
Robinson, 1980), whereas the plus strand contains an unattached 5 ’
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Nucleocapsid
Lipid bilayer
DNA polymerase 
(Reverse transcriptase)
DNA terminal 
protein
PreS2 
(PreS2/S = M )
HBsAg 
( = S)
PreS1 
(PreS1/PreS2/S = L)
Figure 1.1 Schematic cross-sectional representation of the structural 
organisation of the hepatitis B virion. The infectious HBV virion consists of 
an outer envelope of host-cell-derived membrane, in which the products 
of the pre-S2/S ORF are embedded. The surface proteins have a 
common S domain, to which the pre-S2, or pre-S1and pre-S2, domains 
are optionally added, forming the middle (M) and large (L) proteins 
respectively. The inner capsid is formed from HBcAg and encloses the 
partially double-stranded, circular DNA genome and the P protein, which 
is covalently linked to the (-)-strand DNA.
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oligoribonucleotide. These asymmetries result from the novel replicative 
mechanism of the genome (discussed in section 4.8). Despite its compact 
size, HBV DNA encodes all the proteins it requires, with all the regulatory 
elements residing within the proteins.
4.3 Genes and their protein products
HBV encodes four major open reading frames (ORF): the surface, the 
polymerase, the pre-C/C and the X  (Figure 1.2). Two further putative 
ORFs have been described and are termed ORF 5 and ORF 6. In vitro 
translational experiments have looked for the presence of mRNAs for both 
these ORFs without success Chang et al (1994).
4.3.1 Surface gene
The surface gene contains three translational start codons (AUG) and one 
common stop codon (UAA), giving rise to three ORFs: pre-S1, pre-S2 and 
S. These ORFs are translated as the following products: the large protein 
(pre-S1, pre-S2 and S) of 39 kilodaltons (kD) (unglycosylated) and 42kD  
(glycosylated), the middle protein (pre-S2 and S) of 33 and 36kD and the 
small protein (S alone equivalent to HBsAg) of 24 and 27kD.
HBsAg is the most abundant polypeptide in all three HBV-associated 
particles, whereas middle protein is a minor component in all three. The 
large protein is more prevalent than the middle protein in virions and 
filaments, but less prevalent in HBs spheres. It appears that the proportion 
of large protein determines the morphology of the HBs particles 
(Marquardt et al, 1987), while the ratio of middle protein to HBsAg does 
not significantly alter morphology.
Functional roles of the pre-S proteins in the viral life cycle have yet to be 
clearly defined. Pre-S1 probably plays an important role in the entry of the 
virus into hepatocytes (Pontisso et al, 1989).
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Figure 1.2 Genomic organisation of hepatitis B virus. The outer thin 
lines represent the different classes of transcripts, the bold line represents 
the DNA genome. The four major ORFs are indicated in the centre.
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4.3.2 Core gene
Like the S gene, the C gene is preceded by an in-frame ORF termed the 
pre-C region. Translation from the pre-C AUG produces a protein (pre-C 
protein) with a molecular mass of 24kD, and which has the entire HBcAg 
sequence plus a 29 amino acid residue amino-terminal (N-) extension. 
The first 19 amino acids of the pre-C protein form a signal peptide 
sequence which directs the pre-C protein to the endoplasmic reticulum 
(ER), where this region is cleaved; resulting in a 22kD protein that is 
translocated to the lumen of the ER (Garcia et al, 1988).
The carboxy-terminus (C-) has a strongly basic domain that in most HBV 
isolates contains 16 arginine residues, in clusters, in a stretch of 34 amino 
acids. This domain undergoes further proteolysis, in the golgi, at amino 
acid 149 in the carboxyl terminus of HBcAg (Wang et al, 1991), resulting 
in the production of HBeAg (Ou et al, 1988). This cleavage event probably 
involves a cellular, aspartyl-like protease (Jean-Jean et al, 1989, Nassal 
et al, 1989). HBeAg is then secreted in a monomeric form into the blood 
(Wasenauer et al, 1992).
The mechanism which leads to the production and secretion of HBeAg is 
identical for two other hepadnaviruses; duck hepatitis virus (Schlict et al,
1987) and woodchuck hepatitis virus (Carlier et al, 1994).
The role of the arginine-rich domain in the generation of HBeAg is still 
unclear. HBe-like proteins, from which the arginine-rich domain has been 
removed but not the signal peptide, have been found in the sera of HBV 
carriers (Takahashi et al, 1992); this indicates that the signal peptide is 
not the only requirement for secretion of HBeAg. Work by Bruss and 
Gerlich (1988) based on in vitro translation experiments, suggests that the 
arginine-rich domain could act as a translocation stop signal. This domain, 
therefore, would have to be removed in the ER before HBeAg could be 
secreted into serum. However, this has not been supported by later work
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as it has been shown that removal of the arginine-rich domain takes place 
in the golgi and not the ER (Wang et al, 1991, Carlier et al, 1995).
Experiments have shown that the C-terminus is crucial for HBeAg 
production, as cells infected with a recombinant virus truncated by 34 
amino acids at the C-terminus secrete about 20 times less HBeAg than 
those infected with a virus containing the entire pre-C region (Schlicht and 
Wasenauer, 1991). A recent paper, by Carlier et al (1995) confirmed 
these findings and showed that a C-terminus deletion of 60 amino acids 
completely abrogated HBeAg secretion. They indicated that the low 
secretion efficiencies of C-terminally truncated pre-C proteins are due to a 
slowing down in the intracellular transport of the HBeAg precursor. A 
similar situation has been reported for the precursor of the 
Saccharomyces cerevisiae proteinase A (PrA), a vacuolar hydrolase, 
which contains a prodomain proteolytically removed when PrA is about to 
reach its final destination. When the prodomain of PrA is deleted, a two- 
to four-fold delay in delivery to the vacuole is observed (Klionsky et al,
1988). Thus, the arginine-rich domain could also act as a prodomain and 
may contribute to the overall conformation of the pre-C protein which may 
be required for its efficient intracellular transit. When the pre-C sequence 
is replaced by the signal sequence of influenza virus haemagglutinin, the 
arginine-rich domain is not required for efficient secretion. However, in 
this case the HBe-like protein has a dimeric structure (Schlicht and 
Wasenauer, 1991). Such a finding is consistent with the understanding 
that the monomeric structure of HBeAg is determined by an intermolecular 
disulphide bond between a cysteine (Cys) in the pre-C region Cys'7 
(numbering from the methionine of HBcAg) and Cys61 (Wasenauer et al, 
1993, Nassal and Rieger, 1993). An alternative hypothesis is that some 
sequences within the C-terminus interact with a cellular protein, acting as 
a chaperone, in the secretion process. Deletions in this area would 
therefore result in abrogation of these interactions, explaining the 
observed slow intracellular transport of the truncated forms of the pre-C
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proteins. Such sequences could be in the region valine (amino acid 124) 
to arginine (amino acid 133) which have been reported to be at the 
surface of the pre-C protein (Sallberg et al, 1993).
Although the primary amino acid sequence of this protein is nearly 
identical to the HBcAg sequence, HBeAg does not form core particles 
and, unlike HBcAg, is secreted from the infected cells. The prevention of 
particle formation can be attributed to a cysteine residue at amino acid 23 
of pre-C.
The true function of HBeAg has yet to be elucidated; one theory proposes 
that HBeAg acts to induce T-cell tolerance to nucleocapsid antigens 
coexpressed with the major histocompatibilty complex at the hepatocyte 
surface (discussed below in Chapter 1, section 5.4). As HBeAg is able to 
cross the placenta, such a mechanism could explain the high incidence of 
chronic disease in the newborn (Thomas et al, 1988). Low molecular 
weight proteins can induce tolerance. This is particularly true in cases 
where the immune system is exposed to such a protein at an early stage 
of development. This mechanism for tolerisation has been demonstrated 
in a transgenic mouse model for HBeAg (Milich et al, 1990), and may 
explain why infants infected at birth continue to exhibit vireamia and HBe 
antigenemia for many years. Thus, tolerisation to HBeAg in the newborn 
would favour the passage of the virus from generation to generation. A 
second hypothesis as to why >90% of children infected at birth become 
chronic carriers is that the humoral response to the core proteins - 
particularly HBeAg - is capable of inhibiting the cytotoxic T-cell response 
and thus leads to destruction of infected hepatocytes leading to a 
protracted course of infection (Mondelli et al, 1982, Pignatelli et al, 1987). 
Thus, the passive transfer of antibody from the mother would inhibit the 
induction of specific cytotoxic T cells by the child. Guidotti et al (1996) 
suggest a role for the pre-C protein in the virus life cycle. Their 
experiments showed that over expression of pre-C protein eliminated
11
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nucleocapsid particles from the cytoplasm of hepatocytes (in mice) and 
abolished HBV replication, but it did not however affect the abundance of 
pregenomic RNA. This suggests, therefore, that excess pre-C protein may 
inhibit viral replication by destabilising the nucleocapsid particles and in 
this way prevent HBV replication. Lambert et al (1993) have previously 
demonstrated that the pre-C protein can exert a dominant negative effect 
on HBV replication in vitro.
Translation from the second AUG produces the core protein (HBcAg) 
which spontaneously assembles to form the virus nucleocapsid. HBcAg is 
synthesised in the cytoplasm of the infected cell. HBcAg is a 185 
(genotype A) or 183 (all other genotypes) amino acid polypeptide with a 
molecular mass of 21.5kD. The HBcAg of woodchuck and ground squirrel 
hepatitis viruses are similar in size and amino acid sequences, and yet 
the duck hepatitis B virus is considerably larger at 262 amino acids and 
shares very little sequence homology. These differences between 
mammalian and avian HBcAgs are more than superficial. The former 
species participates in forming mixed capsids whereas duck HBcAg is 
excluded, implying that the molecular interactions that drive capsid 
assembly are not conserved between the mammalian and the avian 
hepadnaviruses.
The C-terminus of HBcAg encodes for an extremely basic arginine-rich 
segment (often termed the protamine domain), comprising the final 36 
amino acids (amino acid 150 to 185, genotype A) or 34 amino acids 
(amino acid 150 to 183, other genotypes). This region is highly protease- 
sensitive, confers nucleic acid binding capacity and is required for 
encapsidation (Nassal, 1992). The first 149 amino acids of HBcAg form a 
hydrophobic domain that shows an intrinsic resistance to proteolysis 
(Seifer and Standring, 1994): the first approximately 144 amino acids 
constitute a minimal assembly domain that is responsible for directing the
12
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assembly of core proteins into both dimers and capsids (section 4.9) 
(Figure 1.3).
No crystallographic structure has been obtained for HBcAg. Monoclonal 
antibody (MAb) and site-specific protease studies have resulted in a 
model for the structure of HBcAg (Figurel .4) (Seifer and Standring, 1994). 
Only a small area, between amino acids 145 to 153, is susceptible to 
proteases and antibodies in assembled core particles. This protease- 
sensitive region falls between the two functional domains of HBcAg, 
leading to the hypothesis that it acts as a hinge region similar to that seen 
in other multidomain proteins such as immunoglobulins (Davies and 
Metzger, 1983). A hinge would permit the flexibility required in 
conformational changes that occur during core particle assembly and RNA 
packaging.
HBcAg is involved in packaging the viral mRNA and the viral DNA 
polymerase and it assembles into core particles (Discussed in Chapter 1, 
section 4.8). A protein kinase, of probable cellular origin, is also 
packaged.
4.3.3 X gene
The smallest ORF encodes the X  protein, of 154 amino acids, which has a 
molecular mass of 17kD. It shares nucleotide sequences with both the 
polymerase gene and the pre-C region and contains several regulatory 
signals critical to the replicative cycle (discussed in section 4.6). The role 
in the biology and pathology of HBV has yet to be elucidated. It is 
produced during the viral life cycle, as shown by the induction of anti-X 
antibodies during infection (Moriarty et al, 1985, Stemler et al, 1990). 
However, the HBx protein has never been reliably demonstrated in, or 
isolated from infected liver tissue (Henkler and Koshy, 1996). This is 
probably due to the lack of reliable antibodies to HBxAg. Studies that
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Figure 1.4 Model of the hepatitis B virus core protein dimer. Each 
21.5kD monomer subunit is shown with a globular minimal capsid 
assembly domain (barrel) and a protamine-like nucleic acid binding 
domain (arm). The putative protease-sensitive hinge region links these 
two domains (Seifer and Standring, 1995).
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have shown the expression of HBxAg in chronic liver disease utilised 
antibodies that cross-reacted with cellular proteins.
HBxAg does not appear to be required for HBV replication or gene 
expression in vitro (Blum et al, 1992) and there is no gene encoding a 
corresponding protein in the duck hepatitis B virus (DHBV) (Mandart et al,
1994). However, data from deletion studies in the woodchuck hepatitis 
model suggests that an X  minus mutant is not infectious in vivo (Chen et 
al, 1993, Zoulim et al, 1994), indicating that HBxAg is essential for 
replication in vivo. There are reports of various biochemical activities of 
HBxAg , such as protein kinase (Wu et al, 1990), dinucleotide kinase 
(Shaul, 1991) or protease inhibitor (Arii et al, 1992), but they have yet to 
be unequivocally shown to be functional in vivo. It is known that HBxAg 
can activate the transcription of HBV genes, other viral sequences and a 
variety of cellular genes (Kekule et al, 1993, Seto et al. 1988, Cologrove 
et al, 1989). The mechanism of HBxAg transcriptional activation is still a 
contentious point. Currently there are two models: the first is that HBxAg 
activates transcription directly via associations with DNA-binding proteins. 
This model has been supported through experiments artificially targeting 
HBxAg to DNA, mainly through fusion proteins linking HBxAg to various 
DNA-binding domains (Seto et al, 1990, Unger et al, 1990). Qadri et al 
(1995) have reported an interaction between HBxAg and components of 
the promoter complex, as there was an apparent interaction of HBxAg with 
the TATA binding protein. These experiments suggest a general 
mechanism for HBxAg activation.
The second model speculates that HBxAg transactivates by interfering 
with intracellular signal transduction pathways. Considering the range of 
elements e.g. c-jun (Twu et al, 1993), c-fos (Avantaggiati et al, 1993) and 
NFkB (Lucito et al, 1992) that can be activated by HBxAg and its 
predominant cytoplasmic location in transfected cells (Henkler et al,
1995), this is a plausible idea.
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X responsive elements (XRE) for HBxAg have been reported as the 
following; AP-1- and AP-2-binding sequences in SV40 (Seto et al, 1990), 
NFicB-like sequence in human immunodeficiency virus (HlV)-long terminal 
repeat (Siddiqui et al, 1989; Twu et al, 1989). The 26bp XRE enhancer I 
(Faktor et al, 1990) and HBxAg was found to transactivate a certain gene 
through a different XRE in each cell line e.g. AP-2-binding sequence 
responded to HBxAg in CV-1 cells (Seto et al, 1990), but not in HepG2 
cells (Twu et al, 1989). Thus, the efficacy of transactivation of a target 
gene was found to be dependant on the cell line used (Seto et al, 1989). It 
is likely, therefore, that HBxAg has a repertory of interaction partners, 
selects an appropriate one and transactivates a specific set of genes in 
the cell or that HBxAg catalytically modifies a specific set of transcription 
factors. Maguire e t a I (1991) have shown that HBxAg can bind to CREB or 
ATF-2, enabling the latter to tightly bind to a CRE-related sequence in the 
HBV enhancer I. How this relates to the transactivation function of X 
protein is not clear. A direct interaction of HBxAg with other XRE-binding 
proteins, such as NFKB or AP-1, has yet to described.
HBxAg shares amino acid sequence homology with the Kunitz domain of 
the Kunitz-type serine protease inhibitors, and thus, given that this Kunitz- 
like domain has been shown to be requisite to the transactivation function 
of HBxAg there is speculation that HBxAg functions as a serine protease 
inhibitor in hepatic cells (Arii et al, 1992). Serine proteases inhibitors 
inhibit their targets by binding to the active centre of the protease and its 
surroundings. Digestion analysis, using highly purified serine proteases, 
and immunoprecipitation experiments have indicated a direct interaction 
of HBxAg with tryptase TL2, a major serine protease in hepatic cells 
(Takada et al, 1994).
Deletion studies have indicated that there are two regions which are 
essential for the transactivation function of HBxAg: amino acids 28 to 62 
and amino acids 118 to 142. Both these regions overlap with highly
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conserved HBxAg amino acid sequences among hepadnaviruses, at 
amino acids 58 to 84 and amino acids 98 to 140.
A role in carcinogenesis has been implicated as truncated integrated X  
gene sequences have been associated with the development of 
hepatocellular carcinoma (HCC) (Takada and Koike, 1990). HBxAg has 
the ability to transform normal rodent cells (Seifer et al, 1991) and induce 
HCC in transgenic mice (Kim et al, 1991). Despite this basic property of 
HBxAg, no specific integration site has been identified in human HCC 
(Tokino and Matsubra, 1991). Thus, it is likely that its 
transactivation/oncogenic function manifests via protein-protein 
interaction with cellular factor(s). The HBxAg sequences usually found in 
HCC tumours have 3’ deletions, resulting in truncation and fusion with 
cellular sequences. However, they encode functionally active 
transactivator proteins (Schluter et al, 1994), and transcripts containing 
HBxAg sequences have been detected in HCCs (Paterlini et al, 1995, Wei 
etal, 1995)
Disruption of p53 activity (p53 is the suppressor oncogene protein) has 
been closely related to the development of many human cancers (Gerwin 
et al, 1992). In virus-transformed cells it has been shown that p53 
complexes with viral oncoproteins, such as the adenovirus E1B protein 
(Sarnow et al, 1982) or the Epstein-Barr virus-encoded nuclear antigen, 
EBNA-5 (Szekely et al, 1993); such protein-protein interactions inactivate 
p53 functions, e.g. sequence-specific DNA binding and gene 
transactivation. Experiments have shown that HBxAg forms a complex 
with normal p53 protein (Feitelson et al, 1993) and that it can suppress 
p53-mediated transcriptional activation (Wang et al, 1994). Therefore, by 
altering the activity of p53, HBxAg may be involved in the initial process of 
HBV-related hepatocarcinogenesis.
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The size and number of HBxAgs expressed from the ORF in vivo are 
unknown, but the conservation of its three start codons and the results of 
mutational studies suggest that the smaller potential proteins are 
expressed and are transcription activating (Kwee etal, 1992).
4.3.4 Polymerase gene
The polymerase gene overlaps all the other genes and encodes for the 
polymerase protein. Mutational analysis of the polymerase gene and 
studies on the mechanism of genome replication, indicate that most parts 
of the gene are indispensable for the virus. Such studies suggest that 
polymerase has four clearly distinguishable domains (Schlict et al, 1991). 
From the amino to carboxyl terminus these are: terminal protein, which is 
linked to the 5 ! end of the minus strand DNA and serves as a protein 
primer for reverse transcription of the RNA pregenome into (-) strand 
DNA; a spacer region, which can be deleted without loss of enzyme 
activities; DNA polymerase/reverse transcriptase domain and RNaseH 
domain, which digests the RNA if it is present as hybrids of RNA and 
DNA. Unlike the ORF P of retroviridae it has no protease or integrase 
domain but it has a primase domain that is absent in retroviridae.
4.4 Attachment and entry
Virus attachment is one of the crucial steps that determines the host range 
and organ tropisms of viruses. A serious drawback for the study of the 
attachment of HBsAg to cell surface proteins is the lack of susceptible cell 
systems. There are many cell lines that are permissive for HBV replication 
but are not able to be infected by HBV. An example of this is the human 
hepatoblastoma cell line HepG2, which cannot be infected but replicates 
and secretes HBV efficiently after transient or stable introduction of HBV 
DNA. Bchini et al (1990) have claimed to have achieved successful 
infection in this cell line. Gripon et al (1988) have successfully infected 
primary hepatocytes from adult liver when the cells were treated with
17
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polyethylene glycol. Effective systems are available for some of the 
animal hepadnaviruses, e.g. duck hepatitis B virus (DHBV) and WHV. 
Primary hepatocytes from these animals are susceptible to infection by 
their respective viruses. However, the hepatocytes lose this susceptibility 
within several days in culture. The reason for the non-susceptibility of 
long-term hepatocyte cultures is unknown, but it appears to be due to a 
block in attachment and/or virus entry.
The region, amino acids 21 to 47 of pre-S1 has been shown to be 
involved in attachment to the cell surface. The binding can be blocked by 
antibodies to the pre-S1 sequence and competed for, by the peptide 
sequence itself (Neurath et al, 1986), and MAbs to this region can block 
attachment to HepG2 cells and infectivity for primary human hepatocyte 
cultures (Petit et al, 1991 and 1992). However, although amino acids 21 to 
47 may be essential for the infection process, their attachment to the cell 
surface is obviously not sufficient for infectivity, otherwise HepG2 cells 
would be more susceptible to infection by HBV. A human liver protein that 
specifically binds to this region of pre-S1 has yet to be identified (Petit et 
al, 1992; Dash et al, 1992)
It has been shown that middle surface protein binds to monomeric or 
polymerised human serum albumin via its pre-S2 region (Dash et al, 1991; 
Krone et al, 1990), and polymerised human serum albumin binds to 
hepatocytes. Hertogs et al (1993) have identified human liver annexin V 
as a specific binding protein of small HBsAg. The same group (Hertogs et 
al, 1994), in a later study, described the spontaneous development of anti- 
idiotypic antibodies in rabbits immunised with human liver annexin V, 
which were able to compete with annexin V for the binding to small 
HBsAg, thus indicating a ligand-receptor relationship between annexin V 
and HBsAg. In a recent study De Bruin et al (1995) demonstrated the 
specific binding and internalisation of small HBsAg, conjugated to 
colloidal gold particles, to human hepatocytes. The binding was inhibited
18
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by either anti-annexin V  or anti-idiotypic (anti-HBsAg) antibodies, 
indicating a direct role for annexin V  in binding and uptake of HBV 
envelope proteins.
There are two ways in which animal viruses can enter a cell: by fusion of 
the viral envelope with the cell membrane, and thereby causing the 
release the of nucleocapsid into the cytoplasm, or by receptor-mediated 
endocytosis. The mechanism of HBV entry into hepatocytes is still 
unknown.
In DHBV it was originally reported that entry could be blocked by 
substances that inhibit acidification of endosomes, thus implicating a 
receptor-mediated endocytosis mode of entry (Offensperger et al, 1991), 
but later data suggested that low pH was not involved in the entry 
mechanism (Rigg and Schaller, 1992).
4.5 Uncoating and transport of DNA to nucleus
Even less is known about the steps involved in capsid transport and 
genome release. In DHBV, it is known that 24 hours after infection, viral 
DNA is present in the nucleus and has been converted to covalently 
closed circular molecules (Tuttleman et al, 1986) but it is not known if it is 
the core particles or free DNA that is transported to the nucleus.
4.6 Transcription and regulatory elements
Transcription of double-stranded DNA into RNA is a highly regulated 
process that controls the expression of all genes in a timely and 
structurally ordered manner. All genomes, therefore, contain not only 
genes that encode protein sequences, but also regulatory elements that 
bind cellular or viral proteins which in turn act as positive or negative 
transcription factors.
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There are two types of elements that contribute to transcription.
1. Promoters. These are necessary for the binding of essential 
transcription factors, bringing the RNA polymerase into a position where it 
begins to transcribe from one DNA strand at a defined site.
2. Enhancers. These are segments of DNA that enhance transcription 
initiation at a given promoter, but are not required to be at a defined 
position next to the promoter or even in the same orientation as the 
promoter.
Promoters are, therefore, clearly a defined part of a gene, whereas 
enhancers may act on the expression of several genes. To date, four 
promoters and two enhancers have been described for HBV (Siddiqui, 
1991, Schaller and Fischer, 1991)
Promoters: The promoters direct initiation of RNA synthesis upstream of 
the HBc/e gene, the large HBs gene, the middle and small HBs genes and 
the HBx gene (Figure 1.2). Only the S promoter 1(Sp1), which directs the 
large HBs gene, has a typical TATA box, and only the mRNA encoding 
large HBs protein has a sharply defined 5’ end. TATA-less promoters 
usually have multiple initiation sites, as is the case for the mRNAs of 
HBc/e, middle and small HBs and HBx.
There are four classes of HBV transcripts. These are; the pre-C/C mRNAs 
(3.5kb), the pre-S1/S2 mRNAs (2.4 and 2.1 kb), the S mRNAs (2.1 kb) and 
the X mRNAs (0.9kb). The transcripts are initiated sequentially on the 
circular DNA genome.
Although the two 3.5kb transcripts - the pregenomic and the pre-C - are 
very similar, both terminating at the same polyadenylation site while the 
pre-C transcript initiates approximately 30 nucleotides upstream of the 
start site of the pregenomic RNA, they have very different functions. Pre-C 
RNA encodes the pre-C protein, which is subsequently processed into
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HBeAg. The pregenomic RNA has two roles: it can code for HBcAg and 
polymerase protein, and it can be packaged into viral capsids with the 
polymerase protein, and serve as the template for replication of the viral 
genome. The basal core promoter (BCP) precisely directs initiation of both 
the pre-C and pregenomic RNAs (Yuh et al, 1992). Instead of the 
standard TATA element, a stretch of 15 nucleotides containing four-TA 
sequences, functions as both an initiator and a TATA element for the pre- 
C and pregenomic RNAs (Chen et al, 1995).
All the transcripts are capped, unspliced and end after a common 
polyadenylation signal. There are two polyadenylation sites present on 
the transcripts but the first is ignored. This selective poly (A)-site usage is 
thought to be due to a non-perfect poly (A)-signal consensus sequence, 
activating upstream elements, and a minimal distance from the promoter 
is also important (Cherrington et al, 1992).
Enhancers: Two regions of the HBV genome act as enhancers; enhancer 
I (enh I) and enhancer II  (enh II) and can enhance the activity of all the 
HBV promoters. Enh I has been mapped to nucleotide positions 970 to 
1250, between the surface and X ORFs. It has been suggested that this 
element is responsible for liver-specific gene expression since 
transcriptional activation by this enhancer is greater in some cultured 
hepatoma cells than in nonhepatic cells (Shaul et al, 1985).
Enh II lies immediately upstream from the coding region of the core ORF, 
at nucleotide positions 1616 to 1785. The activity of enh II  is highly liver- 
specific, functioning only in highly differentiated human hepatoma cell 
lines. In addition, enh I I  activity varies in different hepatoma cell lines, 
implying that the differentiation state of the cell line used regulates the 
enhancer.
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4.7 Translation
The pregenome serves as template for both core and polymerase 
translation. HBcAg is synthesised from the first cistron in an unprocessed 
form and polymerase from the second. Theoretically, this should lead to 
inefficient translation of polymerase and, unlike retroviruses, 
hepadnaviruses do not produce core and polymerase as a fusion protein. 
Although the two genes overlap, polymerase is produced separately from 
core (Schlict et al, 1989)
4.8 Encapsidation and replication
HBV utilises a novel replication strategy for a DNA virus. Three 
components are required: the RNA pregenome, the polymerase protein 
and the core protein. Biosynthesis of these proteins is closely coupled to 
replication since the pregenome serves as their mRNA .
Unlike the retroviruses, HBV does not require integration into the host 
genome, and thus polymerase does not have an integrase domain. 
Instead, it harbours the terminal protein domain which is intimately 
involved in replication (Radziwill et al, 1990). While other reverse 
transcriptases require proteolytic cleavages for maturation into active 
enzymes, there is no evidence of such processing in polymerase 
(Bartenschlager and Schaller, 1992).
Once sufficient quantities of HBcAg, polymerase and the RNA pregenome 
have accumulated in the cytoplasm, core particles are formed (discussed 
in 4.10), thus providing the necessary machinery for replication. 
Hepadnaviruses have developed a unique strategy for the encapsidation 
of the correct RNA and polymerase from the pool of cellular nucleic acids 
and proteins available. Polymerase itself is directly involved in 
incorporation of the correct pregenomic RNA into nucleocapsids: this
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requires none of its enzymatic properties but does require the entire 
primary sequence. Furthermore, it preferentially acts on its own mRNA, 
probably as it is being synthesised (Bartenschlager et al, 1990 and Hirsch 
e ta !, 1990).
A region of 85 nucleotides near the 5 ’ end of the pregenomic RNA (this is 
within the pre-C/C region) is the c/s-acting element for encapsidation, 
termed epsilon (e); 8 is essential for packaging and replication of HBV 
(Junker-Niepmann et al, 1990). A similar region has been identified in 
DHBV but deletion analyses have shown that additional sequences close 
to the centre of the pregenomic RNA are also required for RNA 
encapsidation (Calvert and Summers, 1994). The encapsidation signal 
contains several nested inverted repeats with the capacity to form a 
bulged stem-loop structure (Figure 1.5) (Knaus and Nassal, 1993, Pollack 
and Ganem, 1993). Studies by Tong et al (1992 and 1993) have shown 
that both sequence and base-pairing within s are important. Of the 
possible eight stop codons that can arise in s by a single nucleotide 
change, only A i896 (codon 28) has been found in patients. Tong et al 
(1992) constructed the other seven and tested their replication capacities. 
Two stop codons (at codon 23 and 26) failed to replicate and the 
remaining five (12,13,14,18 and 21) did not replicate as competently as 
A1896 The replication competence of the three stop codons (12, 13 and 
14) in stem I suggests that this region of s can tolerate small sequence 
changes. This is also true of the bulge area, as the mutated codon 18 was 
still replication competent. Flowever, mutations occurring in the loop area 
(codon 23) and stem II  (codons 21 and 26) had a greater effect on 
replication. When codons 23 and 26 were mutated, no replication was 
evident and although replication did occur when codon 21 was mutated, 
the efficiency was very much decreased when compared to the other 
mutants. Therefore, it is evident that disruptions to the sequence within 
this region can interfere with encapsidation.
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uCodon 15
5 '- A U C U
A — U
U ::: G 1896
c — G
c — G
U ::: G 1899
G — C
U — A 1901
A — U
c — G
U ::: G
u — A
G — C
u — A
A — U
U
G A C
Codon 28
Figure 1.5 Predicted secondary structure of the hepatitis B virus 
encapsidation signal. The start codon (AUG) of HBcAg is highlighted in 
bold and boxed. The positions of codons 15 and 28, of pre-C, are 
indicated (kindly supplied by D. Williams).
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Mutational analyses suggest that, in addition to the overall structure, the 
sequence of the loop and the first two nucleotides in the bulge are 
important for productive interaction with polymerase (Reiger and Nassal,
1995). Polymerase binds directly to s. The other four nucleotides, when 
mutated, do not significantly influence encapsidation (Laskus et al, 1994; 
Lok et al, 1994) but reverse transcription is affected (Knaus and Nassal 
1993; Fallows and Goff, 1995)
A model for HBV replication is given in Figure 1.6 (Nassal and Schaller,
1996) The classical model assumed (-) DNA synthesis was a continuous 
process starting de novo from within the 3 ’-proximal direct repeat (3’- 
DR 1)  proceeding continuously to the 5’-end of the RNA template (Seeger 
and Maragos, 1991), where immediately on translation from the full length 
mRNA acting as the pregenome, polymerase binds to 8 on the same RNA. 
The revised model proposes a discontinuous mechanism whereby a short 
DNA primer, covalently linked to polymerase, is translocated to DR1*. This 
model is similar to the replication mechanism observed for retroviruses. 
However, in HBV it is 8, rather than a host-derived tRNA, that positions 
the reverse transcriptase over the origin of replication. Owing to the 
terminal redundancy, DR1 and 8 are present twice on the pregenome. 
Reiger and Nassal (1996) have demonstrated that replication origin 
function is confined to the 5 -8  while primer translocation occurs only to 
the 3-D R 1*. The authors hypothesise that, in vivo, the two ends of the 
pregenome are held spatially close by some kind of circularisation 
mechanism. The molecular basis for this spatial arrangement is still 
unclear.
Binding of polymerase to s suppresses core translation, deprives the RNA 
of ribosomes and triggers the addition of HBcAg dimers, thus stabilising 
the complex. Further HBcAg dimers are attracted to the RNA via their 
nucleic acid binding domains, thus completing the capsid shell. This
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Classical replication model
e
(-)-DNA
iMilJ 
DR2 DR1*
Revised replication model
DR2 DR1*
( A )n  3 '
translocation
(A)n 3‘
Figure 1.6 Classical and revised models for initiation of reverse 
transcription in hepatitis B virus. The classical model assumed (-) DNA 
synthesis to be a continuous process starting within the 3’-DR1*. The 
revised model proposes that protein bound to 8 copies part of the s 
bulge and translocates to the 3 ’-D R 1* and the primer extends from 
there (Nassal and Schaller, 1996).
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mechanism ensures the efficient co-encapsidation of the pregenome and 
polymerase, and prevents indiscriminate reverse transcription of cellular 
RNAs by polymerase while also explaining the low number (probably one) 
of polymerase molecules per particle (Bartenschlager and Schaller, 1992).
The next step in the process is the conversion of the pregenome into the 
partially double-stranded, circular DNA genome (Summers and Mason, 
1982). Polymerase binds to a recognition signal on the RNA pregenome 
between DR2 and DR1, priming DNA synthesis via its terminal protein, 
domain and pulls the RNA through its active centre, looping out the newly 
synthesised minus (-) strand DNA. Concurrently, the RNaseH activity of 
polymerase degrades the RNA template to the last 15 to 18 nucleotides 
(Loeb et al, 1991). This short oligoribonucleotide serves as a primer for 
the second (+) DNA strand (Lien et al, 1986); it is transferred to DR2 at 
the 3 ’ end of (-) strand DNA, via their matching 11 nucleotide sequence, 
thus circularising the genome. Elongation from this point leads to the 
characteristic partially double-stranded, circular HBV genome (Figure 
1.7).
4.9 Assembly and release
Though very little is understood about the molecular interactions that 
underlie the various steps of virion assembly, it is almost certain that 
specific core amino acids are closely involved in drawing together the viral 
polymerase and RNA pregenome into the nucleocapsid, while different 
residues are probably involved in envelopment of the finished core 
particle by HBsAg.
The ability to assemble into particles resides in the first 144 amino acids 
of HBcAg (Birnbaum and Nassal, 1990; Nassal, 1992) (Figure 1.3). 
Deletion beyond residue 139 completely abrogates capsid assembly. As 
detailed earlier, although a considerable amount of work has been carried
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Figure 1.7 Dual role of P-e interaction in the hepatitis B virus 
replication cycle. The binding of polymerase (P) protein, translated 
from the pregenome, to 5’-s triggers core protein dimers to initiate 
capsid assembly, and also initiates reverse transcription (Nassal and 
Schaller, 1996).
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out on the effect of carboxy (C)-terminal deletions, considerably less has 
been investigated on the effect of amino (N)-terminal deletions. Chang et 
al (1994) have shown that HBcAgs lacking the first 28 or 37 amino acids 
are incapable of participating in HBcAg oligomerization. Studies involving 
the introduction of foreign sequences into the HBcAg (usually for 
engineering highly immunogenic, multivalent capsids for vaccine 
purposes), have shown that there are three regions not essential for 
particle formation: the immediate N-terminal, around amino acid 80 and at 
the C-terminus at either amino acid 144 or 156 (Schodel et al, 1992; 
Clarke etal, 1990; Francis et al, 1990).
Although the protamine region is dispensable for capsid assembly, this 
does not exclude it from playing a role in the assembly process. There are 
17 arginine residues within the 36 amino acids of the protamine region 
and they are clustered into four repeat sequences (amino acids 150 to 
156, 157 to 163, 164 to 171 and 172 to 179). Studies involving deletions 
of these four regions have shown that they are closely involved in the 
interactions between HBcAg and RNA and DNA (Hatton et al, 1992), with 
the arginine residues of repeat I primarily responsible for RNA binding 
(Hatton et al, 1992). The motif SPRR is commonly found in DNA binding 
proteins and is found in repeats II, I I I  and IV. Replication takes place in 
the capsid, and as the carboxy-terminal has been shown to be required for 
HBV replication (Nassal, 1992; Beames and Lanford, 1993), a role for the 
DNA binding motifs in facilitating replication can be envisaged.
It appears that a critical concentration of HBcAg is necessary for 
assembly. First of all, dimers of HBcAg are formed (Zhou and Standring,
1992), which then assemble at 0.8pM concentration (Seifer et al, 1993) to 
isometric particles of T3 symmetry i.e. 180 HBc subunits form one particle 
(Birnbaum, 1990). This process appears to be facilitated by RNA (Seifer 
et al, 1993), as ablation of HBcAg RNA binding motifs drastically 
increases the initial dimer concentration required for capsid formation.
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Antibody binding studies have shown that the protamine region faces the 
interior of the core particle, supporting a role in the binding of RNA and 
drawing it into the nascent capsid (Seifer and Standring, 1994).
HBcAg has four cysteine residues at amino acids 48, 61, 107 and 185 
(Figure 1.3); mutational analysis has shown that these residues serve to 
stabilise the core particles via disulphide bonds as capsids formed from 
cysteine-minus HBcAg, (under oxidising conditions), are far less stable 
than their cysteine containing counterparts (Zhou and Standring, 1992), 
with homologous Cys 61-Cys 61 and Cys 185-Cys 185 the key disulphide 
bonds stabilising the assembled HBcAg (Nassal, 1992; Zhou and 
Standring, 1992). Formation of disulphide bonds between HBcAgs are not 
required for capsid assembly (Zhou and Standring, 1992).
5. Immune response to HBV, focusing on HBcAg
The immune mechanisms responsible for viral clearance and liver cell 
damage in HBV infection are not well understood. HBV has not been 
shown to be cytopathic, and the histopathology and clinical symptoms 
observed in HBV infection are believed to be the result of elimination of 
infected hepatocytes by the immune response.
It is generally understood that HBV is completely cleared by the immune 
system during acute viral hepatitis B infection. Rehermann et al (1996) 
have recently demonstrated that traces of HBV can still be detected in the 
blood several years (even decades) after clinical recovery, thus 
maintaining the CTL response and apparently creating a negative 
feedback loop that keeps the virus under control.
Despite HBcAg and HBeAg sharing a large proportion of their amino acid 
sequence - approximately 149 amino acids - they are immunologically 
quite different. HBcAg behaves in both a T-cell dependent and
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independent manner, whereas, HBeAg only acts in a T-cell dependent 
manner and is a relatively poor B-cell immunogen (Bichko et al, 1993).
5.1 Humoral immune responses
There is a protective immune response directed mainly against the 
surface proteins of HBV, with the a determinant (amino acids 124 to 137) 
exhibiting the major antigenic effect. Early studies showed that anti-HBc 
and anti-HBe do not act as virus neutralising antibodies. When 
monoclonal antibodies to these proteins are injected into chimpanzees 
they do not prevent infection, whereas infection is prevented with 
monoclonal antibody to HBsAg (Iwarson et al, 1985); similarly, babies 
born to mothers with high levels of anti-HBc have these antibodies 
passively transferred, yet still develop chronic infection. It is surprising, 
therefore, that there is documented evidence that immunisation of 
chimpanzees with HBcAg, either purified from liver or produced from 
bacteria, can lead to protection (in a population of animals). This is 
probably due to HBcAg acting as a T-cell immunogen, as HBcAg 
efficiently induces HBcAg-specific Thelper (Th) cells in mice. Anti-HBe 
also appears to be protective, suggesting a role for HBc/eAg in protecting 
against HBV re-infection.
Hepatocytes, infected with HBV, have been shown to express 
nucleocapsid antigens on the cell surface which is essential for antibody 
directed cellular cytotoxicity or complement mediated lysis by anti-HBc or 
anti-HBe antibodies (Schlict and Schaller, 1989). An increase in 
catabolism of complement factors C1q and C3 have also been observed 
(Potter et al, 1989; Thomas etal, 1979).
Reports have indicated that X induces antibody responses (Moriarty et al, 
1985; Stemler et al, 1990). Antibodies to polymerase have been detected 
in patients with acute and chronic disease (Weimer et al, 1989).
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By using recombinant HBcAg and HBeAg as well as denatured HBcAg, 
MAbs recognising HBcAg were obtained and immunodominant regions 
identified. The major B-cell epitope in HBcAg is located between amino 
acids 73 and 89 (Colucci et al, 1988; Salfeld et al, 1989; Sallberg et al, 
1991). This epitope is believed to be part of a larger conformational 
epitope (Ferns and Tedder, 1986). The peptide used by Colucci et al 
(1988), although it encompassed this epitope, had a much reduced 
binding affinity compared with that of HBcAg particles indicating that it is 
part of a discontinuous or conformational epitope. Colucci et al (1988) 
also described an epitope spanning amino acids 107 to 118. Two B-cell 
epitopes have been described in HBeAg: a linear epitope, e1, and a 
probable discontinuous epitope, e2, located between amino acids 130 and 
138 (Salfeld et al, 1989). Bichko et al (1993) analysed the humoral 
immune response to denatured HBcAg and identified a highly antigenic 
region between amino acids 134 and 140, a similar location to the e2 
epitope described by Salfeld et at (1989). A second region, from amino 
acids 134 to 154, was also antigenic.
Machida et al (1989) characterised an epitope in the arginine-rich 
carboxyl-terminus of HBcAg, between amino acids 150 and 159. It is of 
interest that variants often appear in this region (Chapter 1, section 6.2, 
Figure 1.8)
Pushko et a! (1994) investigated the exposed and masked regions of 
HBcAg after assembly of the nucleocapsid. Two areas were found to be 
exposed: between amino acids 78 to 83 and 127 to 133. Despite both 
regions being exposed on the core particle, only the region between 
amino acids 78 and 83 is within the immunodominant region recognised 
by anti-HBc, whereas anti-HBe recognises both these areas: amino acids 
76 to 89 and 127 to 133 (Salfeld et al, 1989; Sallberg et al, 1991 and 
1993)
29
CD<
c
£
0
Q .
o1
CD
O )<
<1)
CD
X
O )
S
CD
X
c
' 0
0
L_
Q_
O1
0
"O
0 
H — *
0
oc
ZD
E
o
© o_ =3
4 -  " O
c  O  
O Q_ 
TO O
S i
2  g
O)<©QQ
X
co0O
3"DO
CD
3<
00
0x:
E
o
0
0
_c
CD
"DC0
0"O
Q .
0
CL
03
CD)
0
0
0
o
o
CD
G)
00
CD
3
<
Oi
0
:
0
0C0
a.:
0
o
o1
0
0
-C
c
o
0
c
00
0
l _
CL
0
o
0
E
0szo
CO
oo
0
i _3D)
0
■o
0
>
0
0
O
c
03
O '
00
_Q
3
0
x:
o
c
0
0
CL
o1
0
L_
CL
0
0O
3
■oO
CL
CD
3<
"Oc
o
o
0
0
0
H
B
eA
g.
 S
ub
st
itu
tio
n 
of 
G 
to 
A 
at 
nu
cl
eo
tid
e 
po
si
tio
n 
18
96
 
in
tro
du
ce
s 
a 
sto
p 
co
do
n 
wh
ich
 
su
bs
eq
ue
nt
ly
 
te
rm
in
at
es
 
pr
od
uc
tio
n 
of 
H
B
eA
g.
 
Sh
ad
ed
 
ar
ea
 
re
pr
es
en
ts
 
the
 
si
gn
al
 p
ep
tid
e
Chapter 1
5.2 T-cell responses
5.2.1 Cytotoxic T lymphocytes (CTL)
The CTL response in acute self-limiting hepatitis is generally vigorous and 
multispecfic (Penna et al, 1991). Ferrari et al (1991) showed that the 
major CTL response was to the products of the pre-C/C ORF, thus 
indicating that the immune response to HBcAg/HBeAg is an important 
contributory factor to viral clearance and liver cell injury in acute hepatitis 
(Penna et al, 1991; Bertoletti et al, 1991; Milich et al, 1991). HBcAg- 
specific responses are greater than HBsAg-specific responses and 
increase during active disease (Tsai et al, 1992; Vento et al, 1987). 
Rehermann et al (1995) showed that a CTL response against multiple 
epitopes within polymerase is also present in acute viral hepatitis. 
Usually, in chronic HBV infection, the CTL response is not detectable. 
When it is detectable, however, it is more highly focused and weaker 
compared to that observed in acute HBV infection (Penna et al, 1991, 
Nayersina et al, 1993). There is often a CTL response at low precursor 
frequency at the site of inflammation (Barnaba et al, 1989). The reason for 
this difference is not clearly understood but it is believed to represent a 
crucial determinant of the final outcome of infection with HBV, and 
indicates that CTL play a critical role in clearing HBV infection; thus, 
failure to recognise or respond to CTL epitopes may play a role in viral 
persistence.
Bertoletti et al (1991) identified an HLA-A2-restricted epitope in HBcAg, 
overlapping with HBeAg, spanning the residues amino acids 11 to 27 in 
patients with acute hepatitis. Again, the response from chronic hepatitis 
patients was significantly weaker or absent. The optimal sequence was 
later identified as being amino acids 18 to 27 (Bertoletti et al, 1991). 
Missale et al (1993) have described HLA-A2 and HLA-Aw68-restricted 
CTL epitopes within HBcAg, spanning amino acids 141 to 151, which also 
contain the nuclear localisation and encapsidation signals.
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Rehermann et al (1995) described six HLA-A2-restricted CTL epitopes 
within the highly conserved reverse transcriptase and RNAseH domains of 
the polymerase protein; they showed that the CTL response to 
polymerase is polyclonal, multispecific and mediated by CD8+ T cells in 
patients with acute hepatitis, but that there is no detectable response in 
patients with chronic infection. DNA sequence analysis of the viruses, in 
patients who did not respond to peptide stimulation, indicated that CTL 
nonresponsiveness was not due to infection by viral variants that differed 
in sequence from the synthetic peptides. CTLs specific for one of the 
epitopes, were unable to recognise several naturally occurring viral 
variants, except at high peptide concentration, underlining the HBV 
subtype specificity of this response. Furthermore, CTL responses against 
polymerase, core and surface epitopes were detectable for more than a 
year after complete recovery and seroconversion, reflecting either the 
persistence of trace amounts of virus or the presence of long-lived 
memory CTL in the absence of viral antigen.
Since viral persistence is not due to escape from CTL recognition under 
these conditions, their data suggest that HBV may retreat into 
immunologically privileged sites from which it can seed the circulation and 
reach CTL-inaccessible tissues, thereby maintaining the CTL response in 
apparently cured individuals and, perhaps, prolonging the liver disease in 
patients with chronic hepatitis.
HBV-specific CTLs can persist in the blood for several decades after 
clinical and serological recovery from acute hepatitis B infection. This 
indicates that there is continuous priming of the CTL response by 
persistent virus or viral antigens long after apparent clinical recovery 
(Rehermann et al, 1996). Memory CTL responses (response in the 
absence of antigenic stimulation) apparently survive for much longer 
periods than was originally thought (Rehermann et al, 1996). Since an 
absence of CTL correlates with high viral load in patients with chronic
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hepatitis B, the active maintenance of the CTL response may play a role 
in controlling HBV replication.
Spontaneous clearance of HBV-DNA and HBeAg seroconversion in 
chronic hepatitis is generally preceded by an exacerbation of liver disease 
activity and an increase in CD4+ proliferative T-cell responses is observed 
(Tsai et al, 1992; Jung et al, 1995), indicating that latent immune- 
mediated clearance mechanisms can become spontaneously activated in 
some individuals. Flares are also seen prior to HBsAg clearance by 
interferon alpha therapy (Alexander et al, 1987). These discoveries 
support the idea that HBV-specific CTL are present in chronically infected 
patients but are not effective enough to clear HBV, and that, in some 
individuals, this defect is reversible. Rehermann et al (1996) investigated 
this possibility; and their results indicate that chronically infected patients 
who have a spontaneous or interferon-induced remission, do develop a 
CTL response and that this response is similar in strength and specificity 
to that observed in acute hepatitis. Thus, specific immunotherapeutic 
enhancement of the CTL response in chronically infected individuals 
could lead to viral clearance and resolution of disease.
5.2.2 T helper lymphocytes
Depending on their lymphokine profiles, Th lymphocytes can be divided 
into at least three different subsets (Mossman et al, 1986): the Th1 cells 
secrete gamma interferon (IFN-y), interleukin-2 (IL-2) and tumour necrosis 
factor (TNF) and promote cell-mediated effector responses; the Th2 cells 
produce IL-4, IL-5, IL-6 and IL-10, which influence B-cell development, 
enhancing humoral responses; and ThO cells which release all of these 
cytokines. A subset of CD4+ T cells have cytotoxic functions in vitro 
(Jacobson et al, 1984; Erb et al, 1990).
Studies in mice have shown that the Th response to HBcAg and HBeAg 
supports the production of anti-HBs and anti-HBe which are virus
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neutralising (Milich et al, 1987), as well as the generation of HBc/HBeAg 
CTL.
Barnaba et al (1994) investigated T-cells that infiltrate the liver in chronic 
hepatitis. They found a population of CD4+ cells that had cytotoxic 
properties when freshly isolated from tissue biopsy specimens. They had 
a Th1 cytokine profile and expressed CD56, also expressed on natural 
killer (NK) cells. These cells were not found in the peripheral blood of the 
same patients or of control subjects. These findings suggest that 
compartmentalisation of this Th subset in the liver may be an important 
pathogenic step, contributing to the lesions that occur during the active 
phase of hepatitis infection.
Using overlapping peptides, Ferrari et al (1991) studied the proliferative 
response of peripheral blood mononuclear cells from patients with acute 
hepatitis, and identified three peptides to which the majority of their 
patients reacted; amino acids 1 to 20, amino acids 50 to 69, amino acids 
117 to 131, indicating non-HLA dependent binding. Diepolder et al (1996) 
- also using overlapping peptides - identified Th responses specific for 
amino acids 50 to 69, 81 to 105, 117 to 131, and 141 to 165, thus 
indicating that there are at least two dominant Th cell epitopes, with both 
areas being within HBcAg and HBeAg, and that the HBc-specific Th 
response is polyclonal within an individual and directed against multiple 
epitopes. In acute hepatitis, T-cell activation was closely associated with 
elimination of HBeAg and HBsAg from the serum (Jung et al, 1995). 
Recovery from chronic hepatitis is accompanied by increased T-cell 
responses to HBcAg and HBeAg (Tsai et al, 1992).
Pre-S2-specific T cells have been implicated in the suppression of anti- 
HBs, perhaps mediating the induction of chronic hepatitis. They lyse 
HBsAg specific B cells that present HBsAg peptides in the context of the
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major histocompatibility complex (MHC) class I pathway (Barnaba et al,
1990).
The X protein has been shown to be immunogenic at the Th cell level 
(Jung et al, 1991). Several regions were identified: amino acids 11 to 45, 
61 to 105, and 111 to 135. The significance of X-specific Th cells is not 
yet understood.
5.3 Interferon
The role of interferons in HBV clearance is unclear, although adding 
interferon to transfected cell cultures leads to reduced HBV-DNA  
production, implying a direct action. Interferon, in the acute infection, is 
produced in large amounts. Interferon increases expression of hepatocyte 
HLA antigens, assisting in the resolution of acute HBV infection. In those 
who develop chronic infection, interferon production is impaired and an 
appropriate immune response does not occur. If interferon was the sole 
factor in determining the development of chronic HBV infection, then all 
patients with chronic infection would respond equally well to therapeutic 
doses. This is not the case, however, and thus other factors must be 
involved. Interferon treatment causes a sustained loss of virus replication 
in only a proportion (approximately 40% ) of HBeAg patients with non­
cirrhotic chronic HBV infection.
5.4 Tolerance
Lymphocyte activation and tolerance are two possible outcomes of 
lymphocyte recognition of antigens. Antigens that generate immune 
responses are termed immunogens whereas those that induce tolerance 
are called tolerogens. Normally, all self-antigens are tolerogens but 
foreign antigens, depending on the dose, can act as tolerogens (Sarzotti 
et al, 1996). It was previously believed that tolerance is immunologically 
specific and is therefore due to the deletion or the functional inactivation
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(or anergy) of antigen-specific T  and/or B lymphocytes and hence inhibits 
lymphocyte activation by subsequent exposure to immunogenic forms of 
the same antigen. However, a study by Sarzotti et al (1996) on the 
induction of protective CTL responses in newborn mice by a murine 
leukaemia virus, indicated that immunological nonresponsiveness was not 
due to clonal deletion of CTL but induction of a nonprotective type 2 
response. The understanding that immature or developing lymphocytes 
are more susceptible to tolerance induction than mature or functionally 
competent cells (Billingham et al, 1953) has recently been challenged. 
Several groups have apparently shown that the neonatal immune system 
(in mice) can be primed to recognise and attack foreign antigens if the 
antigen is introduced to the T  cells under the right conditions (Sarzotti et 
al, 1996; Ridge et al, 1996; Forsthuber et al, 1996). The maintenance of 
tolerance requires the continuous availability of tolerogenic antigens to 
interact with immature lymphocytes as they develop from precursors. 
However, tolerance to foreign antigens can be induced even in mature 
lymphocytes when these cells are exposed to antigens under conditions 
that are inadequate for activation.
Murine experiments indicate that a Th cell-specific tolerance against 
HBcAg/HBeAg may be the basic immunological defect in neonates born to 
HBeAg-positive carrier mothers (Milich et al, 1990). The atypical 
immunological responses observed in neonates probably results from in 
utero exposure to HBeAg. HBeAg can cross the placenta (Lee et al, 1986) 
thereby gaining access to the thymus, inducing T-cell tolerance by 
deletion of the immature HLA class II-restricted HBeAg/HBcAg-specific Th 
cells. Tolerance of T  lymphocytes is a particularly potent way for 
maintaining long-lived nonresponsiveness, as Th cells are critical control 
elements for all cellular and humoral immune responses.
To substantiate this in the human infection, Hsu et al (1992) investigated 
the cellular immunity to HBcAg in HBV carrier children and neonates born
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to hepatitis B virus carrier mothers. Results showed a significant 
proliferative response of PBMCs to HBcAg in children with raised ALTs 
but not in those who were HBeAg-positive with normal ALTs.
T-cell anergy has also been proposed as a mechanism for the 
maintenance of self-tolerance and regulation of the immune response 
(Rocha et al, 1995). Diepolder et al (1996) investigated this possibility in 
HBV infection and showed that Th1 clones, but not ThO, isolated from a 
patient with acute hepatitis, could be anergised in vitro by stimulation with 
specific peptides.
For tolerance to be maintained, HBeAg must be continually present, as 
removal of the tolerogen would encourage the emergence of HBc/HBe- 
specific thymocytes. Consequently, although an infant may be exposed in 
utero, if they are not infected at birth then the longer the time between 
exposure to HBeAg and infection with HBV, the less chance there is of 
developing tolerance and therefore chronic hepatitis. The frequent loss of 
tolerance in young adult, chronic HBV carriers may be the result of a 
regressing thymus which no longer deletes HBeAg/HBcAg-specific T- 
cells.
It has been shown in the mouse model that the degree of T-cell tolerance 
to HBeAg depends on the MHC background of the mouse (Milich et al,
1991). Extrapolation of this finding to the human response may explain the 
different rates of spontaneous HBeAg seroconversion observed in chronic 
HBV carriers.
The infecting virus may also have a role in the development of tolerance 
given that perinatal transmission experiments in woodchucks show that 
the majority (70%) of animals infected with the HBeAg producing virus 
developed chronic infection, while woodchucks infected with the A 1896 pre-
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C mutant developed self-limited infection (Chen et al, 1992). A study by 
Raimondo et al (1993) confirmed these results in children.
Brunetto et al (1991) noted that loss of immunotolerance and 
seroconversion to anti-HBe was often associated with the appearance of 
an HBeAg-minus virus. Tarazawa et al (1991) highlighted two cases of 
fulminant hepatitis infection that was the outcome of babies born to anti- 
HBe-positive mothers who had mixed populations of the HBeAg producing 
virus and a HBeAg-negative mutant.
6. Genetic variability
Comparative sequence analysis of HBV DNA from a single chronic carrier 
has shown that the HBV core gene has a substitution rate of 2.2 x 10‘5 
/nucleotide/year. This figure is approximately 100-fold higher than that for 
herpesviruses, but 10-fold lower than for retroviruses (Okamoto et al, 
1987) HBV, like other viruses with high mutation rates, can theoretically 
exploit variability as a strategy to evade the immune system within an 
infected host. However, due to its compact genetic organisation one would 
assume only a few of the mutations that arise during replication are 
admissible to the pool of viruses for selection. Despite this, patients with 
chronic and fulminant hepatitis have shown great diversity in the viruses 
cocirculating, with some regions of the genome being poorly conserved 
between different isolates (Kaneko et al, 1989).
6.1 Pre-C
The observation that some patients in the Mediterranean and the Far East 
had detectable HBV DNA in their serum yet were negative for HBeAg 
(Bonino et al, 1981, Lok et al, 1984), led to the discovery of a variant of 
HBV that was unable to produce HBeAg (Carman et al, 1989, Brunetto et 
al, 1989a). A single base substitution, of a guanine (G) to an adenonine
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(A), was found to occur at nucleotide 1896 (Ai896'. codon 28 of the pre-C 
region), introducing a translational stop codon (Figure 1.9).
Changes in the pre-C region can theoretically lead to ten potential stop 
codon mutants. A i896 is by far the most common. The area, from 
nucleotide positions 1896 to 1899, is a likely hotspot for reverse 
transcription errors due to the four guanosine residues found together 
here. G to A mutations at nucleotides 1899 (Carman et al, 1989; Brunetto 
et al, 1989a; Fiordalisi et al, 1990) and 1898 (Carman et al, 1992) have 
been described but they do not affect translation of HBeAg. Other 
mutations have been found including loss of the pre-C initiation codon, 
(Tong et al, 1990) a G to A at nucleotide 1897 which also introduces a 
stop codon (Protzer et al, 1996) and nucleotide insertions and deletions 
resulting in frameshifts (Okamoto et al, 1990).
As this area is overlapped by 8, the 3’ end of HBx and DR2, the absence 
of many potential stop codons in nature could result from reduced virus 
viability. Seven of these mutants have been constructed and tested for 
replication capacity (Tong et al, 1992). Five were able to replicate but at 
levels much lower than that of the prevalent stop codon mutant (A189e) and 
the other two were completely defective in replication.
There has been some evidence that the genotype of HBV may influence 
the rate of occurrence of pre-C mutants. Li et al (1993) showed that 
genotype A was rarely A 1896- This could be explained by detrimental base- 
pairing in 8, whereas those with genotype D frequently selected A 1896 
(Rodriguez-Frias et al, 1995). The distribution of pre-C variants can 
probably be explained by their effects on 8.
It is clear that pre-C variants can be selected at or after seroconversion to 
anti-HBe, both in acute (Carman et al, 1991a) and chronic (Okamoto et al,
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1990) infection, and during interferon therapy (Gunther et al, 1992; 
Fattovich etal, 1995).
Pre-C variants of HBV have not been shown unequivocally to be related 
causally with disease severity. For example, Liang et al (1991) and 
Kosaka et al (1991) have shown that patients with fulminant hepatitis and 
their infective anti-HBe-positive contacts are infected with an almost 
identical HBV isolate containing A i896) yet others have shown either that 
HBeAg positive cases are infected with HBeAg producing strains (Carman 
et al, 1991b) or even that the association in anti-HBe-positive patients is 
tenuous (Laskus et al, 1993). Similarly, pre-C mutants are found in 
chronic carriers who progress to severe hepatitis or have the infection 
resolve after seroconversion to anti-HBe (Okamoto et al, 1990; Tur-Kaspa 
et al, 1992). However, Lindh et al (1996), who examined liver damage 
histologically, found no association of A 1896 with severe liver damage. On 
the contrary, HBcAg-negative patients with Ai896 had less inflammation 
and fibrosis than those with G i896. This suggests a role for HBcAg in the 
necroinflammatory process, as withdrawal of HBcAg correlates with less 
liver damage. Transfection studies have failed to show differences in 
replication or encapsidation between strains with and without A1898 
(Hasegawa etal, 1994).
Previously, in hepatomas, the cysteine residue at codon 23 in pre-C has 
been documented to be highly variable (Clementi et al, 1993, Manzin et 
al, 1992). A study by Hosono et al (1995) on HBV derived sequences from 
Taiwanese hepatomas failed to find any mutations at this position. Given 
that the earlier studies were from Italian hepatomas mutations at this 
amino acid may be related to the ethnic origin of the host.
Differences in the biology of HBV isolates have been demonstrated. For 
example, a study by Hasegawa et al (1994), showed that a virus taken 
from a patient with fulminant hepatitis exhibited an enhanced core particle
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formation and more efficient encapsidation than the virus from a control 
case; mutagenesis studies confirmed that this was not due to A i896. 
Perhaps mutations in the X gene, enhancer regions, or the core promoter 
are important in this regard, but there is no firm evidence available to 
support this.
A recent case pair (Mphahlele et al, submitted) demonstrates that A1896 
strains are independently transmissible and can lead in adults to acute 
hepatitis with viral clearance (Figure 4), with the appearance of anti-HBe 
(even though HBeAg was never produced).
6.2 Core
HBcAg contains B-cell, Th and CTL epitopes (described in Chapter 1, 
section 5.2.2). Studies in recent years have attempted to show that the 
distribution and nonsynonymous nature of mutations observed in HBcAg 
is a nonrandom event and thus provides evidence of immune selection. 
These results will be discussed in greater detail.
Due to the different ways of analysing HBcAg mutations that have been 
employed by the various groups in this field, attempting to make direct 
comparisons is difficult and may be misleading. However, I have 
endeavoured to collate the current data (Figures 1.8 and 1.10).
Two cross-sectional studies by Rodriguez-Frias et al (1995) and Carman 
et al (1995) observed an association between amino acid substitution in 
HBcAg and the presence of a pre-C stop codon. This association was also 
identified by Akarca and Lok (1995). Rodriguez-Frias et al, (1995) 
identified two areas of high variability, amino acids 11 to 27 and 74 to 83. 
Amino acids 1 to 27 have been identified as a HLA-A2 epitope (Bertoletti 
et al, 1991; Penna et al, 1991) and it is known that alterations at amino 
acid positions 21 and 27 can inhibit CTL response in chronically infected
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people (Bertoletti et al, 1994). Mutations at these positions were observed 
in a few of their patients although no details on the HLA-type of the 
patients were given. The authors related the variation seen in the region 
amino acids 74 to 83 to genotype background (mutations in this area were 
only seen in those with genotype D) rather than to an escape mechanism. 
However, this area is the major B-cell epitope (Salfelds et al, 1989) and 
variation here has been described by two other groups (Carman et al, 
1995; McMillan et al, 1996). Clusters of amino acid substitutions in other 
areas of HBcAg have been described, in particular at amino acids 84 to 
101 and 147 to 155 (Chuang et al, 1993; Ehata et al, 1992). These 
patients were from Asia and the different clusters may be related either to 
the viral strain circulating in these areas or to the genetic (HLA) 
background of the patients.
Higher rates of variation in epitopic areas compared to non-epitopic areas 
have been described (Carman et al, 1995; Akarca and Lok, 1995). 
Primarily, they were observed in B and Th cell epitopes with little variation 
observed in the two described CTL epitopes. This result could be 
attributed to the lack of HLA-A2, -Aw68 types in the patients studied. 
However, neither of the groups examined the HLA type for all of their 
patients this has to be considered a possibility. Carman et al (1995) did 
give details of those patients who were HLA-A2, 10 out of 28 were HLA- 
A2 but only two of these selected any change in the HLA-A2 epitope. 
Other HLA types were not examined in this study. Of the patients in the 
Akarca and Lok (1995) study who did select mutations in this area, 77% of 
them were at amino acid 21 or 27. One selected a change (serine to 
asparagine) which has been shown to inhibit CTL recognition of the 
standard epitope. This change was not observed in any of the patients in 
the study by Carman et al (1995). Three patients (from the Akarca and 
Lok study) selected an isoleucine to valine substitution at amino acid 27; 
valine at this position has been shown to have a 10-fold increased binding 
when compared to isoleucine. As these latter three patients seroconverted
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to anti-HBe, it may be that this substitution enhanced CTL recognition and 
thus HBe seroconversion. The substitutions observed by Carman et al 
(1995) at this position, valine to isoleucine, were only seen in patients 
who were anti-HBe with active disease. However, this analysis (by 
Carman et al [1995]) was a cross-sectional study and therefore the 
observed changes may not be true amino acid substitutions.
Hosono et al (1995) examined HBcAg sequences derived from the liver of 
hepatoma patients. Integrated DNAs contained fewer mutations than 
replicating HBV DNA present in the hepatomas, probably as a result of 
the tumour no longer being under selection pressure. There was a high 
rate of amino acid substitution within the Th epitope (amino acids 1 to 20) 
at positions 5 and 13. Mutations at these positions have also been 
described in HBeAg and anti-HBe-positive chronic patients (Asahina et al, 
1996; Bozkaya et al, 1996; Lee et al, 1996). Hosono et al (1995) found 
these mutations to be mutually exclusive. This was also observed by Lee 
et al (1996). It is feasible that only one mutation is required to affect 
recognition or binding of the HLA class II site.
Until recently, most of the studies on variation in HBcAg have been cross- 
sectional, but now a few groups have analysed longitudinal samples from 
individuals, giving a more authentic picture of HBcAg selection. Asahina 
et al (1996) sequenced sequential whole genomes from patients with 
chronic hepatitis B before and after an acute exacerbation. The field of 
HBV variation has been eagerly anticipating a study of this nature, as this 
gives an all round impression of selection events in the genome and the 
effects on the different genes. However, the failing in this study was that 
only three patients were studied. To show statistical significance much 
greater number of genomes would have to be studied. The findings of this 
study showed mutations mainly located in the surface and pre-C/C genes 
of these patients. The common A 1896 variant was selected in two of the
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three patients and HBcAg mutations also present in two were not 
particularly associated with recognised epitopes.
Hur et al (1996) examined sequential samples from five patients, of 
Oriental origin, with chronic hepatitis. Gradual changes were observed in 
pre-C and HBcAg with a cluster of mutations around amino acids 84 to 97 
detected in all cases. Although this area is not a described HBcAg 
epitope, it has been cited as an area of high mutation by other groups 
studying patients from the same geographical area. Thus it may be an 
epitope under immune pressure that is yet to be described.
Bozkaya et al (1996) analysed the sequential HBcAg sequences of 55 
chronic hepatitis cases, the largest study published to date. Results from 
this study agreed with the findings of the cross-sectional analysis by 
Carman et al (1995), that the rate of HBcAg variation is lower in those who 
are HBeAg-positive with normal ALTs compared to those with raised ALTs 
or who are anti-HBe-positive.
The rates of nucleotide and amino acid substitutions observed were 
similar in interferon treated versus untreated patients and in responders 
versus non-responders. This is contrary to the findings of Naoumov et al 
(1995), but in accordance with Fattovich et a / (1995).
The mutations described in the study by Bozkaya et al (1996), were 
associated with aminotransferase flares. However, the similar nature (rate 
and location) of the mutations between HBeAg-positives with raised ALTs 
and those who cleared HBeAg imply that these mutations were not 
responsible for seroconversion to anti-HBe. As half of the nucleotide 
changes resulted in amino acid changes, it is likely that immune pressure 
was influencing their selection.
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Okumura et al (1996) sequenced HBcAg before, during and after an 
exacerbation of hepatitis, focusing on the central region of HBcAg. Their 
results indicate that there is a higher rate of mutation during the 
exacerbation compared with before and after the peak of ALT, concurring 
with the results of Bozkaya et al (1996). Changes were not observed in 
asymptomatic HBV carriers without flares of hepatitis during the same 
time frame. These results indicate further evidence for an unidentified 
epitope(s) in the central HBcAg region.
Some specific amino acid substitutions are notable but remain 
unexplained. For example, a threonine to serine at amino acid 12 is only 
found after selection Aisge in Mediterranean patients (Carman et al, 1995). 
Amino acid 12 is within a Th epitope, spanning amino acids 1 to 20, and 
the possibility that this mutation leads to escape from Th cell responses 
has been raised (Carman et al, 1995).
Several studies have shown selection of isoleucine to leucine at amino 
acid 97 (Horikita et al, 1994; Bozkaya et al, 1996; Hur et al, 1996; 
Okumura et al, 1996), the significance of this mutation remains unclear.
A longitudinal study by Naoumov et al (1995) indicated that specific 
mutations in HBcAg can interfere with T-cell function, particularly in 
patients with advanced chronic HBV infection and poor response to 
interferon (IFN). Patients who failed or relapsed after an initial response to 
IFN had more missense mutations before treatment, which can probably 
be accounted for by a longer duration of infection. It has previously been 
documented that HBeAg and HBsAg seroconversion occurs more 
frequently in patients who have had a shorter duration of infection (Perillo 
et al, 1990). Those that did respond not only had fewer missense 
mutations but they coexisted with wild-type sequences. One of the 
patients who failed to respond to treatment had mutations at amino acids 
21 and 27. Mutations at these positions have been shown to act as
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antagonists to the T-cell receptor (Bertoletti et al, 1994) and this perhaps 
indicates a possible mechanism for the failure to respond to IFN.
Deletions in HBcAg have been described in patients with chronic hepatitis 
(Wakita et al, 1991; Ackrill et al, 1993; Akarca and Lok, 1995) and in 
asymptomatic carriers (Akarca and Lok, 1995). Usually these deletions 
are in frame, thus truncated HBcAg is produced. However, such proteins 
are unable, on their own, to assemble into core particles (D. Williams, 
PhD thesis, University of Glasgow, 1997) and are therefore viral dead 
ends, but they may play a role in down-regulation of viral replication. Most 
of the deletions described are situated around the central region of HBcAg 
(between amino acids 70 and 120), the area which contains major B and 
Th cell epitopes (Figure 1.8).
The clinical significance of these defective HBcAgs remains uncertain. 
Core deletions in patients with chronic hepatitis are of low prevalence but 
do appear to be maintained (Akarca and Lok, 1995). Frameshift deletions, 
resulting in early termination of HBcAg and in the loss of the first nine 
amino acid from polymerase, have been identified. Curiously, these 
viruses had a potential start codon for polymerase shortly upstream of the 
deletion (Akarca and Lok, 1995). A patient with an unusual serological 
profile, HBsAg and HBeAg positive but anti-HBe negative with severe liver 
damage, exhibited several frameshift deletions, varying between amino 
acids 39 and 130, with a HBcAg consisting of only the first 35 amino acids 
(Zoulim et al, 1996). Anti-HBe was detected intermittently at very low 
levels. This may be explained by full length HBcAg being present in the 
liver. Similar deletions were observed by Fiordalisi et al (1994) in patients 
with the same serological profile.
Interestingly, patients which exhibit a more severe form of HBV infection; 
such as fulminant hepatitis (Alexopoulou et al, 1996; Asahina et al, 1996 
and Kaneko et al, 1995), those who have had liver transplants (McMillan
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et al, 1996) or are suffering from HCC (Hosono et al, 1996), have multiple 
mutations in HBcAg with several documented in the C-terminus of HBcAg 
(Figure 1.10). Mutations in the C-terminus between amino acid 170 and 
183 are seldom seen in chronic hepatitis (Figure 1.8). Unexpectedly, there 
are mutations described in the arginine-rich region that is involved in RNA 
binding (from amino acids 150 to 154). This region has many documented 
mutations (Akarca and Lok, 1995; Bozkaya et al, 1996; Asahina et al, 
1996; Lee etal, 1996).
There does appear to be an association between the number of mutations 
in HBcAg and the outcome of disease, with the least being in HBeAg- 
positive individuals with minimal disease, and the most in anti-HBe- 
positive patients with severe hepatitis or those with fulminant hepatitis 
(Carman et al, 1995; Ehata et al, 1992; Chuang et al, 1993). However, this 
is not substantiated by all studies. Valliammai et al (1995) did not find any 
significant mutations in HBcAg in HBeAg-positive or anti-HBe-positive 
patients. However, the numbers of patients analysed in this study were 
very small therefore its significance is ambiguous. It is, however, unclear 
whether these substitutions predispose patients to progressive hepatitis or 
occur as a result of severe disease (perhaps mediated by immune 
pressure on HBcAg-expressing hepatocytes).
6.3 X gene and c/s-acting regions
Figure 1.11 correlates variation within the X region with clinical and 
serological parameters
6.3.1 X gene
Deletions within the X gene have been detected in individuals from a 
variety of clinical backgrounds: chronic carriers with normal serological 
markers (Laskus et al, 1994; Kidd-Ljunggren et al, 1995), patients without 
normal serological markers (Liang et al, 1990; Uchida et al, 1995), and an
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anti-HBc-negative highly viraemic carrier (Repp et al, 1992). Deleted 
HBxAgs have also been found in sera from chronically infected 
woodchucks (Kew et al, 1993). Like the human virus counterpart, these 
deleted HBxAgs normally (if not always) co-exist with the full length form.
In their analyses of X gene sequences, Kidd-Ljunggren et al (1995), 
proposed a hypervariable area (from amino acid residues 26 to 52) and 
four conserved regions from residues: amino acid 13 to 25, amino acid 53 
to 77, amino acid 89 to 115 and amino acid 132 to 143. One of these 
conserved regions (amino acid 132 to 143) has been implicated to be 
important for interaction of the X  protein with cellular proteins (Takada and 
Koike, 1994) and encompasses one of the regions, from amino acids 118 
to 142, found to be essential for its transactivating function. Their 
proposed hypervariable region overlaps the other region essential for 
transactivation, from amino acids 29 to 62 (Arii et al, 1992; Kim et al,
1993).
6.3.2 Core promoter and enhancers
The X gene contains important c/s-acting elements, including DR2, the 
core promoter and enhancer II. The core promoter directs the 
transcription of the pre-C/C gene, leading to production of HBeAg, and it 
also has a role in the formation of pregenomic RNA. The proposed RNA 
polymerase binding site (nucleotide positions 1630 to 1636) also lies 
within the core promoter (Corden et al, 1980). Such an important control 
mechanism, one would imagine, would be fairly conserved. However, 
several groups have described variability in this region (Figure 1.11). A 
study on chronic HBV carriers with anti-HBe (Okamoto et al, 1994), 
revealed a large number of patients with mutations at or around the 
proposed RNA polymerase binding site but the transcription initiation site, 
which lies 25 nucleotides downstream, was highly conserved. 82% were 
found to have core promoter mutations, had an A to T change at 
nucleotide position 1762 and/or a G to A change at nucleotide position
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1764, presenting a consensus sequence of AGG at these positions. In two 
of the chronic carriers studied, the core promoter mutated as they 
seroconverted to anti-HBe without detectable simultaneous mutations in 
the pre-C region. The authors proposed that such mutations would lead to 
a HBeAg negative phenotype through regulation of transcription. This was 
their explanation for the lack of pre-C mutants. In the study by Kidd- 
Ljunggren et al (1995), 90% of the HBeAg positive/anti-HBe negative 
patients had conserved sequences at nucleotide positions 1762 and 1764 
and 4/5 HBeAg negative/anti-HBe positive patients had one or more 
mutations at these positions. This apparently supports the correlation 
between HBeAg/anti-HBe status and the presence or absence of 
mutations at these two positions in the core promoter. However, no 
information on their pre-C sequence was given in those patients who were 
HBeAg negative and had mutations at nucleotide positions 1762 and/or 
1764. Mutations at nucleotide positions 1762 and 1764 have been 
described in people with fulminant hepatitis (Ogata et al, 1993; Hasegawa 
et al, 1994; Kaneko et al, 1995), chronic hepatitis, with or without anti- 
HBe, (Nishizono et al, 1995, Kidd-Ljunggren et al, 1996 and McMillan et 
al, 1995) in individuals who have serologically cleared HBV (Blum et al,
1991) but not in HBeAg-positive healthy carriers (Nishizono et al, 1995). 
Thus nucleotides 1762 and 1764 appear to be mutation hotspots.
Nishizono et al (1995) investigated the effect of mutations at nucleotide 
positions 1762 and 1764 on promoter and enhancer activities and found 
that they were not significantly different from wild type. The significance of 
mutations in the core promoter area has yet to be fully evaluated as 
similar point mutations and deletions in symptomatic (Kidd-Ljunggren et 
al, 1995) and non-symptomatic (Horikita et al, 1994), chronic HBV carriers 
in the core promoter have been described.
Another variant that occurs frequently is a T to C at nucleotide position 
1727, which lies within the core upstream regulatory sequence. It has
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been observed in fulminants (Repp et al, 1992; Alexopoulou et al, 1996) 
and in chronic carriers (Nishizono et al, 1995) but not in asymptomatic 
HBeAg-positive carriers (Nishizono et al, 1995), or those with acute HBV 
infection (Kaneko et al, 1995).
Mutations within enhancer I have been described in fulminants 
(Alexopoulou et al, 1996), and in a patient without normal serological 
markers (Uchida eta l, 1995).
As the X region is involved in essential functions controlling viral 
replication mutations in this region could affect transcription and 
replication. As mentioned earlier the most common point mutations are 
T 1762 and A 1764, though it has not been shown to have a significant effect 
on core promoter and enhancer I I  functions (Nishizono et al, 1995). The 
techniques the study used could not distinguish between transcriptional 
levels of pre-C mRNA and pregenome RNA, thus unequivocal conclusions 
on protein expression could not be attained.
Baumert et al (1996) cloned and sequenced an HBV genome that was 
associated with an outbreak of fulminant hepatitis. The virus contained 
many mutations in all regions of the genome and was functionally 
characterised by more efficient encapsidation of the pregenomic RNA, 
leading to elevated levels of replication. Two adjacent point mutations in 
the core promoter, C to T at nucleotide position 1768 and T  to A at 1770, 
were identified and investigated. These two mutations led to enhanced 
encapsidation and a high level of replication when compared with the wild 
type virus. Both these mutations lie outwith the encapsidation signal thus 
suggesting a trans-acting role for the core promoter in encapsidation and 
replication.
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The possible affects of mutations in the X  gene region were not 
appreciated at the time work began for this thesis. Therefore, no 
sequencing of this area was undertaken.
6.4 The role of CTL in genetic variability
CTL play an essential role in the control of virus infection. Host cell 
invasion is signalled to CTL by HLA class I molecules which bind short 
peptide fragments generated by the cytosolic processing of endogenously 
synthesised viral proteins and bring them to the surface of infected cells. 
Interaction of the T-cell receptor (TCR) with the peptide/HLA class I 
molecule complex leads to activation of the T-cell lytic function. Some of 
the amino acid residues of the peptide are crucial for binding to HLA 
molecules, normally amino acid 2 and amino acid 7, whereas the amino 
acid located in the central region are accessible to TCR recognition 
(Matsumura et al, 1992; Madden et al, 1993). One or two of these internal 
residues are usually crucial for TCR interaction since recognition of the 
peptide can be totally abolished by conservative substitutions at these 
positions (Evavold et al, 1992).
Substitution of TCR contact sites can also influence the CTL response by 
creating analogue peptides that can still interact with the TCR but may not 
be able to deliver a full stimulatory signal (Jameson and Bevan, 1995), 
thus inducing anergy (Sloan-Lancaster et al, 1993) or acting as partial 
agonists or antagonists of the TCR (Jameson et al, 1993; Racioppi et al, 
1993).
Due to the molecular requirements for antigen recognition by T cells, it is 
conceivable that viral mutations that affect HLA binding or TCR contact 
sites might abolish viral recognition by destroying CTL epitopes or by 
inhibiting CTL function. It has also been reported that residues flanking
50
Chapter 1
the immunogenic sequence could alter processing or transport of the viral 
peptide thus affecting its presentation (Couillin eta l, 1994).
Experiments carried out in a transgenic mouse model of HBV replication 
indicate that CTL can cause the clearance of intracellular virus not only by 
lysing liver cells expressing HBV antigens but also by suppressing HBV 
gene expression without liver cell destruction (Guidotti et al, 1994). This 
effect is mediated by cytokines, principally IFN-y and TNF-a, presenting 
the possibility of a more effective mechanism for HBV to escape immune 
surveillance, as a single mutation within the cytokine responsive regions 
of the HBV genome would abrogate the effect of the entire CTL population 
instead of abrogating the effect of the CTL response against individual 
epitopes.
Although no direct evidence has been documented, the above are 
possible strategies which HBV could adopt to evade immune surveillance 
and persist within the infected host. Escape from immunosurveillance by 
CTL targets is a biological possibility, as shown for lymphocytic 
choriomeningitis virus (Moskophidis and Zinkernagel, 1995) and HIV 
(Klenerman et al, 1996). Could this be happening in HBV?
Several studies have identified mutations scattered throughout the 
sequences of different HBV antigens, some of which appear to be within 
regions recognised by HBV-specific T  cells (Akarca and Lok, 1995; 
Bertoletti et al, 1994; Rodriguez-Frais et al, 1995). However, in most of 
these studies the HLA haplotype of the infected patients was not 
determined, consequently, these findings do not prove that the mutations, 
shown to arise, emerged as a result of selective pressure exerted by T 
cells .
In patients with acute HBV infection who normally develop a strong 
polyclonal CTL response against multiple epitopes in the viral envelope,
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nucleocapsid and polymerase (Nayersina et al, 1993), the likelihood of 
mutant selection by the CTL response is theoretically low. A number of 
CTL epitopes have been described within viral sequences that are critical 
for specific viral functions. For example, the nuclear localisation and 
genome encapsidation signals of HBcAg span amino acid residues 141 to 
151 which also contain the CTL epitope recognised by HLA-A31 and HLA- 
Aw6 8 -restricted CTL (Missale et al, 1993). Similarly, an important 
topogenic sequence in the transmembrane domain of HBsAg overlaps an 
HLA-A2-restricted CTL epitope located between amino acid residues 250 
and 269 (Nayersina et al, 1993). Mutations in these epitopes might be 
lethal for the virus and therefore incompatible with escape from this arm of 
the immune system.
The multispecificity of the CTL response suggests that abrogation of the 
response against the epitope where the mutation arose should not render 
the infected cell invisible to CTL if other epitopes are simultaneously 
expressed on the same cell and other CTL specific for them can reach the 
infected cell.
In contrast to acute self-limited disease, the CTL response in chronic HBV 
is usually weak. If this response were also mono- or oligo-specific, the 
probability of mutant virus selection at this stage of infection would be 
greatly enhanced. This would depend on CTL responses being vigorous 
enough to exert selection pressure. In such cases mutations within critical 
epitopes would protect the infected cells from lysis by CTL. This is 
supported from results by a study by Bertoletti et al (1994) in which two 
patients with chronic HBV showed a strong HLA-A2-restricted CTL 
response narrowly focused on the amino acid residues 18 to 27 of HBcAg 
but failed to respond to any of the other HLA-A2-restricted CTL epitopes 
in HBV that are normally immunogenic in acutely infected individuals. On 
sequencing the infecting virus, the patients appeared to be infected by a 
homogenous population of variant virus carrying mutations within the
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HBcAg epitope, from amino acids 18 to 27, that could reduce HLA binding 
and TCR recognition of the epitope. These variant epitopes were not 
recognised by the dominant CTL population present, which were only able 
to recognise the wildtype (or prototype) epitope. The variant epitopes 
appeared unable to induce a new population of CTL specific for 
themselves and hence were poorly antigenic. In addition, they were able 
to act as TCR antagonists by inhibiting the response to the prototype 
epitope when both variant and prototype peptides were simultaneously 
expressed on the surface of the same target cell (Bertoletti et al, 1994).
The world-wide prevalence of HLA-A2, A31 and -Aw6 8  together is 
approximately 65%.
These results reveal the scenario of antagonism, whereby the antagonism 
is protecting the infected cell from lysis by CTL specific for the prototype 
epitope thereby giving the variant virus time to replicate and infect other 
cells. However, this is dependent on whether cytokines which are being 
actively released by liver infiltrating cells, are unable to clear the variant 
virus before it has a chance to spread. At the same time the wild type 
virus will also spread but will be eliminated by the activated wild type- 
specific CTL. If the variant virus is strongly immunogenic it will prime a 
new CTL response which, if sufficiently effective, could clear the mutant 
virus. If, however, the new epitope is poorly immunogenic, as was found in 
the above two patients, the CTL response would be unable to clear the 
‘new’ virus and the virus would persist. Such an outcome could be 
advantageous for both the virus and the host. It would allow survival of the 
virus and, if the mutations cause complete lack of recognition by CTL, 
then there would be no further liver cell damage and hence resolution of 
disease to a healthy carrier state.
The criticisms of the above study are that they failed to demonstrate the 
conversion of the wild type to the mutant sequence. Therefore, not
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unequivocally demonstrating CTL escape and responses against other 
HLA-restricted epitopes were not measured and therefore cannot be ruled 
out. Yet it does illustrate how a mutant virus can persist in the chronically 
infected host despite a vigorous CTL response which is ineffective against 
it. Both these patients fulfil two crucial conditions for viral escape, a 
response against the prototype epitope is present and adequately strong 
to exert a selective pressure and the CTL repertoire is narrow and 
focused.
A study by Rehermann et al (1995) examined the ‘frequency’ of CTL 
escape mutants in patients with chronic HBV infection. They analysed 
eight separate HLA-A2-restricted epitopes, defined in patients with acute 
HBV infection, in twelve patients chronically infected with HBV. Four of the 
patients gave weak responses, while the other eight were totally 
undetectable. No sequence changes in the epitopes, differing from the 
prototype sequence, were found in any of the patients. Thus suggesting 
that CTL escape is not a common mechanism for HBV to evade immune 
recognition.
From the data currently available it appears unlikely that HBV variability 
plays an important role in viral persistence by evasion of CTL recognition. 
To address this possibility completely, further studies using improved CTL 
detection strategies that permit scanning of the entire HBV-specific CTL 
repertoire in infected patients should be performed in order to evaluate 
the frequency of CTL escape in chronically infected patients and their 
importance to viral persistence.
A much more effective strategy of escape than mutations within individual 
epitopes would be mutations within cytokine response elements. If 
cytokines prove to exert as strong an antiviral effect in natural HBV 
infection as is observed in the transgenic mouse model, this is an area
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which may prove fruitful in explaining viral persistence and ongoing 
disease.
Whether these defective CTL responses, in chronic HBV patients, are due 
to an actual lesion of the hosts immune system or to viral mutations 
affecting immune surveillance and thereby virus escape, still remain open 
issues.
6.5 Interferon therapy and pre-C/C variability
A study by Naoumov et al (1995), addressed the question of whether 
variations in the pre-C/C gene affect the response to alpha interferon. 
They examined the sequence of the pre-C/C region of 12 patients before, 
during and after treatment with interferon. Of the 7 ( 2  of whom had 
cirrhosis) who responded to treatment (23 samples), 24 missense 
mutations were noted, with no significant changes observed after 
seroconversion. Of the 5 (all had cirrhosis) who failed to respond or 
reactivated after treatment was withdrawn (also representing 23 samples), 
141 missense mutations were identified. This was shown to be statistically 
significant (p=0.001). Multiple variations in the pre-C/C region persisted 
during therapy and new mutations appeared with the relapse of hepatitis. 
Interestingly, the HLA-A2 epitope in HBcAg, from amino acids 21 to 27, 
was only mutated in the non-responders/reactivators. No mutations were 
observed in this area for those who responded. Substitutions in this region 
are known to diminish HLA-A2 restricted cytotoxic T-cell function, thus 
showing specific mutations in HBcAg that probably interfere with T-cell 
function occur frequently in patients with advanced chronic hepatitis and 
this may affect such individuals response to interferon.
A similar study by Fattovich et al (1995) showed that those who respond 
to interferon treatment were more likely to have mutations within the Th 
epitope, amino acids 50 to 69, and there was no correlation with outcome
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to therapy and presence or absence of a pre-C stop codon. However, a 
study by Zhang et al (1996) investigated the influence of genotype and 
pre-C variability on response to interferon in anti-HBe chronic patients. 
The overall response rate of 49% was normal for this group of patients 
(Brunetto et al, 1989b and 1993). A higher response rate was observed in 
those with genotype A or who had wild type pre-C as compared to those 
infected with genotype D/E or who had A i896- This was independent of 
both the level of viral replication antecedent to therapy and interferon 
doses, thus raising the issue that prior characterisation of pre-C sequence 
or genotyping of virus present may help to predict the response to 
interferon in HBeAg negative patients.
7. Aims of thesis
The main aim of this thesis was to examine whether mutations in HBcAg, 
in those individuals who seroconvert to anti-HBe yet still have active 
disease, correlate with disease. Longitudinal studies would be carried out 
to examine variation in HBcAg in anti-HBe-positive patients. Mutations 
that were observed would be correlated with the known Th and B-cell 
epitopes. As it was envisaged that the HLA type of the patients would not 
be known, variation in CTL epitopes would not be addressed. The 
understanding that these mutations may represent immune escape by 
HBV would be tested.
Groups of patients from two geographical areas would be studied. The 
distribution of HBcAg mutations would be compared between these areas.
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Materials
2.1 Bacterial strains (E.coli)
Strain DH5a
2.2 Bacterial growth medium
Luria-Bertani Liquid Medium (LB)
NaCI 10g/I
Bactopeptone 10g/I
Yeast extract 5g/l
Luria-Bertani Solid Medium
As for liquid plus 15g Bacto-agar. pH was adjusted to 7.0 prior to 
sterilisation. Before use LB media was supplemented with 100pg/ml 
ampicillin.
2.3 Chemicals
Acetic acid Rathburn Chemicals Ltd,
Walkerburn, Scotland 
Acetronitrile Rathburn Chemicals Ltd,
Walkerburn, Scotland.
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Agarose
Ammonia persulfate (APS) 
Ampicillin (PenBritin)
Ammonium solution 
t-amyl alcohol (TAA)
Anisole 
Boric acid 
Bromophenol blue 
Citric acid
Deoxynucleoside triphosphates 
Diethyl ether
Dimethylformamide (DMF)
DIPEA
EDTA
Ethane di-thiol (EDT)
Boehringer Mannheim, 
Lewes, E. Sussex.
Bio-Rad Laboratories, 
Richmond, California, USA. 
SmithklineBeecham, 
Pharmachemicals Ltd. 
Dublin, Ireland.
BDH Analar,
Poole, UK.
Rathburn Chemicals Ltd, 
Walkerburn, Scotland. 
Aldrich Chemical Company, 
Gillingham, Dorset, UK. 
BDH Analar,
Poole, UK.
Sigma Chemical Company, 
Poole, UK.
BDH Analar,
Poole, UK.
Pharmacia LKB,
Uppsala, Sweden.
Rathburn Chemicals Ltd, 
Walkerburn, Scotland 
Rathburn Chemicals Ltd, 
Walkerburn, Scotland. 
Aldrich Chemical Company, 
Gillingham, Dorset, UK. 
BDH Analar,
Poole, UK.
Aldrich Chemical Company, 
Gillingham, Dorset, UK.
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L-Glutamine
Hydroxy benzotriazole (HOBT) 
Hydrochloric acid 
Isopropylthiogalactoside (IPTG) 
Lectin-Phytohaemmaglutinin 
Methanol, HPLC grade 
Molecular biology grade water 
Penicillin/Streptomycin 
Phenol
Phenol/chloroform 
Piperidine 
Proteinase K
N,N’-methylene bisacrylamide
NaOAc
NaCI
Na2H P 0 4
Life Technologies Ltd., 
Paisley, UK.
Novabiochem (UK) Ltd, 
Nottingham, UK.
BDH Analar,
Poole, UK.
Life technologies Ltd., 
Paisley, UK.
Sigma Chemical Company, 
Poole, UK.
Rathburn Chemicals Ltd, 
Walkerburn, Scotland.
BDH Analar,
Poole, UK.
Life Technologies Ltd., 
Paisley, UK.
Sigma Chemical Company, 
Poole, UK.
Camlab Ltd.,
Cambridge, UK.
Rathburn Chemicals Ltd, 
Walkerburn, Scotland. 
Boehringer Mannheim, 
Lewes, E. Sussex, UK. 
BDH Analar,
Poole, UK.
BDH Analar,
Poole, UK.
BDH Analar,
Poole, UK.
BDH Analar,
Poole, UK.
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Repel cote 
SDS 
Sucrose
N, N,N, N-tetramethylethylenediamine 
(TEMED)
Transfer RNA (tRNA)
Trifluoroacetic Acid (TFA)
Thioanisole
Tri-isopropyl silane (TIPS)
Tris base 
Fmoc8 K7 resin
(Fmoc Gly4)-Lys2-Lys- Ala-Diamcryl KA 
Ultrosyn C
2.4 Radiochemicals
Chapter 2
BDH Analar,
Poole, UK.
BDH Analar,
Poole, UK.
BDH Analar,
Poole, UK.
BDH Analar,
Poole, UK.
Bio-RadLaboratories,
Richmond, California, USA.
Life Technologies Ltd.,
Paisley, UK.
Rathburn Chemicals Ltd, 
Walkerburn, Scotland.
Aldrich Chemical Company, 
Gillingham, Dorset, UK.
Aldrich Chemical Company, 
Gillingham, Dorset, UK. 
Boehringer Mannheim,
Lewes, E. Sussex, UK.
Peptide and Protein Research, 
Exeter, Devon, UK.
Peptide and Protein Research, 
Exeter, Devon, UK.
Peptide and Protein Research, 
Exeter, Devon, UK.
All radiochemicals were purchased from Amersham International Ltd., 
Maidstone, UK.
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The specific activities were 37Bq/mmol for [a35S]dATP and 60 Ci/mmol for 
[methyl-3H]Thymidine.
2.5 Enzymes
Restriction enzymes
T4 DNA ligase
Sequenase™ DNA polymerase 
(Version 2.0)
Tag™ DNA polymerase
2.6 Human sera
Boehringer Mannheim,
Lewes, E. Sussex, UK.
Boehringer Mannheim,
Lewes, E. Sussex, UK..
United States Biochemicals, 
Ohio, USA.
Life Technologies Ltd.,
Paisley, UK.
Negative (control) serum was donated by various members of lab 109 
over the course of this thesis.
Test sera were taken in the normal course of treatment and had been 
stored for many years, therefore no patient consent was required. Sera 
were kindly supplied by Prof. A Lok (Chapter 5) and Prof. S. Hadziyannis 
(Chapter 6 ).
2.7 Buffers
Binding and wash buffer Tris-HCI, pH 7.5 10mM
EDTA 1mM
NaCI 2.0M
Citrate/phoshate buffer Citric acid 0.08M
Na2H P 0 4 0.1M
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Denaturing buffer Tris.HCI, pH6.7 100mM
SDS 4.0%
2-mercaptoethanol 1.4M
Gel loading buffer Sucrose 4.0g
Bromophenol blue 2.5g
Dissolved above in 6 ml 1xTE, 
brought to a final volume of 1 0 ml 
with 1xTE.
Hepes/bicarb buffer Hepes 11 mM
NaHCO 10mM
Dispensed into 80ml aliquots and 
autoclaved before use.
PBS-Tween 20 solution x 10 NaCI 1.45M
Na2H P 0 4 0.075M
NaH2P 0 4 0.028M
Glycerol 0.5%
pH adjusted to 7.2 with NaOH or HCI.
10xPBS NaCI 255g
Na2H P 0 4 32 .1g
NaH2P 0 4 11.1g
Dissolved in 31 water.
Reagent K TFA 81.5%
Thioanisole 5.0%
Phenol 5.0%
H20 5.0%
EDT 2.5%
TIPS 2.5%
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10xSDE
SDS-PAGE running buffer 
10XTBE (for sequencing)
1XTE 
50xTAE
2.8 Kits
QIAquick gel extraction kit 
QIAquick spin PCR purification kit 
Blood extraction kit 
QIAgen DNA kit
EDTA 25mM
NaOAc 250mM
Trisbase 52mM
Glycine 53mM
SDS 0.1%
Trisbase 242.Og
Boric acid 123.66g
EDTA 14.88g
Dissolved in 21 pH=8.3.
Tris, 1M pH8.0 10mM
EDTA, 0.5M 1mM
Trisbase 242.Og
Acetic acid, glacial 57.1ml
EDTA, 0.5M pH 5.0 100ml
Made up to a final volume of 11 
with water.
QIAGEN,
Dusseldorf, Germany. 
QIAGEN,
Dusseldorf, Germany. 
QIAGEN,
Dusseldorf, Germany. 
QIAGEN,
Dusseldorf, Germany.
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Geneclean
Sequenase (Version 2.0)
DNA sequencing kit
2.9 Plasmids
pUC containing inserts of either 
(C) were available in the lab.
For cloning of HBcAg (Chapter 8 ) 
pET3a
pKK223.3
pRK5
pT7Blue
2.10 Miscellaneous
Betaplate printed filtermat 
Betaplate sample bag 
Betascint
Dynabeads
Foetal calf serum (FCS)
Bio101,
La Jolla, USA.
United States Biochemicals, 
Ohio, USA.
type core (A) or pre-C mutant core
A. Abbots, Institute of 
Virology, Glasgow'. 
Clontech Laboratories, 
California, UK.
Prof. H. Will,
Hamburg, Germany. 
AMS Biotechnology, 
Oxon, UK.
LKB Wallac, Pharmacia,
St. Albans Herts, UK.
LKB Wallac, Pharmacia,
St. Albans Herts, UK.
National Diagnostics,
Aston Clinton, Bucks,
UK.
Dynal, Oslo, Norway. 
Advanced Protein Products, 
W est Midlands, UK.
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Immulon 2 plates
Iscove’s modified Dulbecco’s medium
Kodak X-Omat film 
100bp Ladder
1 Kb Ladder
Lymphoprep™
Mineral oil
96 well plates and lids for sequencing
96 well plate for lymphoproliferation
RPMI 1640,1 Ox
Sequagel
Sequagel- 6
Whatman paper
Dynatech Laboratories, 
Billinghurst, West Sussex,
UK.
Life Technologies Ltd.,
Paisley, UK.
Kodak Ltd., UK.
Life Technologies Ltd.,
Paisley, UK.
Life Technologies Ltd.,
Paisley, UK.
Nycomed,
Oslo, Norway.
Sigma Chemical Company, 
Poole, UK.
Costar, High Wycombe,
Bucks, UK.
Gibco (Nunclon), Paisley, assay 
UK.
Life Technologies, Ltd.,
Paisley, UK.
BS and S,
Edinburgh, UK.
BS and S,
Edinburgh, UK.
Whatman International 
Ltd., Maidstone, UK.
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Methods
3.1 DNA extraction from serum
3.1.1 Proteinase K method
25^il of human serum was extracted at 37°C overnight in the presence of 
1 OjliI 10xSDE, 10(il proteinase K (10mg/ml), 7.5pil 6 %SDS, 1 pil tRNA (or 
glycogen) and 46.5pil H20 . The following morning the DNA was extracted 
once with phenokchloroform (1:1), and twice with chloroform alone. The 
DNA was then precipitated from the aqueous layer in the presence of 2 
volumes 100% ethanol, 10% v/v NaOAc and washed; once with 100%  
ethanol and once with 70% ethanol. Finally, the ethanol was allowed to 
evaporate completely and the DNA resuspended in 30pil molecular biology 
grade water (hereafter referred to as H20 ). DNA was stored at -20°C for 
future use.
3.1.2 NaOH method
20(j.l of 0.2M NaOH was added to 20\i\ of serum and incubated overnight 
at room temperature. The following morning 19.6|il of 0.2M HCI was 
added. The extracted DNA was diluted 1:10, in 1xTE, prior to use in the 
pulse chain reaction (PCR).
3.2 Removal and purification of oligonucleotides from column
Oligonucleotides were synthesised on a Biosearch 8600 DNA synthesiser. 
They were removed from the resin by washing 1.5ml ammonia solution 
(high grade) through the cartridge, subsequently deprotected at 55°C for 5
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hours (h) and dried overnight in the speedivac. The oligonucleotide was 
then resuspended in 1 0 0 pl H20 . Prior to use for PCR, the O D 26o was read 
and pmol/pl was calculated. Oligonucleotides that were used for the PCR 
or sequencing were not purified further.
Oligonucleotides used for cloning purposes were purified on a 6 % 
acrylamide, 1xTBE, 9M urea gel. 80ml of the gel mix was polymerised with 
160jil of 25% (w/v) APS and 60pl TEMED. This was poured between two 
20x22cm glass plates separated by 1.5mm spacers, and a 10 tooth comb 
was then inserted at the top. 30 to 50|iil of the oligonucleotide was mixed 
with an equal volume of gel loading buffer and then heated at 99°C for 1 0  
minutes (min) before being loaded immediately onto the gel. In a separate 
well 1 0 ml of gel loading buffer was loaded to act as a molecular weight 
marker. The gel was run at 10mA for 2-3 h in 1xTBE. To visualise the 
oligonucleotide, the gel was removed, wrapped in cling-film and viewed 
against a white chromatographic plate by UV shadowing.
In a successful synthesis a predominant band, with several lower 
molecular weight bands, was observed. The top band was excised with a 
sterile scalpel, ‘chopped-up’ and incubated at 37°C for 16 h in 1 ml elution 
buffer (0.5M ammonium acetate, 1mM EDTA, 0.5% (w/v) SDS). The tube 
was centrifuged at 2 ,0 0 0 rpm for 2  min and the aqueous layer removed. 
The oligonucleotide was phenol:chloroform extracted (500pl was added), 
ethanol precipitated, washed in 70% ethanol, dried and finally redissolved 
in H20 . Concentration of the oligo was determined either by running it on 
a 1 % agarose gel or reading the O D 26o as before.
3.3 Polymerase chain reaction
3.3.1 First round PCR
In a 50pl reaction, 5|ul of extracted DNA was added to 1x buffer (Tris/KCI - 
supplied as 10x by the manufacturer), 1.5mM MgCI2, 250|uM of each
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deoxynucleotide triphosphate (dNTP), 50pmol of each of the relevant 
primers (see Appendix 1), 2 units (U) Thermus aquaticus ( Taq) DNA 
polymerase, made up to the final volume with H20 . The reaction mix was 
overlaid with 2-3 drops of mineral oil to prevent evaporation and was then 
cycled as follows:
initial denaturation of 3 min at 95°C, followed by 5 cycles of:
denaturation 1 minute at 95°C
annealing 1 min 15s at 55°C
elongation 1 min 30s of 72°C
This was followed by 35 cycles of:
denaturation 1 min at 90°C
annealing 1 min 15s at 55°C
elongation 1 min 30s of 72°C
This was followed by a final elongation step of 5 min.
Lowering the denaturation temperature to 90°C after the first 5 cycles was 
thought to prolong the Taq activity. Subsequently, the protocol was 
modified to a final reaction volume of 2 0 pl.
3.3.2 Second round PCR
lpil of first round product was added to a 50jal reaction mix containing the 
following: 1x buffer, 1.5mM MgCI2, 250|iM  of each dNTP, 50pmol of 
relevant primers (Appendix 1), 1U Taq polymerase. The reaction mix was 
then made up to the final volume with H20 . The reaction was overlayed 
with 2-3 drops of mineral oil and cycled as above, with the exception of 
only 25 cycles of the 90°C, 1min. denaturation step performed.
Biotinylated primers were employed occasionally in the PCR for specific 
sequencing applications (3.6.2); these are identified where appropriate.
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3.3.3 PCR mutagenesis
The ser15 oligonucleotide, 6 6  nucleotides in length (Appendix 1), was 
used to amplify a 280bp pre-C fragment, introducing a codon for serine at 
codon 15. The PCR product was purified using the QIAGEN PCR 
purification kit (Boner et al, 1995).
3.3.4 Screening for inserts using the PCR
With 15pl of 2M NaOH, 50|il of an overnight LB plus ampicillin culture, 
was heated to 65°C for 5 min. 100|il of Tris (pH7.5) was subsequently 
added and 1 |nl of this mixture was then added to a 20pl PCR reaction 
(3.3.2)
3.4 Purification of PCR products and DNA fragments
3.4.1 Geneclean method
Prior to sequencing, PCR products were purified using the Geneclean kit 
to remove excess primers and nucleotides. Briefly, 20-30pil of PCR 
product was made up to 50pil using 1xTBE, 150[il (i.e. 3 volumes) of 
sodium iodide and 5pl glass milk were added and incubated at room 
temperature for 5 min, centrifuged at 12,000rpm for 1 minute and the 
supernatant discarded. The pellet was resuspended in 500pl NEW  wash, 
centrifuged at 12,000rpm for 1 minute and supernatant removed. This was 
repeated three times. After the final wash the pellet was resuspended in 
20-30pil of H20 , and DNA was eluted by incubation at 55°C for 3 min. After 
spinning for 1 minute; the supernatant (DNA) was then removed to a fresh 
eppendorf tube and stored at -20°C.
Restriction enzyme digests, prior to electrophoresis on a minigel 
submarine agarose gel, were also purified in this way.
DNA fragments excised from agarose gels were purified by one of the 
following methods:
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3.4.2 Using the Geneclean kit
Three volumes of sodium iodide was added to the weighed 1xTAE gel 
slice and incubated at 55°C until the gel had melted (approximately 5 
min). 5|il of glass milk was added and the procedure continued as detailed 
above. If a 1xTBE gel was used 0.5 volumes of TBE modifier (supplied 
with the kit) and 4.5 volumes of sodium iodide were added and the 
procedure followed as above.
3.4.3 QIAquick gel extraction kit
After excision, the gel slice was weighed and three volumes of buffer QX1 
was added to one volume of gel. This was then incubated at 50°C for 10 
min. To aid dissolution of the gel, the tube was inverted 2-3 times during 
this period. The correct pH (<7.5) is important for efficient binding, and 
thus if the pH>7.5, 10ptl 3M sodium acetate (pH 5.0) was added. The 
sample was loaded onto the QIAquick column and centrifuged at 
12,000rpm for 60s. The flow-through fraction was discarded and 0.75ml of 
buffer PE was loaded onto the QIAquick column and allowed to stand for 
5 min. The column was then centrifuged for 30-60s, the flow-through 
discarded and the column centrifuged again for 60s. To elute DNA, 30pl 
of 10mM Tris-HCI (pH 8.5) or water was added, ensuring the filter was 
covered, and centrifuged for 1 minute. DNA was collected and stored at - 
20°C.
3.5 Mini-gel submarine agarose electrophoresis
This method was used for several purposes:
1. To visualise the result of the PCR.
2. PCR products were visualised on a 1% 1xTBE gel giving an estimate of 
the volume of PCR product to be purified for DNA sequencing.
3. Restriction enzyme digests were run on a 1% 1xTAE or 1% 1xTBE gel, 
excised and purified.
4. DNA fragments and vector were quantified prior to ligation.
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Gels were prepared by boiling 1% agarose in 1xTBE or 1xTAE. When 
cool, 0.05mg/ml ethidium bromide was added and the agarose was 
poured directly into the mini-gel kit (either Bio-Rad or Uniscience). Once 
set, the combs were removed and the appropriate volume of 1xTBE or 
1xTAE was added to the tank. Samples were run at 65v for 15-45 min. For 
DNA fragments which were manipulated further, long-wave ultra violet 
(UV) was used to visualise the DNA; otherwise short-wave UV was used. 
Either 1 kb and 100bp (1 p.g/ml) ladders were run alongside the DNA to 
enable confirmation of the PCR products and vector/fragment sizes.
3.6 DNA sequencing
3.6.1 Using the Sequenase™ version 2.0 DNA sequencing kit
2.5jil of appropriate primer (Appendix 1) was added to 5pil of purified DNA 
heated to 95°C for 2 min, the temperature was reduced to 70°C (allowing 
time for centrifugation to bring the DNA/primer mix back to tip of tube), 
again temperature was increased to 95°C for 30s and finally reduced to 
37°C for 15 min. DNA/primer mix was then placed on ice. 2pl label mix 
(diluted 1:5 with water), 2pl reaction buffer, 1 pil DTT , 5mCi 35Sa dATP 
and 2pl Sequenase™ DNA polymerase (diluted 1:8) were added to the 
annealed DNA and incubated at 19°C for 2 min. 3.5pl of the label reaction 
was added to 2.5pil of each ddNTP and incubated at 37°C for 5 min. 
Finally, 4^1 of stop solution was added. Reactions were stored at -20°C for 
up to 2  weeks.
3.6.2 Biotinylated sequencing
Preparation of strepavidin coated beads (Dynabeads) and single stranded 
DNA for sequencing. 20pl (equivalent to 200pg) of Dynabeads was added 
to a well of the microtitre plate, placed on magnet and the supernatant 
was removed. Dynabeads were resuspended in 20|il of binding and 
washing (BandW) buffer, mixed gently and the supernatant removed. The 
beads were resuspended in 40nl B and W  buffer; 40pil of amplified,
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biotinylated PCR product was then added to the washed beads and 
incubated at room temperature for 15 min. The immobilised product was 
placed on the magnet, the supernatant removed and washed with 40 jj.I of 
B and W  buffer. The wash was then repeated. Finally, the beads were 
resuspended in 8pil of a freshly prepared 0.1M NaOH solution and 
incubated at room temperature for 10 min. The DNA strands were 
separated using the magnet and the biotinylated DNA/dynabeads were 
washed once with each of the following: 50pl 0.1M NaOH, 40pl B and W  
buffer and 50 |liI 1x  TE.
The annealing and labelling reaction steps were followed as detailed in 
3.7.1. Once extension was completed, the product was placed on the 
magnet and the supernatant removed. The newly synthesised DNA 
strands were eluted by the addition of the sequenase stop solution and 
heating the DNA to 72°C for 2 min. The DNA strands were finally 
separated using the magnet.
3.6.3 Running the sequencing reactions
An inner and outer pair of glass sequencing gel plates were cleaned and 
the shorter inner plate was coated with Repelcote, a silicon based 
compound. This ensured the gel only attached to the larger (outer) plate. 
0.4mm spacers were positioned between the plates, at each side, and the 
plates were taped together.
Sequencing gels were prepared using either of the following methods: 
Sequagel. A 5% gel was normally prepared. This entailed mixing together 
18ml of concentrate, 7.5ml of buffer and 49.5ml of buffer. Immediately 
prior to pouring the gel, 600|ul of APS and 60pil of TEMED were added (to 
polymerise the gel mix).
Sequagel-6. To prepare a 6% gel, 60 ml of Sequagel-6 was added to 15ml 
of buffer and 60jil of APS added immediately prior to pouring the gel.
72
Chapter 3
Shark-toothed combs were inverted and inserted into the top of the gel, to 
form the wells, and the gel was left at room temperature (RT) to 
polymerise (approximately 30 min). Once set, the tape was removed and 
the gel placed in a sequencing apparatus, 500ml of 1xTBE was added to 
top and bottom reservoirs and the gel was pre-run at 70W  for 30min thus 
allowing it to ‘warm-up’.
2.5pil of sequencing reactions, denatured at 90°C for 5 min, were added to 
the appropriate wells and run for either 1hour 45 min or 4h 30 min. On 
completion of the run, the gel was fixed in 10% acetic acid, 10% methanol 
for 15 min, blotted onto 3mm Whatmann paper and then dried in a Biorad 
gel drier for 1hour. The gel was then exposed to X-omat film and 
developed following 1-10 days exposure. Each gel was read twice using 
the Sequence Boy machine (Integra Biosciences, Woburn, MA)
3.7 Restriction enzyme digestion of DNA
The manufacturer’s recommended buffers and conditions were used for 
each individual restriction enzyme. Generally, the DNA was incubated 
with 1x appropriate buffer and 2-3U of restriction enzyme for 2 h at 37°C. 
To stop the reaction 0.2 volumes of gel loading buffer was added to the 
digest prior to running on an agarose gel and where appropriate. DNA 
was purified as described in section 3.4.
3.8 Ligation
Both the vector and the insert were cut with the appropriate restriction 
enzymes. The vector and insert were purified as described in section 3.4. 
In all cases, cohesive ends were ligated. The vector and the insert (at a 
molar ratio of 1:5) were ligated at 16°C for 3h in the presence of 1x 
ligation buffer and 1U of ligase, in a total volume of 10^1.
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3.9 Preparation of competent cells
10pl of a glycerol stock of E. coli DH 5a was added to 10mls of LB broth 
and grown overnight at 37°C in a shaking incubator. 8mls of the overnight 
culture was added to 500mls of pre-warmed LB broth and grown at 37°C 
in a shaking incubator until the O.D. measured between 0.2-0.4. The 
culture was transferred to pre-chilled polyproplyene tubes and kept on ice 
for 10 min. The cultures were spun at 2,800rpm for 10 min at 4°C and the 
supernatant decanted. The pellet was resuspended in 80ml 100mM CaCI2 
and kept on ice for 2h. This spin was repeated and the pellet carefully 
resuspended in 10ml 100mM CaCI2. After a minimum of 30min glycerol 
was added, to give a final concentration of 15% and the cells were snap 
frozen in liquid nitrogen and stored at -70°C in 1ml aliquots.
3.10 Transformation of E.coli
10Opil of DH5a was added to 1 0 |llI of ice-cold ligation reaction and 
incubated on ice for 40 min. The cells were heat shocked, 42°C for 2 min, 
and immediately returned to ice for a further 3 min. 10Ojul of LB broth was 
added to the cells and incubated at 37°C for 1 hour. 100pl of the 
transformation reaction was then plated onto a LB agar plus ampicillin 
plate and incubated overnight at 37°C. Linearised (cut) vector was also 
transformed as a control (to measure background re-ligation).
3.11 DNA purification from plasmid (Mini-prep)
1.5pl of an overnight LB plus ampicillin culture was centrifuged at 
2,000rpm for 1 minute and the supernatant discarded. The pellet was 
resuspended in 10Opil of solution I (GET buffer) and left at RT for 5 min. 
200|il of solution II was then added, mixed gently by inversion, and left on 
ice for approximately 3 min, but for no longer than 5 min. 150(j.l of solution 
III was added, vortexed and left on ice for 5 min. 50p\ of phenol/chloroform
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was added, the mix centrifuged at 2,000rpm for 1 min. and the 
supernatant removed and discarded. Two volumes of 100% ethanol was 
added, incubated at RT for 2 min. and subsequently centrifuged at 
2,000rpm for 15 min. Two volumes of 70% ethanol was added, centrifuged 
briefly, the ethanol was removed and the pellet dried in a speedivac. The 
pellet was resuspended in 50pl 1xTE and stored at -20°C.
3.12 Peptide synthesis
All peptides used were made by continuous flow Fmoc chemistry on either 
(Fmoc Gly-Gly-Gly-Gly)-Lys2-Lys-Ala-Diamcryl KA or Ultrosyn C resin, 
using a Novabiochem peptide synthesiser.
This involves the sequential addition of Fmoc protected amino acids. The 
Fmoc group was removed at the end of every cycle using 20% piperidine 
in dimethyl formamide (DMF) for 15 min. PyBOP esters in conjunction with 
HOBt were used for the coupling of amino acids.
Side chain protecting groups were as follows: trityl (trt), side chains of 
asparagine, cysteine, glutamine and histidine; butyloxycarbonyl (Boc), 
side chains of tryptophan and lysine; tertiary-butyl (t-Bu), side chains of 
aspartic acid, glutamic acid, serine and tyrosine, 
pentamethylchromanesulphonyl (pmc), side chain of arginine.
3.12.1 Synthesis of tetrameric peptides
These peptides were synthesised on a branched polylysine core allowing 
the formation of 4 chains of homologous peptides.
3.12.2 Synthesis of monomeric peptides
These peptides were synthesised on Ultrosyn C. This resin is designed to 
make peptide carboxy amides.
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In all cases, the scale of synthesis was approximately 0.1 mmol of free 
Fmoc groups at a concentration of 0.1 mmol per gram of functionalised 
resin for peptides. During the synthesis of the overlapping series of 
peptides, three peptides were synthesised at the same time. In this case 
the amount of resin was adjusted to keep the total scale at 0.1 mmol. 
Prepacked vials containing 0.5 mmol of Fmoc amino acid esters were 
used giving a 5-fold excess of amino acid during coupling reactions.
3.13 Cleavage and deprotection of peptides
After synthesis, the peptide resin was removed from the column and 
transferred to a sintered glass funnel and washed with the following 
solvents (in order): DMF, t-amyl alcohol, acetic acid, t-amyl alcohol and 
finally diethyl ether. The resin was then transferred to a 100ml round 
bottomed flask and dried in an evacuated dessicator. The resin was 
weighed approximately 10% was cleaved as a test cleavage, and the 
remaining resin was stored at -20°C.
The resin to be cleaved, along with 20 to 25ml of Reagent K was added to 
a 100ml round bottomed flask and left at room temperature for 1.5 to 2h. 
The resin/Reagent K mixture, with the peptide now in solution, was then 
transferred to a sintered glass funnel and allowed to drain into a 250ml 
round-bottomed flask. Once all the solution had completely drained a 
small amount of TFA was added to wash the funnel. TFA was then 
evaporated under vacuum from the peptide solution using a rotary 
evaporator until approximately 5ml remained. This was transferred to a 
50ml falcon tube, diethyl ether added to a final volume of 40ml, to 
precipitate peptide, and centrifuged at 2,000rpm for 15 min to pellet the 
peptide. Diethyl ether was carefully poured off. The peptide was washed a 
further two times with diethyl ether. Finally, the peptide was redissolved, 
as appropriate, shell frozen and dried overnight.
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3.14 Analysis of peptides
3.14.1 Mass spectrometry
The molecular weight of the monomeric peptides was determined by M- 
Scan Ltd., Ascot, England, UK, using the fast atom bombardment (FAB- 
mass) ionisation technique (Barber eta l, 1981).
3.14.2 Amino acid analysis
Amino acid analysis was carried out on the branched peptides by 
Cambridge Research Biochemicals Ltd, Cheshire, England, UK. This 
provides the molar ratio of each amino acid contained in the peptide.
3.15 Reverse phase high pressure liquid chromatography (HPLC)
The purity of each peptide was determined by reverse phase HPLC 
monitored at 225nm on a Beckman System Gold HPLC using a dynamax 
300 A C8 analytical column (4.6mm internal diameter x 250mm) A 
gradient of 0-95% acetonitrile (plus 0.05%  TFA) in water (plus 0.1% TFA) 
was run over 5 min at a flow rate of 0.5ml/min
3.16 Purification of peptides
Peptides were purified by reverse phase HPLC on a Beckman System 
Gold system using a Vydak-FB1520 preparative column (20nm internal 
diameter x 50cm) and a gradient of 0-95% acetonitrile (plus 0.05%  TFA) 
in water (plus 0.1% TFA), run over 20 min at a flow rate of 10ml/min. 
Fractions were analysed by reverse phase HPLC.
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3.17 Storage of peptides
Peptides were stored at -20°C in a dry, sealed universal. Peptides were 
warmed to room temperature prior to opening to prevent moisture 
damaging the peptide.
3.18 Dissolution of peptides
Vials containing peptides were brought to room temperature before 
opening. The required amount of peptide was removed and dissolved in 
one of the following ways:
1. In H20 . The desired volume of sterile water was added to the peptide.
2. By bubbling of ammonia (NH3) gas. The desired volume of sterile 
water was added to the peptide and NH3 gas bubbled through until 
dissolution was observed.
3. By addition of acid. Varying concentrations of acid (either 10%, 33% or 
100%) was added dropwise to the peptide until dissolution was observed. 
Sterile water was then added until the required volume was achieved.
Details of the solubility of the constructed peptides are given in Table 7.3
3.19 Enzyme-linked immunosorbant assay (ELISA)
Peptides were dissolved as described in Table 7.3 at the desired 
concentration and adsorbed to 96 well microtitre ELISA plates (Immulon
II) overnight at 37°C. The plates were then washed five times in PBS- 
Tween 20 solution and blocked with 2% BSA in PBS for 1 hour at 37°C. 
Antibodies or human sera were diluted in PBS containing 0.5% BSA and 
50pil of the appropriate dilution was added to the wells. Plates were 
incubated at room temperature for 1 hour and then washed five times in 
PBS-Tween 20 solution. Horseradish peroxidase conjugated-goat anti­
mouse or horseradish peroxidase conjugated-protein A was diluted
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1:1000 in PBS containing 0.5%  BSA and 50pl added to each well. Plates 
were incubated at room temperature for 1 hour and washed a further ten 
times in PBS-Tween 20 solution and 10Opil of a 50mg/ml solution of 
enzyme substrate; 2,2,’ Azino-bis (3-ethylbenzthiazoline-6-sulphonic acid) 
in citrate phosphate buffer, containing 0.01% hydrogen peroxide, was 
added. After 15 min of colour development, the absorbance at 405nm was 
read on a Multiskan plate reader. The background absorbance for each 
serum dilution was determined by incubating the sera on a well with no 
peptide. This value was subtracted from the appropriate reading.
3.20 Separation of peripheral blood mononuclear cells from whole 
blood
20ml of blood was collected into 0.2ml preservative free heparin and 
gently mixed. 10ml of blood was carefully layered onto 15ml Lymphoprep 
in a sterile universal (repeated for the remaining 10ml). The universals 
were centrifuged at 1400rpm for 40 min, the plasma removed and using a 
sterile pastette the mononuclear cells were carefully harvested from the 
gradient interface and placed in a fresh universal.
To an aliquot of hepes/bicarb buffer: 20ml RPMI 1640 (10x concentrated), 
50IU/ml of penicillin, 50mg/ml of streptomycin and 1mM L-glutamine was 
added and the pH adjusted to 7.2 using 5N NaOH. The mononuclear cells 
were washed with this medium and centrifuged at 1400rpm for 5 min. The 
supernatant was decanted into another universal, more medium was 
added to the first universal and both were centrifuged at 1400rpm for 5 
min.
The supernatants were decanted from both universals and the cells 
resuspended using vigorous finger flicks, but never vortexed, to loosen 
the cell pellet. The cells were pooled and made up to a volume of 1ml with 
medium.
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All work was carried out in a class 2 safety cabinet to maintain sterility and 
protect the operator. The cells were counted, in white cell counting fluid, 
and the cell count adjusted to 1x106 cells/ml.
3.21 Lymphoproliferation assay
3.21.1 Using whole blood
1ml of blood, test and control, was added to 9ml Iscove’s medium in 
appropriately marked universals and gently mixed. To each well, of a 96 
well plate, 10Opil of diluted blood was added. Row A contained no 
mitogen/stimulant. Rows B to D contained phytohaemaglutinin (which 
acted as a positive control). The contents of the other rows were specific 
for each experiment, the details are given in the appropriate chapter. 
Triplicate wells were set up for each variable parameter. The plates were 
sealed, using adhesive plate sealers, and incubated at 37°C in 5% C 0 2. 
Three days later the cells were ‘pulsed’ with 1pCi of tritiated thymidine. 
The plates were resealed and incubated for a minimum of 4h.
The cells were then harvested onto a filter mat using a Betaplate 96-well 
cell harvester and dried overnight on the bench. The following day, the 
filter was placed in a sample bag, 10ml of Betascint was added and the 
bag sealed. Betascint was rolled out to cover the entire filter, removing 
any bubbles and resealing if necessary. The filter was read in the 
Betaplate counter using the appropriate programme.
All work was carried out in a class 2 safety cabinet to maintain sterility as 
bacterial contamination would result in distortion of the results, either by 
interfering with the response of the lymphoid cells or by excess label 
being incorporated into the bacterial DNA.
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3.21.2 Using separated peripheral blood mononuclear cells
The method used for testing the lymphoproliferation of separated 
peripheral blood mononuclear cells was similar to that of the whole blood 
assay, except cells and mitogen are mixed together before adding to the 
96 well plate.
15pil RPMI medium and 10pl heat inactivated foetal calf serum (FCS) were 
added to all wells. To row A, 75p\ of RPMI and cell mixture were added 
and to rows B to D, 75|liI of PHA concentrations and cell mixture. To the 
other rows, 75[xl of appropriate mitogen concentration and cell mixture 
were added, the exact contents were dependent on the experiment and 
details given in the appropriate chapter. The plates were sealed and 
incubated at 37°C in 5% C 0 2 . Three days later the cells were pulsed with 
1 (j.Ci tritiated thymidine, the plates were resealed and incubated at 37°C in 
5% C 0 2 for a minimum of 4h. The cells were harvested onto a filter mat 
using a Betaplate cell harvester. The filters were dried on the bench 
overnight and read the following day as detailed in 3.21.1.
The stimulation index (SI) was calculated as the ratio between the counts 
per minute obtained in the presence of antigen and those obtained without 
antigen. An SI above three was considered significant.
3.22 Cloning of Uisse in vaccinia virus
A vaccinia virus with the wild-type HBeAg (containing proline at amino 
acid 15 of pre-C) as a backbone, previously described (Schlicht and 
Wasenauer, 1991), was used to generate the Uisse (serine at amino acid 
15 of pre-C) recombinant virus by conversion of CCT to TCC by PCR 
mutagenesis (Boner et al, 1995). The pre-C fragment was then end-filled, 
using Klenow polymerase, cut with Sal I and C/a I and recloned into a 
vaccinia virus expression vector containing the complete HBV pre-C/C 
gene downstream from the vaccinia virus 7.5K early/late promoter. The
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pre-C/C gene used for expression was taken from a construct containing a 
synthetic HBc gene, which included many restriction enzyme sites not 
present in the wild-type gene (Schlicht et al, 1989). Before use in any 
experiments, the whole recloned fragment was sequenced to verify the 
mutations and to exclude the possibility of any further mutations 
introduced by the PCR.
3.23 Sera and antibodies used in vaccinia analysis.
The three mouse MAbs used were provided by M. Noah (Behring, 
Germany). One of these antibodies (03) was specific for the HBe1 
epitope, and the other two (152 and 158) were specific for the HBe2 
epitope. These are the only two well-characterised HBe epitopes, 
therefore these antibodies were considered sufficient for analysing 
antigenicity. The polyclonal anti-HBc-positive human serum (obtained 
from a chronically infected patient) was strongly HBeAg positive and had 
an anti-HBc titre of ~104, as determined by end point dilution using a 
radioimmunoassay (RIA). The HBc/e specific polyclonal rabbit serum was 
generated by multiple intramuscular injections of recombinant HBc protein 
(100pg/dose) and denatured by boiling for 5 min. in PBS containing 1% 
SDS and 1% 2-mercaptoethanol. No adjuvant was used. This serum 
reacts efficiently with all known HBc gene products, including HBeAg. The 
suitability of these antibodies for the analysis of HBc gene products by 
immunoprecipitation has been described (Nassal, 1988).
3.24 immunoprecipitation and Western blotting of vaccinia­
generated proteins
For the expression and serological characterisation of both HBe proteins, 
HepG2 cells were infected with recombinant vaccinia virus at a multiplicity 
of infection (MOI) of 10 in 1 ml of serum free medium. After 90 min at 
37°C, the inoculum was removed, and 2ml of fresh medium containing
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10% FCS was added. Supernatants were collected 48h after infection and 
used for immunoprecipitation and Western blotting. This allowed secretion 
of the expressed HBe protein to be detected.
2ml of medium was used to prepare a single Western blot sample. 
Immunoprecipitation was performed using the well characterised Mabs 03, 
152 and 158 and an exclusively HBc-specific polyclonal rabbit antiserum 
specific for both HBeAg and HBeAg. 5pl of polyclonal serum (human or 
rabbit) was adsorbed to 25|nl of preswollen protein A-Sepharose. When 
mouse monoclonals were used, MAb solution (5pl; immunoglobulin 
concentration, 1 mg/ml) was adsorbed to 25pl of preswollen protein A- 
Sepharose with 5pl of goat anti-mouse immunoglobulin.
Immunoprecipitation was carried out for 16h at 4°C. The samples were 
washed twice with TNE, boiled in sample buffer with 2% 2- 
mercaptoethanol for 5min, and separated on a 12.5% polyacrylamide gel. 
After Western transfer, the filter was blocked with 1% bovine serum 
albumin and incubated with polyclonal rabbit serum (end dilution, 1:2000), 
and bound antibody was detected by incubation with alkaline- 
phosphatase-labelled protein A and subsequent alkaline-phosphatase 
staining.
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Chapter 4
Results: Section 1
4.1 Reconstruction experiments: Testing sensitivity of 
detection of mixed populations by sequencing
The success of the work carried out in this thesis would depend on the 
sequencing results. It was considered likely that mixed populations 
existed in the patients we wanted to examine. The relevance and 
importance of such mixed populations was not known but we thought it 
unwise to ignore them.
Dilution of PCR products to a single population and subsequent 
sequencing would be a highly accurate method of determining the 
presence of sub-populations but, due to the number of samples we 
intended to sequence, this was thought to prove too time consuming. A 
quicker method would be to sequence the PCR products directly. Thus it 
was considered fundamental to determine the sensitivity of detecting 
mixed populations by this method.
To test the sensitivity of sequencing directly from PCR products two 
plasmids (A and C; where A contains A1896 and C has G i 896), available in 
the lab, were mixed together at varying dilutions, amplified by PCR (3.3), 
the DNA was purified using the Geneclean method (3.4.2) and then 
sequenced (3.6.1).
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4.1.1 Methods
A dilution of 1 pg/jil was prepared for both plasmids. This was the 
elucidated value equivalent to the amount of DNA in the number of virions 
commonly seen in a low level viraemic carrier in 25 pi of serum. Mixtures 
of plasmids A and C were prepared as detailed in Table 4.1
1pl of the indicated mixtures were amplified using primers BC1 and C3 
(see Appendix 1 for primer sequences). These primers allowed 
amplification of the pre-C region, an area of approximately 100 base pairs 
(bp).
Successful amplification was observed by running 5pl of the PCR 
products on a 1% TBE agarose gel. 25pl of the PCR products were then 
purified by the Geneclean method, as outlined in 3.5.1, and resuspended 
in 20pl H20 . 5pl of each mixture was then sequenced, as outlined in 3.6.1, 
using primer BC1. The sequencing results are given in Figure 4.1.
4.1.2 Results
The lower limit for observing mixtures by sequencing directly from PCR  
products is 5%, as shown in Figure 4.1. This was considered to be 
adequate for the purpose of this study as populations below this limit were 
not considered to be present at sufficient levels to play an important role 
in the biology of, or the host response to, HBV.
4.2 Extraction of DNA from serum
A second important factor in the success of the study would be the 
method used to extract DNA from the serum. Concerns here were the 
sensitivity of the procedure and prevention of contamination between 
samples. Some samples would have a high titre of viral DNA, thus the 
possibility of contamination was always present.
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Table 4.1 Relative mixtures of plasmids A and C
PLASMIDS
A (%) C (%)
97.5 2.5
95 5
92.5 7.5
90 10
75 25
50 50
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The standard method that was currently employed in the lab is detailed in 
3.1.1. This is a multi-step procedure thus increasing the chance of 
contamination between samples.
A second method, detailed in 3.1.2, involved fewer steps, thus decreasing 
the risk of contamination between samples.
The sensitivity of this method was compared to the standard extraction 
method.
4.2.1 Methods
A previously extracted serum sample, thus known to be PCR positive, was 
employed as the test sample. This sample was diluted in negative serum, 
in 10-fold dilutions from 10'1 to 10'10 and 25jil of each dilution was 
extracted using both methods.
5pil of each extracted DNA was then amplified for the core region by first 
(3.3.1) and second (3.3.2) round PCR, using C1/C2 and C3/C4 primers 
respectively (Appendix 1). After the PCR, 5pl was run on a 1% TBE 
agarose gel.
4.2.3 Result
Figure 4.2 shows 5pl of each first round PCR product run on a 1% TBE 
agarose gel. Figure 4.3 shows the results from the second round PCR. 
The standard method employed in the lab had a hundred-fold increased 
sensitivity compared to the shorter, less ‘hands on’ method.
4.4 Conclusions
The lower limit of detecting mixed populations directly from amplified PCR 
products was 5%, therefore it was decided that all our sequencing data 
could be gathered using this method.
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Row 2 13 14 15 16 17 18192021 22 23 24
Figure 4.2 Eithidium bromide stained 1% (1xTBE) agarose gel 
showing the C1/C2 PCR products of DNA extracted by the NaOH 
method (top wells - row 1) and the proteinase K method (bottom wells - 
row 2). Lanes 1 and 13 serum dilution 1 0 2, Lanes 2 and 14 serum 
dilution 1 0 3, Lanes 3 and 15 serum dilution 10'4, Lanes 4 and 16 
negative serum control, Lanes 5 and 17 serum dilution 10 5, Lanes 6 
and 18 serum dilution 10'6, Lanes 7 and 19 serum dilution 10'7, Lanes 8 
and 20 negative serum control, Lanes 9 and 21 serum dilution 103, 
Lanes 10 and 22 serum dilution 10"9, Lanes 11 and 23 serum dilution 
10'10, Lanes 12 and 24 negative serum control.
Figure 4.3 Eithidium bromide stained 1% (1xTBE) agarose gel 
showing the C3/C4 PCR products of DNA extracted by the NaOH 
method (A) and the proteinase K method (B). Lanes 1 and 13 serum 
dilution 102, Lanes 2 and 14 serum dilution 103, Lanes 3 and 15 serum 
dilution 10 4, Lanes 4 and 16 negative serum control, Lanes 5 and 17 
serum dilution 10'5 Lanes 6 and 18 serum dilution 10"6, Lanes 7 and 19 
serum dilution 10'7, Lanes 8 and 20 negative serum control, Lanes 9 
and 21 serum dilution 108, Lanes 10 and 22 serum dilution 10'9, Lanes 
11 and 23 serum dilution 10‘10, Lanes 12 and 24 negative serum 
control.
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A recent paper by Alexopoulou et al (1997) assessed changes in the pre- 
C/C region by direct sequencing and sequencing pre-C/C clones from 
different time points of an anti-HBe positive patient. Their cloning results 
indicate the presence of quasi-species in all the samples investigated and 
highlight the superiority of sequencing from clones as a further four amino 
acid changes was observed using this method.
It was decided to continue with the standard serum extraction method 
taking the usual precautions (i.e. using plugged tips, changing gloves 
between each manoeuvre, interspersing every third sample with a 
negative control and adding the DNA last) to prevent inter-sample 
contamination. As this method is time consuming it was decided, as a 
further precaution, not to extract more than 6 serum samples at a time. In 
this way there would be no temptation to ‘cut corners’, perhaps by not 
changing gloves or not including as many negative samples as one 
should.
The quicker NaOH method was employed in repeat extraction where the 
sample was known to be strongly PCR positive.
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Results: Section 2
Chinese HBcAg study
5.1 Background
This study was based on results by Carman et al (1992) in which they 
addressed the prevalence of pre-C mutants in HBeAg and anti-HBe 
positive Hong Kong Chinese patients with chronic HBV infection. To 
correlate the clinical course with variations in the pre-C sequence and to 
determine whether the presence or absence of mutant strains parallels 
fluctuations in HBe status.
The results indicated the presence of two mutually exclusive pre-C 
mutants in this group of patients: A i896 and T i856. The latter causes an 
amino acid change, of proline to serine, at amino acid 15. A1896 was found, 
as the predominant strain only in the anti-HBe phase of infection, while 
T 1856 was also found during the HBeAg phase. As selection of the T i856 
mutation was not observed it is likely that this mutation is present in the 
infecting virus. Two other pre-C mutations were found, A1899 and A1898, only 
in association with A1896 and T 1856 respectively, and neither correlated with 
disease severity.
HBeAg is believed to induce immunological tolerance against HBeAg and 
HBcAg; nonetheless, a strong immune response is eventually mounted 
against HBeAg. Selection of variants that are unable to produce HBeAg
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may be a means of survival employed by the virus. It was of particular 
interest that, as shown in previous work, A 1896 and T 1856 are mutually 
exclusive (Carman et al, 1992; Lok et af, 1994). Since loss of HBeAg 
appears to be beneficial to the virus, T i856 must inhibit selection of a pre-C 
inactivating mutant, or selection of a pre-C stop codon is not necessary 
because similar functions can be ascribed to the two mutations. For 
instance, T 1856 results in the introduction of serine at amino acid 15, 
normally a highly conserved proline, into the signal peptide of HBeAg. In 
the original paper it was hypothesised that the exclusive nature of A 1896 
and T 1856 may be due to the mutant HBeAg being secreted into the serum 
and not remaining on the surface of hepatocytes; thus, it would not be a 
target for B cells and, therefore, would not come under immune pressure. 
Alternatively, it was hypothesised that it may be different antigenically 
(perhaps because of an altered secondary structure) and therefore would 
not be recognised; thus there would be no pressure to select an 
inactivating mutation.
There has been much interest in attempting to link core variation and 
disease. It appears that amino acid substitutions or deletions are more 
common in HBeAg patients with severe disease (Ehata et al, 1992; 
Chuang et al, 1993), and Carman et al (1995) have shown that anti-HBe 
positive individuals with progressive hepatitis are more likely to select a 
large number of amino acid substitutions in HBcAg, particularly after the 
emergence of A1896. Such substitutions occur significantly more often in B 
and Th cell epitopes than in inter-epitopic regions of HBcAg.
5.2 Aims
The overall aim of this section of work was to compare the degree and 
distribution of evolution of HBcAg strains with either of the two pre-C 
variants in those who seroconverted from HBeAg to anti-HBe to those who 
were continuously anti-HBe, and to delineate their distribution.
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The original paper also raised several questions which were addressed:
1. Why are A i 896 and T i 856 never observed on the same genome?
The mutual exclusivity of A i896 and T 1856 was examined by analysing the 
effects of Ui856 on HBeAg synthesis, secretion and antigenicity.
2. What is the phylogenetic relationship between A i 896 and T i 856?
As both variants are equally present in this community they could 
represent separate lineages.
5.3 Patients
Serial serum samples from 10 Hong Kong Chinese (Ch) patients with 
chronic hepatitis were studied. Patient details are given in Table 5.1. 
Group I consisted of three patients who were continuously anti-HBe 
positive, had persistent or episodic increase in serum ALT levels and 
were known, from the previous study, to have A1896. Group II  consisted of 
three patients who were continuously anti-HBe positive, had persistent or 
episodic increase in serum ALT levels and were known to have T i858. 
Group I II  comprised four patients who had spontaneous HBeAg to anti- 
HBe seroconversion but had continued elevation of ALT after clearance of 
HBeAg. Each case had at least 2 or 3 sequential serum samples available 
for study.
5.4 Methods
5.4.1 DNA extraction from serum
DNA extraction was carried out as detailed in 3.1.1 with a slight 
modification for a few samples where only 5pl of serum was available. In 
such cases the same extraction method was used with extra H20  added to 
compensate for the reduced volume of serum and the DNA was 
resuspended in a final volume of 10pl.
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Table 5.1 Patient characteristics. Anti-HBe, antibody to HBeAg; 
W T, wild type (G at nucleotide 1896 and proline at codon 15 of pre-C); 
A i896, G to A mutation; C 1815 mutation of the start codon leading to 
failure to initiate translation; U i856 translates as proline at codon 15 of 
pre-C.
AGE /  SEX SAMPLE HBe STATUS PRECORE SEQUENCE  
DATES (serial samples)
Group I : anti HBe and HBV DNA positive, elevated ALT
case 1, 40 IF 6 / 8 4
11 / 8 7
1 0 / 8 9
case 2, 61 /M 2 / 8 6
7 / 8 7
9 / 8 9
case 3, 3 9 / M 7 / 8 6
9 / 8 9
Group I I : anti HBe and
case 4, 2 8 / M 9 / 8 7
6 / 8 9
case 5, 2 9 / M 7 / 8 8
5 / 8 9
case 6, 2 8 / F 3 / 8 7
6 / 8 9
anti - HBe w t / a 1896
A 1896
A 1896
anti - HBe A 1896
A 1896
A 1896
anti - HBe WT
A 1815
DNA positive and fluctuating ALT
anti - HBe u  1856
U 1856
anti - HBe u  1856
u  1856
anti - HBe U 1856
U 1856
Group I I I : HBeAg to anti - HBe positive, HBV DNA positive and fluctuating ALT
case 7, 2 3 / F 5 / 8 5 HBeAg U 1856
3 / 9 0 anti - HBe U 1856
case 8, 31 /M 7 / 8 5 HBeAg U 1856
1 2 / 8 7 anti - HBe U 1856
case 9, 3 6 / M 5 / 8 5 HBeAg U 1856
5 / 8 6 anti - HBe U 1856
6 / 8 7 anti - HBe U 1856
case 10, 3 2 / M 11/84 HBeAg WT
2 / 9 0 anti - HBe WT
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5.4.2 PCR and sequencing
First and second round PCR was carried out as detailed in 3.3.1 and 3.3.2 
using primers C1/C2 and C3/C4 respectively (Appendix 1). Products were 
purified (3.4.1) and sequenced as outlined (3.6) using primers C1, Coe, 19, 
C4 and BC1 (Appendix 1).
5.4.3 Recombinant vaccinia viruses.
Using HBeAg containing proline at amino acid 15 of pre-C in a vaccinia 
backbone as previously described (Schlicht, 1991), the T 1856 (serine at 
amino acid 15 of pre-C) was generated. Although serine can be encoded 
by the triplets UCC or UCU, all natural cases examined had the codon 
UCC. Thus, this was the codon introduced. This was achieved by 
conversion of CCT to TCC by PCR mutagenesis using standard PCR 
procedures (3.3.3) where the ser15 primer acted as the mutagenic primer.
5.4.4 Cloning, expression and analysis of Tisss in vaccinia virus
As detailed in 3.22, 3.23 and 3.24.
5.4.5 Phylogenetic analysis
Whole pre-C/C sequences were aligned using the Clustal V  program 
(Higgins et al, 1992) as implemented in the Genetic Data Environment 
software package (provided by S. Smith). Alignments were checked 
visually. Phylogenetic trees were reconstructed using a number of 
methods taken from the PHYLIP software package (Felsenstein), 
particularly one invoking maximum likelihood inference (program DNAML). 
To assess the level of support for each node, trees were also 
reconstructed using the neighbor-joining clustering algorithm (program 
NEIGHBOR (Felsenstein)) with bootstrap resampling (1000 replications; 
programs SEQBOOT and CONSENSE (Felsenstein)). The distances 
between each sequence were corrected for multiple substitutions using a 
method that allows different base frequencies and different rates of 
transition and transversion (program DNADIST).
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5.5 Results
5.5.1 Sequencing
Figure 5.1 shows the distribution of amino acid substitutions which are 
related to the known Th and B cell epitopes. The Th epitope (amino acids 
50 to 69) is recognised by essentially all patients studied by other groups 
(Ehata et al, 1993; Akarca and Lok, 1995; Valliammai et al, 1995; Carman 
et al, 1995, Bozkaya et al, 1996) and was recognised by all the patients in 
group I, patient 4 (group II)  and patient 8 (group III). In group I, multiple 
substitutions occurred in the core gene when A i896 emerged; however, few 
appeared thereafter. The initial samples were anti-HBe positive, so the 
presence of anti-HBe alone was not sufficient for selection of core 
substitutions. Although case 3 did not select A i896 , an equivalent mutation 
(T to C 1815) arose. This mutant would also prevent production of HBeAg by 
inactivating the pre-C start codon. Again, the substitutions arose at or 
after the emergence of C 1815. A mean of 9.6 substitutions occurred in this 
group: 79% occurred within known Th or B cell epitopes.
In contrast, cases with T i856 (serine), whether they were continuously anti- 
HBe positive (group II)  or seroconverted from HBeAg to anti-HBe (group
III), selected few HBcAg substitutions (mean: 3.1/case) with only 36% of 
these within epitopes. Thus, in contrast to subjects with A1896, subjects in 
both groups II  and I I I  had ongoing selection without obvious influence of 
the seroconversion event. Subject 10 (group III)  had proline at amino acid 
15 but did not select A 1896 during the study period. His HBcAg substitution 
pattern was indistinguishable from those with serine 15. The mean value 
of substitutions in group II  was skewed by case 6. This patient selected a 
total of 7 substitutions in contrast to the 2 or 3 substitutions seen for all 
the other cases in these groups. The possibility that two sera from 
different patients had been extracted was addressed by re-extracting and 
sequencing both these samples again. The resultant sequences were 
identical to the original. To exclude wrong labelling on collection, two
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further samples from this series were also extracted and sequenced; 
these again confirmed the original sequences. Interestingly, all of the 
substitutions occurred in inter-epitopic regions. It has subsequently been 
shown that superinfection can sometimes occur accounting for genotype 
conversion events (Bollyky et al, submitted, 1997)
Using the Mann-Whitney U test, we have shown that the total number of 
substitutions within epitopes in group I was significantly greater than in 
groups II  and I I I  combined (p = 0.02). Selection of a glycine at amino acid 
63 in the Th epitope was seen in 4 of the 5 cases who selected any 
change in this antigenic region (amino acids 50 to 69). However, glycine 
is normally found at amino acid 63 of adr, ayr, and adw  subtypes, and 
thus the significance of this substitution is unclear.
5.5.2 Serinel 5 prevalence
W e examined the prevalence of serinel 5 at this position in the pre-C by 
constructing a Pileup (using the GCG package) of all the pre-C 
sequences currently available in the Genbank database. As can be seen 
from Figure 5.2, serine is not usually found whereas proline is normally 
highly conserved at this position.
It was noted that this is the only proline found in the pre-C region; 
however it cannot be essential to the virus otherwise our patients would 
not have been infected.
5.5.3 Functional studies on HBeAg
To analyse whether the proline to serine exchange at amino acid 15 had 
any influence on the biosynthesis or antigenicity of the respective HBeAg 
molecules, recombinant vaccinia viruses containing either of these 
variants were generated. This recombinant virus was then used to 
express the protein in HepG2 cells, a human hepatoblastoma cell line. 
After immunoprecipitation with monoclonal or polyclonal sera, the samples
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were analysed by SDS-PAGE and Western blot using a rabbit polyclonal 
anti-HBc/e. As shown in Figure 5.3, there were no obvious differences 
between the proline-containing HBeAg lanes (1-5) and serine-containing 
HBeAg lanes (6-10). Both proteins reacted with the HBeAg-specific Mabs 
(lanes 1-3 and 6-8) and with the HBc/e-specific polyclonal rabbit 
antiserum (lanes 5 and 10) but not with the exclusively HBcAg-specific 
human serum (lanes 4 and 9), indicating that it is HBeAg and not HBcAg 
being produced. By the nature of the experiments it is clear that both 
proteins were being produced and with equal efficiency. Molecular size 
also appeared to be unaltered.
5.5.4 Phylogenetic analysis
The unrooted maximum likelihood tree for the 23 pre-C sequences is 
presented in Figure 5.4. The patients with the proline 15 and A 1896 (cases 
1 and 2) are clearly separated from Tisse (serine 15) strains (cases 4 to 9). 
Case 10 also separated with this group. This finding was also apparent in 
trees reconstructed using the neighbor-joining method, by which the 
separation was strongly supported under the bootstrap criterion. The 
single sequence with the mutated start codon (case 3) is also clearly 
distinct.
5.6 Discussion
At the time this work was undertaken it was assumed that one of the main 
targets for the immune system is the HBcAg. As yet there is no direct 
evidence to support this theory but several sequencing studies over the 
past few years have provided indirect evidence of this (Carman, 1995, 
Akarca, 1995): changes in sequence observed in the core are often 
associated with known epitopes in HBcAg.
In this study we have shown that Hong Kong Chinese who have pre-C 
mutations that inactivate HBeAg translation also accumulate core amino
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Figure 5.3 Comparisons of molecular size and antigenicity of wild 
type HBeAg and proline to serine mutant. Lanes 1-5, proline samples; 
6-10, serine 15 samples. M = molecular size marker. Both proteins 
respectively reacted with HBeAg-specific Mabs (Mabs; lanes 1-3 and 
6-8) and with hepatitis core/e (HBc/e)-specific polyclonal rabbit anti­
serum (lanes 5 and 10) but not with exclusively HBcAg-specific human 
serum (lanes 4 and 9).
#  Stop Codon 
O Serine aa 15 
□  Proline aa15
10% Divergence
Figure 5.4 Unrooted maximum likelihood tree of 23 HBV sequences. All 
branch lengths are to scale. Symbols next to branches indicate status of 
sequences with respect to amino acids at positions 15 (proline or serine) 
and position 28 (stop codon) of pre-C.
Chapter 5
acid substitutions. The underlying mechanism behind this may relate to 
loss of the tolerance mediated by HBeAg. HBeAg and HBcAg contain 
identical stretches of protein sequence (Figure 1.9), so it is possible they 
may share some common epitopes (Chapter 1, section 5); thus, loss of 
tolerance would lead to an active immune response against core. HBeAg 
and HBcAg contain B cell, Th cell and CTL epitopes. There is no formal 
evidence that the substitutions observed arose as a result of escape from 
immune pressure from either T  or B cells. However, previous results from 
our laboratory (Carman et al, 1995) and those presented here show that 
substitutions are more likely to occur in Th and B cell epitopes. As there 
are many possible CTL epitopes, it seems unlikely that substantial escape 
could occur in enough epitopes to allow continued survival (Chapter 1, 
section 6.4). In this regard, it is also relevant that CTL have proved very 
difficult to find in patients with chronic HBV infection (Bertoletti et al, 1991, 
Missale et al, 1993).
The fact that the serinel 5 virus is not a predisposing factor to such 
selection pressures is not entirely surprising. It is found in both the 
HBeAg- and anti-HBe-positive phases, so it is likely that there is always 
some HBeAg production. Good evidence for circulating complexes of 
HBeAg/anti-HBe in patients with recurrent reactivation has been shown by 
Maruyma et al (1993). Thus, in these patients the tolerogenic effect of 
HBeAg would never be completely lost. The finding that case 10 (who had 
proline at amino acid 15 but no pre-C stop codon and is thus still capable 
of producing HBeAg) had an amount of core substitution similar to that in 
the serinel 5 infected cases would support this conclusion.
The fact that HBeAg with serinel 5 is synthesised and secreted and is 
antigenically similar, if not identical (although this was not formally 
assessed) to that with proline at amino acid 15, indicates that the previous 
hypotheses explaining the exclusive nature of Tisse and Aisge were 
probably incorrect. W e now believe that the mutual exclusivity on
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genomes of A i896 and T 1856 can be explained by the resultant perturbation 
in the encapsidation signal (e). This is outlined in Figure 5.5. From the 
predicted structure of s, codons 15 and 28 would appear to lie opposite 
one another in the first stem. The wild-type sequence for proline (CisseCU) 
already introduces a degree of mismatch with tryptophan (UG i896G). 
Introduction of the stop codon (A1896) would have the effect of stabilising 
the stem, as there would now be perfect base pairing. Serine (UisseCC) 
would also give a perfect match with G i896 but would introduce a mismatch 
between T i856 and G i898. Thus, we propose that a subsequent mutation at 
nucleotide 1896 to A (the stop codon) would result in too many imperfect 
base pairs and, therefore, instability in the stem resulting in collapse of 
the structure or, at best, poor encapsidation. Thus, viruses that had these 
two mutations would fail to encapsidate efficiently and would be taken 
over by viruses with a replicative advantage. Studies by Tong et al (1992 
and 1993) have shown that variants in 8 can influence encapsidation 
efficiency (Chapter 1, section 4.8) supporting our hypothesis as to why we 
never observed serinel 5 and A1896 on the same genome. This does not
explain why other mutations, that do not involve 8 but do inhibit 
translation of HBeAg, occur only infrequently (e.g. case 3) in these cases.
It appears that strains containing either A1896 or T i 856 have an equal 
replicative and infectious potential, as they have been found in 
approximately equal numbers in anti-HBe-positive carriers in the Chinese 
community in Hong Kong. This finding is consistent with the phylogenetic 
analysis presented here, which shows that such strains are separate 
lineages (Figure 5.4).
If the development of A1896 is an important part in the biology of HBV 
during chronic infection, then the reason why viruses with serinel 5 fail to 
introduce a different stop codon - there are theoretically nine other stop 
codons - still remains unclear. Carlier et al (1995) have shown that
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- G
•  HBeAg 
■ ■ •  HBcAg
AUG UAG
Figure 5.5 The predicted RNA structure of the encapsidation signal 
of HBV. Translation (bold lines) from the first AUG (□) results in 
HBeAg. Translation from the second AUG results in HBcAg. Codons 
15 and 28 are highlighted in boxes. CCC at codon 15 is proline. UCU 
or UCC codes serine. Codon 28 is UGG in HBeAg producing strains, 
substitution of A at position 1896 leads to a stop codon at codon 28.
Chapter 5
secretion efficiency of HBeAg could be greatly reduced by truncation of 
the C-terminal end. Therefore, it could be envisaged that a truncation or 
mutation(s) in this arginine rich area could have a similar biological effect 
as A i896- However, none of the samples studied had truncations or 
common mutations in this area.
That severe disease occurs in patients with serinel 5 (indistinguishable 
from those with A i 896) who do not have large numbers of core amino acid 
substitutions, indicates that core variation is not the sole cause of severe 
disease but a result of immune pressure, which appears less active or 
less focused in those with the serinel 5 variant.
5.7 Further plan of investigation
5.7.1 Mutating the encapsidation signal.
Testing of the encapsidation theory was always intended to be included in 
the study. An attempt at introducing the serinel 5 into plasmid A (Chapter 
4) using PCR mutagenesis was made at the beginning of the study but 
this failed to prove as straight forward as anticipated. However, due to the 
lack of category I I I  facilities, I was unable to conduct the desired 
experiments, and this line of work was abandoned. If the facility was to 
become available it would be desirable to pursue this avenue of 
investigation. A study by Tong et al (1993) indicates that our hypothesis of 
the effect these mutations have on 8 are probable, so this would be purely 
for academic purposes.
5.7.2 Variability in other HBV proteins.
Variation in the other HBV proteins was not addressed as part of this 
study. There are no documented studies of the above nature that have 
looked for substitutions in other HBV proteins and formally associated 
these with epitopes and progression of disease. Polymerase is unlikely to 
be a strong immune target as this is a protein which has evolved to serve
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several purposes (Chapter 1, section 4.3.4). Variants in HBsAg, 
particularly in the a determinant, are now well documented (Wallace and 
Carman, 1997); whether or not such variants could contribute to disease 
severity is speculation. Perhaps this is an area that could be investigated.
5.7.3 Mutations in the core promoter
Two mutations within the core promoter, at nucleotide positions 1762 and 
1764, are well documented (Chapter 1, section 6.3.2) and have been 
implicated in an HBeAg negative phenotype without a pre-C stop codon 
(Okamoto et al, 1994, Kidd-Ljunggren et al, 1996). The effect of these 
mutations has not been fully investigated, though Nishizono et al (1995) 
investigated their effect on promoter and enhancer activities and found 
that they were not significantly different from wild type.
Such a mutation in the serinel 5 viruses could explain the lack of any pre- 
C stop codons. Thus, sequencing of the serinel 5 viruses in this area 
would be a useful exercise.
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Chapter 6 
Results: Section 3 
Mediterranean study
6.1 Aims
As shown in Chapter 5, there is an association with the appearance of 
HBeAg non-producer strains and core mutations in anti-HBe positive 
Chinese patients. Patients with severe disease have multiple flares of 
hepatitis with corresponding peaks of transaminases. As the immune 
response is believed to be increased during these flares, it is possible that 
a ‘new’ mutant is selected with each peak. The work described in this 
chapter examines in more detail the temporal emergence of core 
substitutions, answering the following questions:
• at which time point do mutations occur in core?
• do they arise with each ALT peak?
• are they associated with particular regions?
• are the flares selecting ‘new’ viruses or inversely are the flares
themselves caused by the presentation of ‘new’ viruses to the immune
system?
6.2 Selection of patients
The study consisted of patients with chronic hepatitis B infection from 
Greece and Italy. No patient had undergone interferon therapy. Prof. 
Hadziyannis (Athens, Greece) kindly provided us with the Greek sera,
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which are coded as H followed by the identity number of sample. The sera 
were from a well followed-up series, taken over several years and 
encompassed several flares of hepatitis. All the Italian samples, coded A 
followed by the identity number of the sample, were taken from an earlier 
study and had been sequenced by either Graham McIntyre or Kathryn 
Colman in our laboratory.
Two groups were selected from the samples available: 6 HBeAg to anti- 
HBe seroconverters and 21 continuously anti-HBe positive patients with 
ongoing hepatitis. For the latter group, initial samples were either the first 
samples available or were taken as soon after anti-HBe seroconversion 
was noted, with later samples taken when the patient still had active 
disease. In the former group, three went on to active disease and three 
went into clinical remission, losing DNA as measured by hybridisation 
after seroconversion. These two groups were chosen because although 
both situations are associated with active hepatitis, the immune effector 
mechanisms may be different. Times between samples are given in 
Figures 6.1 and 6.2.
To time the appearance of mutations that emerged between the first and 
final samples in the continuously anti-HBe group, intermediate samples 
were sequenced in order of collection only in the regions where mutations 
had been detected (i.e. the complete HBcAg was not determined). 
Samples were sequenced in order of collection; no further samples in the 
series were analysed once the appearance of all the mutations detected in 
the final sample (compared to the first) had been timed. An additional 
analysis was performed on a subset of continuously anti-HBe-positive 
patients to address the possibility of transient mutations. Such mutations 
would subsequently be cleared by the immune response, so they would 
not be found in the final sample; this could account for the multiple flares 
of hepatitis observed in these patients. For this purpose, three of the 
continuously anti-HBe positive patients had the complete core sequence
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Figure 6.2 Clinical data, number and distribution of amino acid 
substitutions in continuously anti-HBe positive patients. ALT= alanine 
aminotransferase (Normal<40iu/I), F= female, M= male, W T= G i896, 
MIX= G 1896 3nd A i896, X -  indicates unresolved sequence at that 
position. Only positions at which changes were observed are noted. T= 
described T-helper cell epitopes in HBcAg ; B= described B-cell 
epitopes in FIBcAg or HBeAg. Mixtures of amino acids are shown as 
the two observed amino acids separated by a slash. Sample interval is 
in months. Single letter amino acid codes are given (Appendix 2).
*= Patients for which the entire core open reading frame from 
intermediate samples were sequenced to detect transient mutations.
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analysed from four or five samples each. Clinical details are given in 
Figures 6.1 and 6.2. Representative patient profiles are supplied in Figure 
6.3.
The greater number of patients in this study, in comparison to the Chinese 
study (Chapter 5), augmented the reliability of statistical analyses.
6.3 Methods
6.3.1 Extraction and PCR
Extraction was carried out as detailed in 3.1.1. First and second round 
PCR was carried out as detailed in 3.3.1 and 3.3.2, using primers C1/C2N  
and C3/C4N respectively (Appendix 1).
6.3.2 Sequencing
Products were purified (3.4) and the entire pre-C/C region sequenced as 
outlined (3.6.1), using primers C3, Ca, 19, C4, KC1 and BC1 (Appendix 
1). If sequencing ladders were of poor quality, the first round PCR 
products were re-nested using a biotinylated primer (C4N) and sequenced 
as detailed in 3.6.2.
6.4 Statistical analysis
Substitutions observed in sequential samples were correlated with the 
known CD4 restricted T-helper epitopes (aa 1-20 and 50-69) and with the 
known anti-HBc and anti-HBe B-cell epitopes (aa 74-83, 76-89, 107-118, 
130-138 and 128-135). The region from amino acid 74 to 123 of core has 
been described as a B cell epitope (Tordjeman et al, 1993): however, this 
was not included in the analysis as it was considered too large.
The rate of mutation within the defined epitope was compared to the rate 
of mutation in the remaining core sequence. The relative risk of an amino
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acid substitution occurring within an epitope was calculated using the 
crude odds ratio. 95% confidence limits were calculated using the Exact 
method, p values were calculated with the Chi squared test or, when an 
element with value less than 5 was present, the Fisher’s exact method. 
Comparison of the initial number of amino acid substitutions with the 
number of substitutions which occurred later was made using the paired t- 
test.
6.5 Results
6.5.1 Relationship between pre-C and core mutations
There was a strong temporal association between the selection of pre-C 
mutants that do not allow translation of HBeAg and core protein amino 
acid substitution (Figures 6.1 and 6.2), as was also observed in Chapter 
5. Figure 6.3 demonstrates this in pictorial fashion, highlighting a 
representative sample of patients. For example, of the 15 substitutions 
observed for patient H35, 13 occurred as A 1896 was evolving, with only 2 
subsequent substitutions. Conversely, patient H36 - who failed to develop 
any pre-C stop codon - developed only one substitution during the period 
of observation. In the continuously anti-HBe positive cases (H21, H28, 
H33, H38, A10, A12, A20, A21 and A23) in which Aisse was present in the 
initial sample, few HBcAg amino acid substitutions appeared between the 
initial and final samples (range of 1-4, mean 2.1). This contrasts with the 
other patients in this group, H24, H25, H27, H30, H31, H32, H35, H37, 
and A13, who selected A i896 between the initial and final samples (range 
of 5-16, mean 9.0). In the single HBeAg to anti-HBe seroconverter, where 
multiple samples were available (H20), all observed substitutions 
appeared by the time a mixture of G 1896 and Ai896 had emerged. Hence, 
complete take-over by A1896 is not necessary for the core protein selection 
process.
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Figure 6.3 Serological profiles and HBc amino acid changes in 
selected anti HBe positive patients with active hepatitis. Alanine 
aminotransferase levels (ALT) are shown for each time point studied in 
patients H21, H30, H31, H35, H36, and H37. The pre-C sequence at 
nucleotide 1896 is indicated by an open triangle ( G ^ ) ,  closed circle 
(Aisge) or hatched square (a mixture of Gisse and Aisse). The number of 
HBc amino acid substitutions observed between any two points is 
shown in the open boxes, but the actual changes can be found in 
Figure 6.2. A plus sign before numbers indicates that the HBc changes 
seen in the previous sample are still present in subsequent samples 
and that the indicated number of further changes have appeared. X- 
axis is in months.
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Interestingly, 95% of the nucleotide changes, both in this Chapter and 
Chapter 5, led to amino acid substitutions. The functional aspects of the 
nucleotide changes were not formally addressed. However, in a separate 
study by Mr. E. Dornan, where the distribution of HBeAg in the cell was 
examined, in the patients studied in this Chapter, it was shown that there 
was shift in the distribution of HBeAg from nucleus to the cytoplasm. This 
occurred in patients who had changes within the nuclear localisation site. 
Although all the changes observed in this region led to amino acid 
substitutions it is likely that it is the nucleotide rather than the amino acid 
change that is having an effect on the distribution of HBeAg.
6.5.2 Clinical correlates and distribution of mutations in HBe to anti- 
HBe seroconverters
Figure 6.1 shows the results for those who seroconverted, during the 
period of observation, to anti-HBe. With regard to clinical outcome, 
patients who went into remission not only selected the greater number of 
total substitutions - 19 compared to 9 in those who progressed - but also 
had a higher proportion of substitutions in the common Th epitope from aa 
50 to 69 compared to the remaining core sequence (odds ratio 5.64 [95%  
Cl 2.12-14.85]; p = 0.00045). Statistical results for all epitopes are given 
in Table 6.1. In the group with ongoing disease (Table 6.2), there is no 
apparent correlation between mutations and epitopes. However, if earlier 
and later samples for A34 and A35 had been available for these patients, 
we believe we may have observed a greater number of mutations as was 
the case for the continuously anti-HBe patients (Chapter 6, section 6.5.3).
6.5.3 Timing and distribution of mutations in continuously anti-HBe 
positive patients
Figure 6.2 shows the distribution of the substitutions in the core protein; 
overall, a total of 110 amino acid substitutions were observed for all 21 
patients. It is important to note that only those positions where changes 
were detected are noted, so the horizontal distances in Figure 6.2 do not
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add up to the full length of the gene. The timing of substitutions was 
examined in 13 of the 21 cases (H21, H24, H25, H27, H28, H30, H31, 
H33, H35, H36, H37 and H38) where more detailed series of sera were 
available (Table 6.3). Most (53/77) substitutions in these 13 cases 
occurred between the initial and second samples (range 1-15, mean 5.9) 
rather than between the second and final samples (range 1-4, mean 1.85) 
p = 0.0069 (paired t test). Of the 110 substitutions in all 21 patients, 61 
occurred in B- or Th cell epitopes (odds ratio 1.69 [95% Cl 1.13 - 2.52]; p 
= 0.007). Table 6.4 shows the statistical analysis of the correlation with 
particular epitopes. Significant numbers of substitutions were found in the 
B-cell epitopes from amino acids 74 to 83 (odds ratio 2.63 [95% Cl 1.36- 
4.74]; p=0.00067), from amino acids 128 to 135 (odds ratio 2.15 [95% Cl
0.94-4.37]; p=0.03) and from amino acids 130 to 138 (odds ratio 2.56  
[95% Cl 1.35-4.80]; p=0.0014). The number of mutations found in the 
common Th epitope from amino acids 50 to 69 verged on the level of 
significance (odds ratio 0.55 [95% Cl 0.28-1.08]; p=0.06). Figure 6.3 
shows that even though multiple flares of hepatitis occurred in these 
patients, extra substitutions seldom emerged before or after each peak.
Finally, the entire pre-C/C region of 5 sequential serum samples from 
each of patients H21 and H33, along with 4 sequential samples from 
patient H35, were sequenced to search for transient substitutions: none 
were found.
6.6 Discussion
In this section of the thesis, the emergence of core substitutions was 
examined in continuously anti-HBe patients; their appearance was timed 
and correlated with known humoral and Th cell epitopes. These data were 
compared to those generated in HBeAg to anti-HBe seroconverters 
because although both situations are associated with active hepatitis, it is 
possible that different immune effector systems are in operation.
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At the beginning of the study, seven of the continuously anti-HBe patients 
were infected with HBeAg producing strains and five had a mixture of 
producer and non-producer strains, confirming results from previous 
studies (Chapter 5) that there is an initial burst of core substitutions with 
the simultaneous emergence of a pre-C mutant. This is most likely due to 
the loss of immunotolerance, as HBeAg is believed to induce 
immunotolerance both against itself and HBeAg (which shares much of 
the protein sequence), with the result that loss of HBeAg leads to an 
enhanced immune response, and thus selection pressure, against HBeAg. 
Ongoing selection does occur after this event, but at a greatly reduced 
rate. Most of the substitutions detected occurred between the first and 
second samples (Table 6.3) and, although there were subsequent 
substitutions, these could not be associated temporally with the ALT 
peaks observed in these patients. It seems unlikely, therefore, that a ‘new’ 
virus gives rise to a fresh episode of disease, as one would then expect a 
novel virus at each peak. Despite several episodes of disease, however, it 
was noted that once a substitution arose, it remained until the final 
sample. Also, few substitutions were observed subsequent to the initial 
burst. The correlation in this case appears to be with the emergence of a 
stop codon rather than a flare of hepatitis.
The flaw in only sequencing the area in which substitutions had arisen 
(enabling us to time their appearance) is that this would only highlight 
viruses that were maintained, and not those that were cleared by the 
immune system. To address this possibility, three patients (H21, H33 and 
H35), who had experienced several transaminase flares, were selected 
and the entire pre-C/C sequence from all the samples available, was 
sequenced. This did not reveal any transient substitutions. This is not 
what we would predict were the immune system being stimulated (causing 
the hepatitis flares) by a ‘new’ virus.
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Chapter 6
These results hint at the immune effectors that force viral escape during 
chronic hepatitis. In earlier cross-sectional analyses, where comparisons 
were made to a consensus sequence, anti-HBe-positive cases with active 
disease had greater numbers of mutations in the commonly recognised Th 
epitope (between amino acids 50 to 69) as well as in two of the three anti- 
HBc/e B-cell epitopes. In contrast, in the sequential samples analysed in 
this chapter, where sequences were compared to their predecessors, 
patients who went into remission appeared to select more mutations in the 
Th epitope and those with ongoing disease selected mutations in B-cell 
epitopes. There may be some pressure on the common Th epitope as the 
number of mutations in this area was verging on significance. In the cross- 
sectional analysis the number of Th mutations represented the 
accumulated mutations over time which are therefore consistent with 
these current data.
The influence of substitutions in the other three proteins was not 
addressed in this study, but the results indicate that the mutant strains are 
escaping from the immune response against core protein, rather than 
causing peaks of hepatitis.
6.7 Implications
In acute HBV infection, there is a strong CTL response which clears 
infected hepatocytes (Bertoletti et al, 1991, Penna et al, 1991, Missale et 
al, 1993); however, this is absent in chronic hepatitis. These results may 
help to explain why these patients have ongoing disease in the absence 
of CTL. In those who remit, we hypothesise that the virus has escaped the 
Th response, allowing disease-free persistence. The reason why there is 
not a high level of vireamia in these patients is not clear, but it is possible 
there are two independent Th responses, one of which may stimulate 
production of effective antibodies. In Figure 6.1 it can be seen that in the 
clinically remitted cases, no amino acid changes were seen in the Th
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epitope from amino acids 1 to 20 or in the B-cell epitopes. However, in 
those with ongoing disease after seroconversion, we believe there is an 
ineffective antibody response against infected hepatocytes which does not 
clear infection from all cells, but kills a proportion of infected hepatocytes. 
This puts the virus under selection pressure, manifested by focused 
substitution in B-cell epitopes. The few mutations in Th epitopes in these 
cases is in keeping with this hypothesis.
If such a finding were upheld there is a clear implication for therapeutic 
vaccination: vaccines that mainly stimulate antibody are unlikely to clear 
virus from infected carriers. A vaccine which includes either novel Th 
epitopes, which may be needed to enhance antibody effectors, or one that 
stimulates CTL may be more effective in clearing virus from chronic HBV 
infected individuals.
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Chapter 7 
Results: Section 4 
Overlapping peptide series
7.1 Aims
There has been much debate as to whether the proposed immune 
selection pressure on HBeAg is humoral or T-cell mediated (or both). In 
Chapters 5 and 6, we showed that the number of substitutions in B-cell 
epitopes in continuously anti-HBe positive patients was statistically 
significantly greater compared to other regions of the core protein, yet in 
those who seroconverted to anti-HBe and went into remission, there was 
selection in Th cell epitopes. To provide direct evidence for such immune 
escape we decided to construct a series of peptides, covering the entire 
core region, to use in an ELISA system to test for humoral escape, and in 
lymphoproliferation assays to test for Th cell escape.
7.2 Preliminary study
7.2.1 Background
A number of groups have used peptides to delineate epitopes (humoral, 
CTL and Th) in both HBeAg (Sallberg et al, 1991, Salfeld et al, 1991, 
Penna et al, 1991, Bertoletti et al, 1993) and HBsAg (Manivel et al, 1992). 
Several of these groups had difficulty in showing reactivity of patients’ 
sera to peptides. As the use of patients’ sera would be the basis of our 
experiments, this would clearly be a major problem for our studies.
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In previous studies, peptides were fairly short, around 10 to 15 amino 
acids in length. The major B-cell epitope (from amino acids 74 to 83) is 
believed to be part of a larger conformational epitope, therefore we 
propose that such short peptides may have failed to fold into the correct 
conformation. Second, all the groups had used monomeric peptides. W e  
had the facility to construct peptides with more than one branch (multiply 
antigenic peptides [MAPs]). This technique was originally developed by 
Tam (1988) who observed that antibodies could be detected with a lower 
amount of branched peptides than monomeric peptides (Tam and Zavala, 
1989). Further characterisation of branched peptides was carried out by 
C.A. Robertson (PhD thesis, University of Glasgow, 1994). One of the 
probable reasons for increased sensitivity may be bivalent binding 
between the two arms of the antibody and epitopes on two arms of the 
branched peptide, providing increased stability of the bond. However, an 
epitope in close proximity to the polylysine core may not be able to bind to 
the two paratopes on the two arms of the reactive antibody. Therefore, 
Robertson (1994) tested the effect of varying the distance between the 
epitope and the polylysine core by the introduction of glycine residues 
(acting as spacers) and came to the conclusion that a spacer of four or 
five glycine residues markedly increased the reactivity in the system 
tested.
As a preliminary experiment, reactivity of anti-HBe positive serum to 
peptides was tested. Large peptides can have problems such as folding 
back on themselves during synthesis which can result in;
1. the peptide not achieving its full complement of amino acids
2. steric hindrance caused by close proximity of the peptide chains
3. poor solubilisation of the final product.
7.2.2 Oligopeptides
As the previous studies employed short monomeric peptides without much 
success and the facilities were available to construct branched peptides,
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we decided to test long, branched peptides against known anti-HBe 
positive sera.
7.2.3 Methods
A peptide of 30 amino acids in length, spanning the described major 
epitope of HBeAg between amino acids 74 and 83, was synthesised in 
monomeric (peptide 414-a) (3.12.2) and branched: two (peptide 414-b), 
four (peptide 414-c) and eight (peptide 414-d) branch configurations 
(Table 7.1) (3.12.1). Four glycine spacers were inserted between the 
lysine core and the peptide.
7.2.3.1 Cleavage and dissolution of peptides
Peptides were cleaved (3.13) and dissolved as follows: peptide 414-a was 
soluble in water, while peptides 414-b, -c and -d required the addition of 
33% acetic acid to achieve dissolution (3.18). Peptides were analysed by 
reverse-phase HPLC (3.15) but not purified further.
7.2.3.2 ELISA
The method followed is detailed in 3.19. The comparative reactivity of 
peptides 414-a,-b and -c, were tested in ELISA with anti-HBe positive and 
negative human sera (supplied by the diagnostic virology department, 
Western Infirmary, Glasgow). A range of peptide concentrations (0.156-80  
ng/well) was tested against sera at 1:50, 1:100, 1:200, 1:400 and 1:800 
dilutions.
7.2.4 Results
Figure 7.1 shows the results at a serum dilution of 1:50. The monomeric 
peptide gave the poorest reactivities at all concentrations. Although the 
branched peptides gave higher reactivities, it was not as high as we would 
have anticipated (from work in other viral systems).
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Figure 7.2 shows the results at a serum dilution of 1:200. The monomeric 
peptide gave almost negligible reactivities at this dilution. Again, the 
branched peptides (414-b, 414-c and 414-d) exhibited better reactivities 
when compared to 414-a; 414-c and 414-d demonstrated greater 
reactivities than 414-b.
7.2.5 Conclusions of the preliminary study
The results indicated that it was possible to achieve reactivity using serum 
and that the branched peptides were more reactive against anti-HBe than 
the monomeric peptide. Therefore, an overlapping series of peptides of 30 
amino acids in length was synthesised, with four glycine spacers in a four 
branch configuration. As there was little apparent difference in antibody 
binding between the four and eight branches, it was hoped that the four 
branch configuration may behave better in terms of folding and solubility.
7.3 Overlapping peptide series: Synthesis
7.3.1 Peptide synthesis
All peptides were synthesised in a four branch configuration (3.12.1) and 
were cleaved as detailed in 3.12. Peptide sequences are detailed in Table
7.2
Four other peptides were also synthesised. Results from Chapters 5 and 6 
and a previous study by Carman et al (1995) showed three frequent amino 
acid changes; from threonine (peptide Thi) to serine (peptide Th2) at 
amino acid 12, from glutamic acid to aspartic acid at amino acid 64 
(peptide ThP64) and from threonine to asparagine at amino acid 67 
(peptide ThP67)- Peptide ThPn had glutamic acid at amino acid 64 and 
threonine at amino acid 67. As all of these amino acids reside in Th 
epitopes (amino acids 1 to 20 and 50 to 69), we decided to construct 
these ‘mutant’ peptides to test them in lymphoproliferation studies.
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7.3.2 Dissolution of branched peptides
It was envisaged that, due to the length and branched nature of the 
peptides there may be problems with solubility. Figure 7.3 shows a 
hydrophobicity/philicity plot of HBcAg; peaks above the horizontal line 
indicate areas with a positive charge and peaks below indicate areas 
which are negatively charged. As solubility depends on the charge of the 
peptide, possible problem areas were the positively charged carboxy 
terminal, a highly arginine-rich region (which would also have the problem 
of side-chain protecting groups), and the negatively charged central 
region. To aid dissolution of positively charged peptides, bubbling of NH3 
gas is often employed; addition of acid can aid dissolution of those that 
are negatively charged.
It is usual to begin a synthesis at the carboxy terminal when making an 
overlapping series. On synthesis of peptides P22-18, -19, -20, all were 
soluble in water without the addition of NH3. However, peptides P22-10, - 
12, -13, -14, -15, and P22-16 proved to be insoluble even with the 
addition of acid (Table 7.3 details solubilities of peptides from the initial 
synthesis).
In consultation with Dr. H. Marsden (Institute of Virology, Glasgow), three 
lysine or three aspartic acid residues were added to peptides P22-10, -12, 
-13, -14, -15, -16 with the aim of increasing solubility.
Solubility results of these latter peptides are given in Table 7.4. Addition 
of three lysine residues to P22-12 did improve its solubility but the other 
peptides remained insoluble. Peptides P22-10, -13, -14, -15, -16 were 
then resynthesised as 20 mers (in a four branch configuration) and 
renamed as P22-10N, -13N, -14N, -15N, -16N but all proved to be 
insoluble in water, acetic acid and NH3.
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T able  7.3 Solubilities of p ep tid es  from th e  initial sy n th esis
Pep tide c h arg e
H20
Solubility 
ace tic  acid n h 3
P22-4 - 4 +
P22-5 - 4 - - +
P22-6 - 4 - - +
P22-7 0 + - -
P22-8 + 2 + - -
P22-9 + 2 - + -
P22-10 - 3 - - -
P 2 2 -1 1 - 3 - - +
P22-12 0 - - -
P22-13 + 2 - - -
P22-14 + 3 - - -
P22-15 0 - - -
P22-16 + 1 - - -
P22-17 + 4 + - -
P22-18 + 6 + - -
P22-19 + 12 + - -
P22-20 + 12 + - -
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7.3.3 Monomeric synthesis
As the branched configuration, which have an increased charge, was 
probably contributing to the insolubility of the peptides and we wished to 
maintain the overlapping series, peptides P22-10, -13, -14, -15, -16 were 
synthesised as monomers (3.12.2), firstly as 30 mers, but as these also 
proved to be insoluble, subsequently as 20 mers (P22-10M, -13M, -14M, - 
15M, -16M) (Sequences given in Table 7.5).
7.3.4 Dissolution of monomeric peptides
When synthesised as monomeric 20 mers the peptides were soluble in 
acetic acid though with much reduced yields (Table 7.6).
7.3.5 Purification of peptides
Purification can sometimes improve the solubility, thus it was decided to 
purify all the peptides. All peptides were subsequently purified by Dr. Ania 
Oswianka (Institute of Virology, University of Glasgow) by reverse phase 
high pressure liquid chromatography (HPLC) using a Vydak-FB1520 
column (3.16).
7.3.6 Amino acid analysis of peptides
The amino acid content of the monomeric peptides (3.14.1) and branched 
peptides (3.14.2) were analysed. Except peptide P22-8, all peptides had 
the correct amino acid content. P22-8 was resynthesised and reanalysed 
and subsequently found to have the correct amino acid content.
7.4 Functional analysis of HBcAg peptides
The peptides were used to examine the T- and B-cell response in patients 
with HBV infection. Primarily, we wanted to examine the nature of the ALT 
flares observed in patients with a similar clinical background as those 
studied previously (Chapters 5 and 6) but other outcomes of infection (i.e. 
acute and fulminant) were also studied. In this section of the work we
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collaborated with Professor Hadziyannis (Athens, Greece) as we did not 
have access to many hepatitis cases (over a period of six months there 
were only two acute cases in Glasgow). Professor Hadziyannis has a 
large repertoire of patients and expertise in this area of study.
7.4.1 Lymphoproliferation studies: results
Study 1(Glasgow) The lymphoproliferative response of five non- 
symptomatic chronic carriers against peptides Thi, Th2 and ThPn were 
tested using the whole blood assay (3.21.1), the results are given in 
Figure 7.4; the results of stimulation with phytohaemagglutinin (PHA) are 
given in Figure 7.5. The PHA results are plotted separately as the values 
obtained far exceeded those obtained for the peptides. When the PHA  
and peptide results are plotted together the graph produced is 
meaningless.
A stimulation index (SI) > 3 indicates a response to the antigen tested. 
Patients 4 and 5 failed to respond to either peptides or HBcAg, but as 
their Sis to PHA are low this is not surprising. Patients 1, 2 and 3 
responded well to PHA and HBcAg. However, they failed to respond to 
Th-i or Th2 but there was a response to ThPn.
The PBMCs of two acute hepatitis patients were tested for 
lymphoproliferation (3.21.2) to Th1f Th2, ThPn and P22-16M (this peptide 
contains amino acids 117 to 131, described as a Th epitope by Ferrari et 
al (1991) [Figure 7.6]). Unfortunately, due to a breakdown in the cell 
harvester, the cells from one of the patients could not be read.
The other patient responded well to PHA (43820cpm.). In contrast to the 
results observed with the chronic patients, the acute hepatitis case failed 
to respond to ThPn. However, there was a response seen with Thi, Th2 
and P22-16M.
114
Pa
tie
nt
 1
xepu; uope|nuips xapu j u o p e in tu p s
Th
1 
Th
2 
Th
Pn
 
H
B
cA
g
> 
An
tig
en
 
co
nc
en
tra
tio
n
Pa
tie
nt
 3
xapu ; u o u e in iu ijs xapui uogeiniups
Th
2 
Th
Pn
 
H
B
cA
g
An
tig
en
 
co
nc
en
tra
tio
n
Pa
tie
nt
 5
h'-COiONTCOCNT-O
xapu; uopeiniups
N 0 l / ) ^ - C O ( N t - O
xapu; uope|nuips
Th
2 
Th
Pn
 
H
B
cA
g
An
tig
en
 
co
nc
en
tr
at
io
n
o
03
E0
-4— '
CL
E
> .to1coc
0
>
CD
<O
OQ
X
"Oc
03
Q.
JC
H
"Oc
0
T3
TO
U
E
COto0;u
Q.
0
CL
CD
<O00
X
co
0coco
CL
(/)
0
>TO
to
toTO
"D
O_o
_Q
0
O
CO
0 
>  
-4—»TO
O)
0
C
o
mx
cTO
C
0
TO
CL
Coo
TO
■ocTO
(/>
0
0
i _
13
CD
TO
O
O
Co
I —JZo
Figure 7.5 Whole blood assay responses to PHA in five non- 
symptomatic chronic carriers and a control patient.
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Study 2 (Athens) The overlapping peptide series was tested in 
lymphoproliferation assays using PBMCs from patients with a variety of 
disease profiles: acute hepatitis, fulminant hepatitis, chronic HBV and 
HCC. Patient details are given in Table 7.7. Lymphoproliferation was 
observed (Figure 7.7).
Acute HBV patients: those with acute hepatitis (PBMC10 and PBMC20) 
did not respond to peptides P22-4, -5 and -6, which contain either all or 
part of the Th epitope between amino acids 1 and 20. In fact, PBMC20 
showed little response to any peptide, whereas PBMC10 responded to 
P22-9, which contains the major Th epitope (amino acids 50 to 69) and 
also to P22-16M, which contains the Th epitope at amino acids 117 to 
131.
Fulminant HBV patients: PBMC1 and PBMC15 responded similarly to all 
the peptides. They responded well to P22-4 with stimulation indices of 6, 
and also showed a response to peptides P22-11,-12, -13, -15, -16 and - 
19.
Chronic HBV patients: a definite response to peptides P22-4, -5 and -6 
was observed in 5 out of 18 patients with chronic hepatitis. Unfortunately, 
PBMC11 and PBMC12, who responded well to the Th epitope amino acid 
1 to 20, were not tested against peptides P22-6 to P22-20. Only one of 
the remaining three (PBMC3) responded to other peptides (P22-10M, -12, 
-15 and -16M). The asymptomatic chronic carrier PBMC16, surprisingly, 
showed a response to several peptides (P22-17, -18, -19 and -20), all of 
which are at the C-terminus of HBcAg.
HCC patients: PBMC18 and PBMC22 responded to P22-4 and PBMC18 
responded to additional peptides at the carboxy-terminal of HBcAg.
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Table 7.7 Clinical details of patients tested in the 
lymphoproliferation assay
Patient Diagnosis HBeAg Anti-HBe ALT
PBMC1 Fulminant - + >2000
PBMC2 Chronic - + 305
PBMC3 Chronic + - 48
PBMC4 Chronic - + 491
PBMC5 Chronic + - 57
PBMC6 Chronic - + 158
PBMC7 Chronic + - 121
PBMC8 Chronic + - 214
PBMC9 Chronic + + 118
PBMC10 Acute - + 850
PBMC11 Chronic - + 988
PBMC12 Chronic + + 661
PBMC13 Chronic - + 700
PBMC14 Chronic + - 534
PBMC15 Fulminant - + >2000
PBMC16 Carrier - + 19
PBMC17 Chronic + - 78
PBMC18 HCC - + 67
PBMC19 Chronic - + 42
PBMC20 Acute - + 119
PBMC21 Chronic - + 49
PBMC22 HCC - + 5
PBMC23 Chronic - + 59
PBMC24 Chronic - + 33
PBMC25 Chronic - + 43
HCC= hepatocellular carcinoma. 
Anti-HBe= antibody to HBeAg.
ALT= alanine aminotransferase (N<40iu/I).
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Study 3 (Athens) To determine whether lack of response was due to a 
mutated sequence, amino acids 1 to 30 of HBcAg was subsequently 
sequenced for all the above patients (Table 7.8). Branched chain peptides 
were constructed (by Dr. A. Oswianka, Institute of Virology, University of 
Glasgow) that contained the variant amino acids (Table 7.9). 
Unfortunately, as yet, only one patient (PBMC13) has been tested against 
their variant peptide (7.4.2, study 6). This study is still in progress.
7.4.2 B-cell studies: results
Study 4 (Athens) Three patients were tested by IgM ELISA (3.20) 
against the overlapping peptide series. Their diagnoses were as follows:
BC1
BC2
BC3
Positive control 
Negative control 
Control
Fulminant HBV infection.
Chronic anti-HBe-positive, with severe 
exacerbations of hepatitis.
Chronic HBeAg-positive at phase of 
seroconversion.
Anti-HBe-positive, with very high level anti-HBc 
IgM.
Chronic HDV infection, HBsAg-positive, HBV-DNA  
negative.
Negative for HBV infection.
The results are given in Figure 7.8. The antibody class which was being 
measured was IgM, therefore a patient with HDV infection was used as 
the negative control.
The positive control sample, when compared to the negative control, 
reacted to all the peptides but with varying intensity. The fulminant 
hepatitis (BC1) case reacted similarly to the positive control, indicating a 
strong anti-HBc response in this patient. The reactivities of BC2 and BC3
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Table 7.8 Sequence of aa 1 -30 of HBcAg from patients 
analysed by lymphoproliferation assays
Patient
PBMC1
PBMC2
PBMC3
PBMC4
PBMC5
PBMC6
PBMC7
PBMC8
PBMC9
PBMC10
PBMC12
PBMC13
PBMC14
PBMC15
PBMC17
PBMC18
PBMC19
PBMC20
PBMC21
PBMC22
PBMC23
Sequence
MDIDPYKEFGATVELLSFLPSDFFPSVRDL
M DIDPYKEFGATVELLSFXPSDFFPSVRDL
MDIDPYKEFGATVELLSFLPSDFFPSVRDL
MDIDPYKEFGASVELLSFLPSDFFPSVRDL
MDIDPYKEFGATVELLSFLPSDFFPSVQDL
MDXDPYKEFGATVELLSFLPSDFFPSVRDL
MDIDPYKEFGATVELLSFLPSDFLSSVRDL
MDIDPCKEFGATVELLSFLPSDFFPSVRDL
MDIDPYKEFGATVELLSFLPSDFFPSVRDL
MDIDPYKEFGASVELLSFLPSDFFPSVRDL
MDIDPYKEFGATKELLSFLPSDFFPSVRDL
M DIDPYKEFGASVEILSFLPHDFFPSVRDL
M DIDPYKEFGATVELLSFLPSDFFPSVRDL
MDIDPYKEFGATVELLSFLPADFFPSVRDL
MDIDPYKEFGATVELLSFLPSDFFPSVRDL
MDIDPYKEFGATVELLSFLPSDFFPSVGDL
MDIDPYKEFGATVELLSFLPSDFFPSVRDL
MDIDPYKEFGATVELLSFLPXDFFPSVRDL
MDIDPYKEFGASVELLSFLPXDFFPSVRDL
MDIDPYKEFGATVELLSFLPSDFFPSVRDL
MDIDPYKEFGATVELLSFLPSDFFPSVRDL
Single letter codes for aa are given in Appendix 2
Table 7.9 Sequences of the variant peptides derived 
from the PBMC series of patients
Peptide Sequence
S1 A T V E L L S F L P S D F F P S V R D L
S2 A S V E L L S F L P P D F F P S V R D L
S3 A S V E L L S F L P H D F F P P V R D L
S4 A T V E L L S F L P A D F F P S V R D L
S5 A T V E L L S F L P L D F F P s V R D L
S6 A T V E L L S F L P S D F F P s V Q D L
S7 A T V E L L S F L P S D F F P s V G D L
S8 A T V E L L S F L P S D F L S s V R D L
Peptides span aa 11-30 of HBcAg
Single letter aa codes are given in Appendix 2
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were generally lower. Patients BC1 and BC3 reacted to the N-terminal of 
HBcAg, peptides P22-4, -5 and -6.
A very strong response was observed to the major B-cell epitope (amino 
acids 74 to 83); peptides P22-11 and -12 by the positive control serum 
and also by patients BC1 and BC2. Patient BC3 did respond, with a 3-fold 
and 10-fold increased response over the negative control, but not to the 
same extent as the other two patients. Interestingly, patient BC1 and the 
positive control serum reacted to P22-10, a monomeric peptide; the 
intensity of this reaction was unexpected. Patient BC1 also reacted to the 
C-terminal of HBcAg , peptides P22-18, -19, and -20.
Study 5 (Athens) Peptides P22-4, -5 and -6 were also constructed as 
monomers. They were compared to their branched counterpart in an 
ELISA (3.20) against various patients’ sera regardless of diagnosis 
(information on the patients was not supplied by Professor Hadziyannis 
despite a number of requests) (Figure 7.9). In the preliminary study we 
had shown that branched chain peptides were more sensitive when used 
in an ELISA. Professor Hadziyannis repeated this experiment, using 
different peptides, confirming that the branched chain peptides are 
superior in the detection of anti-HBc.
Study 6 (Athens) Patient PBMC13’s response to the overlapping 
peptide series was also tested by ELISA, for both IgG (Figure 7.10) and 
IgM (Figure 7.11). Clearly, patient PBMC13 has a stronger IgG than IgM 
response. There does not appear to be a particularly strong response to 
the major B-cell epitope but he has, like the earlier patients, responded to 
peptides P22-4 and -5. A variant peptide (S3) (Table 7.9) was produced 
because of PBMC13 lack of reactivity in the lymphoproliteration assay to 
peptides P22-4, -5 and -6 (Figure 7.7). This peptide (and the other variant 
peptides) were tested by ELISA, both IgG and IgM. The reactivities
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Peptides P22-4 and P22-4M
1 2 3 4 5 6 7 8
Patients
Peptides P22-5 and P22-5M
Ec
1 2 3 4 5 6 7 8
Patients
Peptides P22-6 and P22-6M
Ecin
Patients
Figure 7.9 Comparison of reactivity of branched and monomeric 
peptides P22-4, -5 and -6 tested against anti-HBc positive sera. 
Peptides were tested at 5fig/well.
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against the variant peptides are shown in Figure 7.11. The OD values are 
generally low except for peptide S4 in the IgM assay.
7.4.3 Conclusions and discussion
Professor Hadziyannis’s group were given the peptides in July 1994, 
despite this all of the above results are only preliminary, each experiment 
only having been completed once or twice. Therefore, it is difficult to make 
any conclusive statements concerning these results. W hat is clear is that 
the peptides I synthesised do work in these systems.
The non-uniform response observed when whole blood was tested (on 
several occasions one of the triplicate test wells gave background 
readings despite the other two wells giving positive readings) was 
considered to be an inherent problem with the whole blood assay and 
therefore it was decided to use PBMCs.
The patients in study 1 did not respond quite as well to the peptides or 
HBcAg as we may have hoped, probably because the patients were 
asymptomatic HBV carriers and not experiencing active disease during 
the period of testing their PBMCs. There was virtually no response to Tt^. 
The absolute failure of these patients to recognise Th2 could be related to 
the HBcAg sequence in these patients. Unfortunately, the HBcAg 
sequences of the patients were not examined. However, in accordance 
with Ferrari et al (1991) the majority (3/5) of the patients did respond to 
the major Th cell epitope. This was not observed in study 2 where only 
2/25 (PBMC10 and 13) responded to these peptides in the assays. The 
number of cells primed to react to HBcAg peptides is likely to be low 
therefore a greater number of replicates, at least six, would be required to 
give conclusive results.
In study 2, where the lymphoproliferative response of patients with a 
variety of disease profiles was tested, not all patients responded equally
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well to the peptides indicating a patient-specific response. There was no 
apparent correlation between HBeAg/anti-HBe status or ALT level and 
response to peptides. The dominant response was to P22-4 (which 
contains the Th epitope amino acid 1 to 20). In all patients who responded 
to amino acids 1 to 20, a decrease in response was observed as the 
epitope was gradually omitted from the peptides in the overlapping series, 
thus indicating that the epitope lies between 14 and 23.
There was a good response to several peptides in those with fulminant 
hepatitis (with both cases responding to the same peptides), indicating an 
active Th response in these individuals. Interestingly, sequencing of the 
first 30 amino acids of HBcAg of the patients in study 2 showed that the 
most variant amino acid was amino acid 21(4/20). The Th epitope has 
been described to be between amino acids 1 to 20 but our results indicate 
that in may be between 14 and 23. However, it is possible that adjacent 
residues, not involved in binding can have an effect on binding of the 
peptide to the groove of the MHC, for this reason amino acids outwith this 
region were included in the variant peptides. Several of the patients 
(PBMC4, 7, 9, 17, 22,) who failed to respond to peptides P22-4, -5 and -6 
did not have variant sequences and PBMC13, who did respond to these 
peptides, had the most variant HBcAg sequences (from amino acid 1 to 
30). Therefore, from the sequencing data, it seems unlikely that the lack of 
response is due to variation in the Th epitope.
Results were available for comparison only between branched and 
monomeric peptides for the B-cell studies. The branched peptides are 
clearly more reactive than the monomers. W hat is puzzling is what exactly 
these sera are reacting to. The peptides tested, P22 -4, -5, -6, span the 
region amino acids 1 to 43. No B-cell epitope has been described in this 
region which, of course, does not mean that there is not one! When 
patients’ sera were tested against the overlapping peptide series, three of 
the patients (BC1, BC3 and PBMC13) and the positive control also
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responded to these peptides, implying that there is something interesting 
happening in this region - an undescribed B-cell epitope? Although there 
was no direct comparative data on branched versus monomeric peptides 
for the lymphoproliferation assay, monomeric peptides were equally 
efficient at stimulating proliferation as branched chain peptides, indicating 
that there will be little difference between the two configurations when 
they are examined directly. Further work is still being carried out in this 
area.
A recent report from Italy has shown that biotinylation of monomeric 
peptides enhances the binding efficiency of the peptides (Professor 
Hadziyannis, personal communication).
As expected all patients reacted to the major B-cell epitope, providing 
good evidence that the peptides are specific for HBcAg. The fact that the 
positive control (IgM anti-HBc positive) reacted to all the peptides is of 
concern. The reactivities to peptides P22-13, -14, -15 and -16 were low 
but, as these peptides are monomeric, this was expected. Reactivity to 
peptides P22-17, -18, -19 and -20 (branched peptides) was also low (only 
2 or 3 x background), though an epitope has been described in HBcAg in 
this area (between amino acids 150 and 159) by Machida et al (1989). 
Patient BC1 reacted well to this epitope (approximately 6 x background).
One of the original aims of this section of work was to test sera around the 
time of an acute exacerbation to determine whether a flare of hepatitis is 
caused by a ‘new’ virus or whether the flare results in appearance of a 
‘new’ virus. Unfortunately, although a preliminary experiment has been 
completed, I was not provided with the data before presentation of this 
thesis but these studies are ongoing.
Patient PBMC13 was tested against the variant peptides in an ELISA. 
Although he did respond in the IgM assay to one of the variant peptides
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(S4), this peptide did not contain the variant specific to him. His variant 
peptide was peptide S3, to which he failed to respond. Have these 
variants rendered this epitope unreactive? In the test for IgG he had weak 
reactivities to most of the variant peptides. Why he should respond to a 
variant which he does not have is not clear. Perhaps our assumption that 
mixtures below our level in detection (5%) by direct sequencing are 
unimportant was wrong; to determine whether or not PBMC13 has this 
variant we would have to sequence clones of HBcAg from this serum.
7.5 Future work
Due to the reduced sensitivity in antibody binding studies with monomeric 
peptides we propose the use of entire core proteins in future studies. 
Sequential cloned HBcAgs from patients experiencing acute 
exacerbations of hepatitis tested in an ELISA would determine whether or 
not antibody escape is occurring. These recombinant HBcAgs would have 
the advantage of having the correct epitopic conformation. Alternatively, 
biotinylation of our monomeric peptides may increase their sensitivity (as 
referred to earlier in this Chapter [7.4.3]) or could be used in conjunction 
with the recombinant HBcAgs to delineate any further epitopes .
Several patients reacted to the N-terminal peptides in the B-cell studies, 
indicating the presence of a B-cell epitope. Further investigation is 
required to determine whether this is a true B-cell epitope. If it does prove 
to be an epitope, then patient PBMC13 would be an excellent test patient, 
to look for B-cell escape here, as we have already demonstrated that he 
does not recognise his own peptide. To test whether there is ongoing B- 
cell escape subsequent or previous serum samples would have to be 
sequenced, the relevant peptides constructed and tested.
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Results: Section 5
Expression of HBcAg
8.1 Aim
The aim of this section of the thesis was to express HBcAg, from patients 
sequenced in Chapter 6, for use in antibody binding studies.
The peptides which we produced (Chapter 7), were also to be used for 
this purpose. W e considered the possibility that the peptides may not form 
the correct conformation, despite their length. Thus, to overcome this 
potential drawback we decided to express the HBcAg of some of the 
Greek patients (sequenced in Chapter 6) and use these in conjunction 
with the peptides.
There was also the possibility that the mutated core proteins described in 
Chapters 5 and 6, may not have the same antibody binding efficiency as 
compared to the standard HBcAg. This has clearly been observed with 
HBsAg (Wallace et al, 1995 ), where changes in the a determinant have 
either reduced or completely abrogated binding efficiency in diagnostic 
assays. This raises the possibility of false negatives and, such variant 
HBcAgs could be used in new generation anti-HBc diagnostic assays.
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8.2 Selection of HBcAg sequences to be cloned and expressed
In parallel to this study, a separate study was being carried out (by Mr. E. 
Dornan) in our laboratory, to examine changes in the distribution of 
sequential HBcAg sequences from patients, in hepatocytes, during the 
course of infection. Therefore, the same HBcAg sequences were selected 
for cloning and expression in the antibody binding study. The hope was 
that, by collating the data from both studies, we may be able to determine 
whether the mutations observed did represent humoral escape or whether 
they affected the distribution and accumulation of HBcAg in the 
hepatocyte (subsequently having a detrimental effect on the hepatocyte). 
HBcAg from the first and last sample in the serum series for each patient 
were used. The pairs used were as follows:
Gr2 and Gr6, from patient H20 
Gr22 and Gr25, from patient H27 
Gr45 and Gr49, from patient H32 
Gr50 and Gr54, from patient H33 
Gr82 and Gr86, from patient H37 
Patient details are given in Figure 6.2.
8.3 Strategies employed in the cloning of HBcAg: methods and 
results
Several strategies were employed in our attempt to express the above 
HBcAgs. They are outlined below.
Strategy 1
The C1/C2N PCR products of the above patients were amplified (3.3.2) 
using primers C5/C4N, producing a product with an Eco R1 site at the 5’ 
end and a Hin d ill site at the 3 ’ end. The products were digested (3.7) 
with Eco R1 and Hin d ill and subsequently electrophoresed on a 1%, 
1xTBE agarose gel (3.5). The products were excised and purified by the
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Geneclean method (3.4.2), ligated with the vector pRK5 (3.8) and 
transformed in E.coli. (3.10).
At this point the procedure was stopped since pRK5 was primarily used 
for expression in mammalian systems it was envisaged that it would not 
be suitable for expression in E.coli.
Strategy 2
C1/C2N products were amplified using primers CPK and C4N, thus 
producing a product with an EcoR1 site at the 5’ end and a Hin d ill site at 
the 3’ end. The amplified products were ligated (3.8) directly into the PCR 
cloning vector, pT7Blue, and transformed in E.coli. After 16h, the plates 
were examined and five white colonies were picked from each plate, 
transferred into a glass universal containing 3mls of selection medium (LB 
broth plus 100pg/ml of ampicillin and tetracycline) and grown overnight at 
37°C in a shaking incubator. Cultures were subsequently mini-prepped, 
restriction enzyme digested (3.7), with Eco R1 and Hin d ill and then 
electrophoresed on a 1%, 1xTBE agarose gel (3.5). DNAs from the clones 
which contained inserts of the correct size were subcloned using Eco R1 
and Hin d ill sites, and ligated with pKK223.3 and transformed in E.coli. 
(3.10). Colonies were picked, transferred into a glass universal containing 
3mls of selection medium (LB broth plus ampicillin) and grown overnight 
at 37°C in a shaking incubator. Cultures were subsequently mini-prepped, 
digested (3.7), with EcoR1 and Hin d ill, and electrophoresed (3.5).
When a large number of colonies were obtained, they were screened by 
PCR (3.3.4). Potentially positive clones were sequenced (3.6.1) using 
primer BC1 (Appendix 1) to ensure the correct insert had been cloned.
Restriction enzyme digestion with Eco R1 and Hin d ill produced a product 
that was shorter than expected (Figure 8.1). A mapplot analysis (Figure
8.2 ) revealed that Gr49 had an internal Hin d ill. A mapplot analysis was
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Figure 8.1 Eithidium bromide stained 1% (1xTBE) agarose gel showing 
the products of restriction enzyme digestion of pT7Blue/inserts with Eco 
R1 and Hin dill. Row 1 (top wells): lane 1- Gr2, lane 2 - 1 kb molecular 
weight marker, lane 3 - Gr6, lane 4 - Gr22, lane 5 - Gr25, lane 6 - Gr45, 
lane 7 - Gr49, lane 8 - Gr86, lane 9 - Gr82, lane 10 -1 kb molecular weight 
marker. Row 2 (bottom wells): lane 13, 1kb molecular weight marker, lane 
14 - Gr50, lane 15 - Gr54. Arrow indicates shorter than expected band in 
lanes 7 (Gr49) and 9.( Gr82).
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then performed on all the HBcAgs to be used in the study, revealing that 
Gr82 also had a Hin d ill site (Figure 8.3). A new primer was prepared 
replacing the Hin d ill site with a Pst 1 site; Gr 49 and Gr82 were then ‘put 
through1 the procedure again.
When the inserts were screened by the PCR (using primers CPK and 
C4N) method, positive inserts were obtained for Gr2, Gr45, Gr49, Gr60, 
Gr65, Gr82, Gr86 (Figure 8.4). However, when they were sequenced they 
did not have the correct insert. The sequence of the insert was that of the 
Eco R1 site with pT7 sequence
When these ‘positive clones' were then digested with Eco R1 and Hin d ill 
or EcoR1 and Pst 1, only two of the plasmids showed an insert, Gr2 and 
Gr65 (Figure 8.5); there were no inserts evident in the others. On 
resequencing, even these proved to be incorrect.
Strategy 3
DNA was extracted from the serum samples for all patients (3.1.1) and 
amplified using primers CPET3 and CD3, if unsuccessful, CPET3 and 
Bamtag were tried (Appendix 1). On successful amplification the same 
methods as for strategy 2 using the vector pET3a were then employed.
There appeared to be some contamination in strategy 2 from the PCR 
cloning vector. Therefore it was decided to use original first round 
products as the starting product. The primers (CPET3 and CD3 [or 
Bamtag]) were designed to amplify the C ORF and not to the pre-C region 
because we did not want to express HBeAg. However, this time the 
contamination appeared to be from the first round product as the 
sequence obtained was that of the pre-C region. This may have been due 
to possible contamination by the original product amplified by C1/C2N - 
these primers amplify the entire pre-C/C ORF. It is difficult to explain how 
this product could have been carried through all the steps involved in the
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Figure 8.5 Eithidium bromide stained 1% (1xTBE) agarose gel showing 
the products of restriction enzyme digestion of pKK223.3 inserts with 
Eco R1 and Hin d ill Lanes 1 and 9 - 1kb molecular weight marker. 
Lanes 2 and 3 show positives inserts for Gr2, lane 4 shows a positive 
insert for Gr 65, lanes 4 to 8 show positive clones by PCR of Gr45 
(lane 5), Gr49 (lane 6) Gr82 (lane 7), Gr86 (lane 8) digested with Eco 
R1 and Hin d ill with no inserts evident.
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cloning procedure and inserted into the pKK223.3, especially as C1 does 
not have an Eco R1 site but there was no other explanation forthcoming.
Strategy 4
As referred to earlier, several of the Greek samples were cloned for the 
hepatocyte expression study into the mammalian expression vector pRK5. 
Cloned pRK5/HBcAgs were used as a last attempt to clone into pET3a. 
HBcAg was amplified by PCR (3.3.1), using primers CPET3 and Bamtag 
(Appendix 1). 25ptl of the amplified products were electrophoresed (3.5), 
excised and purified by the Geneclean method (3.4.2). The excised DNA  
was digested (with Bam  H1 and Nde 1) as detailed in 3.7 and the DNA 
further purified (3.4.1). The DNA fragments were ligated with pET3a (3.8) 
and transformed in E.coli. (3.10). Plates were examined the following 
morning; colonies were picked, transferred into a glass universal 
containing 3mls of selection medium (LB broth plus 100fig/ml of ampicillin) 
and grown overnight at 37°C in a shaking incubator. Cultures were 
subsequently mini-prepped, restriction enzyme digested (3.7), with Nde 1 
and Bam  H1, and electrophoresed (3.5) to identify plasmid clones 
containing HBcAg.
There appeared to be some contamination in strategy 3 by the original 
amplified product, in this attempt we decided to re-extract the serum 
samples and amplify directly using the cloning primers in the hope that 
there would be no contamination from earlier products.
Despite having a low background level of re-ligation and many colonies 
on each test plate, all colonies failed to have an insert. Each colony was 
then tested by the PCR for inserts, again this proved to be negative.
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8.5 Conclusions
For some unknown reason, but not for want of trying, I failed to 
successfully clone any HBcAgs from the Greek patients. The spectre of 
contamination was addressed at several times during the course of 
cloning and all the normal steps to prevent it were taken. It is unlikely that 
there was inherent contamination of the original PCR products as the 
same products were used in the study by Mr. E. Dornan. As indicated 
above, several different avenues were explored in attempt, often 
desperate, to successfully clone the HBcAgs. Unfortunately, time was 
against us and this section of the work remains incomplete.
At the time ! was attempting to clone the HBcAgs several other people in 
the laboratory were successfully cloning HBcAg, and other areas of the 
HBV genome, why I had so much trouble still remains a mystery. As I will 
describe later in the general discussion, we remain committed to this 
approach as the best means of resolving the issue of potential antibody 
escape.
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General discussion and future work
The fundamental conclusions which can be made from the work carried 
out in this thesis are:
•  that serinel 5 and A1896 are separate lineages.
•  that HBV evolves within individuals.
•  that selection of A 1896 is temporally associated with substitutions in 
HBcAg
• that substitutions are associated with HBcAg B- and Th-cell epitopes.
• that HBcAg substitutions are not associated with multiple flares of 
hepatic activity.
•  that the distribution of HBcAg amino acid substitutions are different 
between the Chinese and the Mediterranean groups.
•  that amino acid substitution in HBcAg is dependant on selection of a 
pre-C variant.
•  that branched chain peptides work in both antibody binding and T-cell 
studies.
•  and that they are more reactive in ELISA when compared to 
monomeric peptides.
What is the selection pressure for pre-C stop mutants in chronic hepatitis?
Sequencing of HBcAg from patients has shown that A1896 arises during the 
course of chronic infection. As it does arise so frequently, we propose that 
there is a selection pressure that gives rise to this particular mutant. What 
this pressure could be is still unknown. If it is immune mediated then 
which particular arm of the immune system is responsible for this pressure
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is still unresolved. However, as discussed in Chapter 1 (section 6.4) it is 
unlikely that CTL are involved. Primarily, this is because CTL are virtually 
non-existent in chronic hepatitis B infection and therefore are not vigorous 
enough to exert selection pressure. Also, as described CTL epitopes in 
HBcAg and HBsAg span critical areas (the nuclear localisation and 
genome encapsidation signals in HBcAg and an important topogenic 
sequence in the transmembrane domain in HBsAg) in these genes, 
mutations in these areas could be lethal for the virus. Rehermann et al 
(1996) have described CTL in chronic hepatitis patients, however the 
response was a latent one and required augmentation with IFN treatment 
to reactivate the CTL response, indicating once again that patients with 
chronic HBV infection do not have an active CTL response. It has been 
proposed that the Th-cell response to HBcAg/HBeAg may contribute to 
selection of pre-C stop variants.
Jung et al (1995) have shown that Th-cell responses are also often 
weaker, though present, in chronic hepatitis infection than in acute 
infection, yet the fine specificity of HBV nucleocapsid recognition by Th 
cells is similar in both acute and chronic HBV patients. However, those 
patients examined that had a pre-C variant failed to respond to 
HBcAg/HBeAg and derived peptides. W as this due to escape? It seems 
unlikely, as the pre-C region seldom induced T-cell proliferation, 
indicating the absence of a Th epitope in this area. Also, the sequencing 
results (from Chapter 7) of the PBMC patients showed that those who 
failed to respond to peptides that contained one of the HBcAg Th epitopes 
did not have variant amino acids in this region.
HBeAg is a secreted protein and, as pre-C mutants often appear around 
the time of seroconversion to anti-HBe, the possibility that the selection 
pressure is humoral is feasible. Lindh et al (1996) indicate that selection 
of the pre-C mutant is an escape mechanism that reduces the host’s 
immune response (and therefore liver damage). In that study, the pre-C
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mutant was associated with less liver damage than the HBeAg producing 
strain but, in the patients we have studied, we believe there is ongoing 
pressure as increased ALTs were still observed after appearance of a pre- 
C stop variant.
Pre-C mutants other than A i896 can be selected (Chapter 5), but Aisge is by 
far the commonest. A possible explanation for this could be stabilisation of 
s. It has been proposed that stabilisation of s and subsequently improved 
encapsidation (and so replication) may be a stronger reason, from an 
evolutionary perspective, for selection of these mutants than ‘switching off’ 
HBeAg to escape the immune system. If it is the immune pressure causing 
selection of A 1896 then why are different pre-C stop mutants (or mutants 
which do not allow initiation of pre-C translation) not selected in those with 
serine15? Figure 5.5 shows that serine15 (UCC) also stabilises 8, so 
perhaps there is no need to select a stop mutant. It is possible that other 
pre-C mutants may interfere with other functions of the pre-C region. 
However, if A i896 is evolutionarily ‘fitter’, why is this not found to be the 
infecting virus in most cases?
HBeAg has been implicated in mediating inhibition of HBV replication 
(Lambert et al, 1993). Over expression of HBeAg in transgenic mice 
greatly reduces the cytoplasmic content of HBV nucleocapsid particles 
(Guidotti et al, 1996). As shown for DHBV in vitro, a high level of 
replication is cytopathic for the hepatocyte (Summers et al, 1990), thus the 
regulation of replication could represent a means of survival for the virus. 
Selection of a pre-C variant in this instance would remove the regulatory 
effect of HBeAg and subsequently increase viral replication. However, if 
the finding of Summers et al (1990) is correct, then it would not be in the 
interest of the virus to select pre-C variants as this would result in 
increased pathology in the host. The almost universal take-over by variant 
viruses with pre-C stop codons, observed in this thesis and many other 
studies, do not bear this finding out.
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There are two ways to decipher whether the role of pre-C variants is to 
enhance replication. One is by using a cell line which is susceptible to 
HBV replication: a cell line which expresses the proposed viral receptor, 
annexin V, is now available. A second method would be to use an animal 
model: work on a SCID mouse model for hepatitis viruses is currently 
under investigation by our laboratory. In both instances, by infecting the 
cells or animal model with variant viruses either solely, to test their 
cytopathic effect, or as mixtures to assess replicative advantage, some of 
the above points could be answered experimentally. Unfortunately, such 
systems would not be useful for addressing the role of immune selection 
on HBV.
Are serine15 and A 1896 truly separate lineages and is one ‘taking-over’?
The phylogenetic analysis (Chapter 5) indicated that serine15 and Aisge 
are circulating independently in the Hong Kong Chinese community. This 
poses the question of whether both these mutants evolved together or 
whether serine15 is in the gradual process of becoming the dominant 
strain in this community.
A large retrospective study examining HBcAg sequences in the Hong 
Kong Chinese community over the past 50 years would document the 
distribution of these two variants and determine whether they are truly 
independent. If serine15 is evolutionarily ‘fitter’, then we would see a 
gradual change in their distribution. To assess this properly, multiple 
sequential samples from a large study group, in the region of one hundred 
individuals, would have to be examined. Careful selection of the clinical 
background (?and the HLA type) of the patients would be essential in 
order to ensure viral factors are being investigated and that there is not 
too much influence from host factors. Studies to search for shifts in the 
viral sequence over the last 50 years have not, to our knowledge, been 
done, but it would be interesting to see how many of these variants are
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indeed viral dead ends and how many have become established in the 
population. There is some evidence that the A i896 variant is transmitted on 
a large scale (Bollyky et al, submitted); such a retrospective study would 
provide experimental evidence.
Why serine15 is particular to the Hong Kong Chinese community and is 
not observed in any other part of the world, remains unclear. Of course 
there are many areas of the world in which the pre-C sequence of HBV 
has not been extensively studied, for example South America, thus 
perhaps it is prevalent in other populations. There has been one report of 
HLA type influencing the outcome of infection (Thursz et al, 1995), where 
HLA-DRB1*1302 was found to be associated with protection against 
persistent HBV infection in children and adults in the Gambia, but whether 
the HLA background of an individual could have an influence on the 
infecting strain has yet to be demonstrated.
Is there a geographical difference in HBcAg variation?
Our results on Far Eastern patients are in agreement with Ehata et al 
(1993), in that there is a cluster of amino acid substitutions between 
amino acids 84 and 101; there were statistically more substitutions here 
than in the rest of HBcAg (p=0.0001). Mutations have also been observed 
for the region between amino acid 84 and 101 in studies by Bozkaya et al 
(1996), Hur et al (1996), Akarca and Lok (1995), and Hosono et al (1996) 
all of whom studied patients from the Far East. When this area is 
analysed according to the groupings, only group I  is significant (group I, 
p=0.001; group II, p=0.01, group III, p=0.18), implying that the association 
may be with A i896- Interestingly, when this region is analysed in the 
patients from Chapter 6, who are of Mediterranean origin, there is no 
significant difference in the rate of amino acid substitution between this 
region and the rest of HBcAg (p=0.94; Cl: 0.45-1.89; CR 0.98) in those
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with A i896- This indicates that there is a geographical difference in regions 
of amino acid substitution that must be related to host.
Therefore, we have shown that the overall rate of core variation is not only 
dependent on geographical location, but also on selection of a pre-C stop 
codon, as these genomes have a higher rate of mutation compared to 
serine15.
The threonine to serine substitution (at amino acid 12 of HBcAg) often 
observed in Mediterranean patients after selection of A 1896 is not observed 
in the Far East. Interestingly, groups which have analysed HBcAg 
sequences from the Far East quote the consensus amino acid at amino 
acid 12 as serine (Hosono et al, 1995; Lee et al, 1996). This, indicates a 
difference in the strains circulating in the Far East and Mediterranean 
countries.
As most investigators in this field examine patients from the Far East the 
difference in HBcAg substitution between these groups has not previously 
been demonstrated. It is an interesting finding but, if anything, it 
complicates the picture of HBcAg variation and its possible role in 
pathogenesis by increasing the parameters that may be involved. From 
now on, not only should individual and collective variants be assessed but 
so must also the genotype, (possibly subtype) and host factors.
Core variation: is it only due to random errors during reverse transcription 
of the pregenome?
A longitudinal study by Bozkaya et al (1996) followed HBeAg-positive 
patients for up to seven years. When their sequences were analysed, 
identical nucleotide and amino acid sequences were found despite high 
serum HBV DNA levels. In the same study, those who were HBeAg- 
positive and had raised ALT or seroconverted to anti-HBe had a much
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higher mutation rate (1.9+ 0.3 and 2.4 + 0.4 compared with 0.4 + 
0.1/nucleotide position/year). This suggests that the former group are still 
in the immune tolerant phase of the disease and that random errors that 
occur during reverse transcription of the pregenome are uncommon. W e  
interpret these results such that the background level of random mutations 
is 0.4 + 0.1/nucleotide position/year and a higher mutation rate therefore 
indicates positive selection.
Is HBcAg variation related to disease severity or does it represent immune 
escape?
The initial aim was to answer the above question. The clinical features of 
a group of anti-HBe positive, viraemic chronic patients, seen most 
commonly in the Mediterranean and the Far East, prompted this question. 
Why should such patients have continued disease after seroconversion to 
anti-HBe?
The appearance of replication-competent core protein variants during 
infection raises the probability that this protein is under immunological 
pressure. The size and organisation of the HBV genome may hinder the 
development of some mutations yet this study has confirmed that it can 
tolerate multiple substitutions (the highest number of described 
substitutions in one HBcAg was 16; [Chapter 6]) thus highlighting, I 
believe, its remarkable capacity for adapting to the changing 
immunological environment yet maintaining the integrity of its open 
reading frames.
As discussed earlier (Chapter 1, section 5.4) it is currently believed that 
HBeAg induces tolerance, thus explaining the high proportion of neonates 
that become chronically infected and why most HBeAg positive chronic 
carriers initially have minimal disease. Eventually, tolerance to HBeAg 
seems to be lost, the immune system is ‘switched on’ to HBeAg, with the
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result that hepatitis is induced. If a particularly vigorous immune response 
was activated, this could lead to pressure on the virus to ‘switch off this 
response, providing a possible explanation for pre-C variants. If variants 
did not appear then, as HBeAg-producing hepatocytes are eliminated, so 
is the virus. Once the mutant has been selected there appears to be very 
little back selection; if an HBeAg-producing strain was reintroduced it 
would probably be quickly recognised and destroyed. If HBeAg is the only 
immune target, this would bring host and virus back to the status quo. 
However, the patients studied here had continued flares of hepatitis even 
after seroconversion to anti-HBe and development of a pre-C variant, 
implying that the immune system is then directed against another antigen.
As HBcAg/HBeAg have sequence homology, the immune response may 
target HBcAg only after HBeAg has been ‘removed’ from the equation by 
a pre-C variant; thus, my work focused on examining the nature and 
distribution of variation in HBcAg.
The sequential sequencing (Chapters 5 and 6) allowed us to show 
unequivocally that there is an initial burst of amino acid substitutions 
simultaneously or soon after the appearance of a pre-C stop codon. 
Statistical analysis of the observed substitutions proved them to be 
significant in B- and Th-cell epitopic areas, indicating that there is immune 
pressure in HBcAg. This was not observed in a sequential study by 
Asahina et al (1996) in which there were no observed core mutations even 
after selection of a pre-C stop codon. However, in this paper, only one 
patient selected a pre-C mutant. Simultaneous pre-C/C mutations were 
observed in 11 patients (from both Chapters 5 and 6). Bozkaya et al 
(1996) also observed appearance of HBcAg mutations at the time of, or 
shortly after, the appearance of pre-C stop codon.
As discussed in Chapter 1 (section 6.2, Table 1.11) there appears to be 
an association with substitutions in the C-terminus of HBcAg and severe
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disease. Recent clinical data was available for some of the Greek patients 
studied in Chapter 6. When the C-terminus of these patients was 
examined for substitutions, five had substitutions in this area (H25, H27, 
H33, H35 and H36). An update on health status was available for: H27 - 
currently inactive; H33 - died of HCC in 1995; H35 - underwent a course 
of IFN treatment in 1994 and is currently in remission; and H36 - still 
experiencing episodes of severe disease activity. No further information 
was available for H25. Two of the patients (H33 and H36) help to 
substantiate our theory but the other two patients (H27 and H35) do not. 
Perhaps, once again, the difference in positions of substitutions within 
HBcAg is ethnically influenced. All the patients in Table 1.11 are of Far 
Eastern origin. Unfortunately, no recent clinical information was available 
for those patients studied in Chapter 5.
Why should these patients have continued disease if they no longer have 
the appropriate epitope? One possibility is that these mutations result in 
presentation of a ‘new’ epitope to which the immune system responds. 
Yet, as we have shown from the sequential study (Chapter 6) in which we 
sequenced patients over multiple flares of hepatitis, there is very little 
further mutation after the initial burst that is associated with the 
appearance of the pre-C variant. Therefore, the variation in HBcAg is 
associated with disease progression but is not the cause of the disease; 
the assumption is made that liver injury is caused by the immune 
response to the virus. This leads to another possibility, that the new 
variants observed cause the virus itself to be pathogenic. This was not 
experimentally assessed in this thesis but work in our laboratory has 
shown that certain HBcAg mutations can cause a shift in localisation of 
HBcAg in the cell. The differential accumulation of HBcAg may (perhaps) 
cause cell damage. Again, this possibility could be formally assessed with 
the use of the cell culture system or animal model discussed earlier.
Unfortunately, this question remains incompletely resolved. The former 
seems unlikely for three reasons. Firstly, if a substitution appears which
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leads to a fresh immune attack, the prediction is that this virus population 
would be cleared. However, in all 12 of the cases studied in depth 
(Chapter 6), mutants selected between the initial and second samples 
remained until the final sample; this is unlikely to be a chance occurrence. 
Secondly, few mutations were seen subsequent to the initial burst even 
though there were intermittent flares of hepatic activity in these patients. 
Thirdly, sequencing complete core genes from four or five sequential sera 
from each of three patients did not disclose transient mutations which 
would be predicted to stimulate and be cleared by a new immune 
response, such that they are not present in the final sample. Taken 
together, this evidence indicates that the mutated virus strains are 
escaping from the immune response against HBcAg, rather than causing 
peaks of hepatitis. That mutations occur within B-cell epitopes indicates 
that selection may be antibody-mediated and casts doubt on the widely 
held notion that anti-HBe is innocuous and merely a marker of infection. 
Furthermore, anti-HBe has been shown in the chimpanzee to favour viral 
persistence (Iwarson et al, 1985). W e had hoped to provide direct 
evidence for this from our T- and B-cell studies but unfortunately time was 
against us. These studies are ongoing and will hopefully help to elucidate 
what is happening in HBcAg. Comparison studies between monomeric 
and branched peptides have shown that the latter are more sensitive for 
anti-HBe binding studies (Chapter 7). W e believe that the direction we 
were tried in Chapter 8, using recombinant HBcAg, is probably the best 
route for trying to determine whether there is antibody selection as several 
of the overlapping branched peptides were insoluble. Ideally, we would 
like to test sera from anti-HBe chronic patients with multiple flares of 
hepatitis, before, during and after these flares using recombinant HBcAg 
(rHBcAg) derived from their circulating HBcAg at each time point. If later 
rHBcAg failed to bind to earlier sera this would be an indication that a
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‘new’ antibody response has been initiated against a variant virus. A 
simultaneous experiment testing PBMCs from the same time points using 
the overlapping peptide series (preliminary results have shown that the 
configuration of the peptide is not important in lymphoproliferation studies) 
would address whether Th escape is occurring. This would hopefully, 
once and for all, determine whether these flares are associated with new 
variants or not and whether they are immune mediated. It is possible that 
either substitutions appear in protein products of the other three genes of 
the virus or that HBcAg mutations in a strain which is present at less than 
5% of the population, account for the flares of hepatic activity. This was 
not assessed in this study as it is logisticaliy difficult and time-consuming 
if statistical significance is to be achieved.
There is some evidence that the sequence context of substitutions may be 
as important as the variation itself (Bollyky et al, submitted). Thus, in 
future studies, there will need to be consideration of whether there are 
several nucleotide or amino acid motifs associated with a particular 
disease pattern. These analyses have to take into account the natural 
genotype variability, as a substitution in a genotype in which it seldom 
occurs, may be significant. Also, it is unlikely that there will be perfect 
associations between variants and functional effects as that would not 
take any host factor into account. Fulminant hepatitis, regarded as an 
‘end-of -the-road’ infection that is not in the interest of the viral 
persistence, has been linked to HLA type (DR-1302/2) (H. Thomas, 
personal communication). This is consistent with the observation that the 
isolate from a case of fulminant hepatitis had an identical nucleotide 
sequence to that observed in the patient with minimal disease who was 
the source of the infection (Alexopoulou et al, 1996). What is more difficult 
to reconcile to a simple host factor is the finding of outbreaks of fulminant 
disease and the preferential transmission of fulminant hepatitis from anti- 
HBe carriers; there have been several outbreaks of fulminant hepatitis
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from a single source (Oren et al, 1989). As shown for the multiple 
mutations that can inhibit HBeAg production, there are probably multiple 
ways of causing a similar functional effect in a regulatory region. New 
evidence suggests that the pre-C mutant is not the sole cause of fulminant 
hepatitis but that it is caused by a combination of mutations, including 
those within pre-C and the X  gene (Bollyky et al, submitted, 1997). 
Additionally, A i896 strains can be transmitted independently and cause 
typical acute hepatitis.
Finally, HBV, with its compact organisation, seems to be highly evolved 
but we have shown that it does have the potential for significant change 
within HBcAg, that it has important effects on immune recognition and that 
there is interplay between mutation events both in place and over time. 
W e have shown that with the appearance of HBeAg negative variants, in 
particular GiegsA, there is strong indirect evidence that selection pressure 
builds on HBcAg epitopes. Despite extensive studies on pre-C/C variation 
and the vast amount of data published from these studies, from our 
laboratory and others world-wide, there is still no clear evidence for a 
causal link between specific mutations or the degree of substitution in 
HBcAg and the outcome of infection with HBV as, unfortunately, there has 
not been any good published data on the functional effects of HBcAg 
variants. Several groups have now changed direction and are now 
focusing on HBxAg. Many important regulatory elements reside within 
HBxAg and it is likely that variants occurring in this region will affect either 
gene expression or viral replication to some degree. The eventual 
outcome, I believe, will be explained by host and viral interactions, with 
the consequence that variants of HBV will behave differently in each 
population. Future studies, described here and which were initiated from 
work in this thesis will decipher their role.
139
Appendix 1: Details of primer sequences used in the course of
this thesis
Primer Primer
Nam e______________________________ Sequence____________________
sense- 5 'to 3'
C1 CGGGATCCGAGGAGTTGGGGGAGGAGATT
C3 CGGGATCCCTTTGTACTAGGAGGCTGTAG
Cot CATACAGCACTCAGGCAAGC
CPET3 GGAATTCCATATGGACATTGACCCT/GTATAAAG
19 AGACCACCAATGCCCCTATC
antisense3' to 5'
Bamtag G A G C C C TT  A G A G TTA C A C T  C G C G T T  C T  G C G G G G
C G C A G T T G C C G C C G A T C C C TA G G G C  
BC1 G G AAAAG AACT CAG A AG G C AA
C2 G A G A A TTC A C C TTA TG A G TC C A A G G
C2N C C C C G TA A A G T TC /TC C G /C A C C TT
C4 G A G A A TTC TA C TA A C A TTG A G A TTC C C A
C4N C C TTA T  G A G TC C A A G G G /A A TA
C5 A G T C G A A T T C C T T T  G TA C TA G G A G G C T G T AG
CD 3 TG C TG G G TC TG C C A A A TTA C C A C C C A C C
CPK G G A A TT CA T G G AC A T T  G AC C C
K C 1 G C G A A TC C A C  A C TC C  AAAAGA
S eri 5 G G G G T  C G A C C G C A C C A T G C A A C TT TTTC A C C T
C T G C C T  AAT CA T C T  C T T  G TT  CA T G TT  C C A C T G TT  
W B 2 A A C T G C A G C C C TT A T  G A G T  C C AAG G G /AAT A
Single letter amino acid codes are given in Appendix 2. 
The underlined amino acids identify the tag sequence
Appendix 2 One and three letter abbreviations for amino acids
Amino acid 
code
Three letter code One letter
Alanine Ala A
Arginine Arg R
Asparagine Asn N
Aspartic Acid Asp D
Cysteine Cys C
Glutamine Gin Q
Glutamic acid Glu E
Glycine Gly G
Histidine His H
Isoleucine lie 1
Leucine Leu L
Lysine Lys K
Methioinine Met M
Phenylalanine Phe F
Proline Pro P
Serine Ser S
Threonine Thr T
Tryptophan Trp W
Tyrosine Tyr Y
Valine Val V
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